Systematic analysis of fHbp sequence coverage by antibodies against meningococcal GMMA from african group W strains by Aruta, Maria Grazia
  
 
 
 
 
SYSTEMATIC ANALYSIS OF FHBP 
SEQUENCE COVERAGE BY 
ANTIBODIES AGAINST 
MENINGOCOCCAL GMMA FROM 
AFRICAN GROUP W STRAINS 
 
 
Maria Grazia Aruta 
 
 
 
Dottorato in Scienze Biotecnologiche – XXVIII ciclo 
Indirizzo Biotecnologie Industriali e Molecolari 
Università di Napoli Federico II 
 
 
 
 
 
 
 
 
 
  
 
  
  
 
 
Dottorato in Scienze Biotecnologiche – XXVIII ciclo 
Indirizzo Biotecnologie Industriali e Molecolari 
Università di Napoli Federico II 
 
 
 
 
 
 
 
 
 
 
SYSTEMATIC ANALYSIS OF FHBP 
SEQUENCE COVERAGE BY 
ANTIBODIES AGAINST 
MENINGOCOCCAL GMMA FROM 
AFRICAN GROUP W STRAINS 
 
 
Maria Grazia Aruta 
 
 
 
Dottorando: Maria Grazia Aruta 
 
Relatore:  Prof.  Giovanni Sannia, 
Dr.  Oliver Koeberling 
 
Coordinatore: Prof. Giovanni Sannia 
  
  
  
 
 
 
 
 
 
 
 
Il miglior riconoscimento 
per la fatica fatta 
non è ciò che se ne ricava, 
ma ciò che si diventa  
grazie ad essa. 
 
John Ruskin 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
Index 
 
Summary ..................................................................................................................................... 1 
Riassunto .................................................................................................................................... 3 
II Introduction .............................................................................................................................. 7 
2.1 Neglected diseases ............................................................................................................ 7 
2.2 Meningitis .......................................................................................................................... 7 
2.2 Neisseria meningitidis ........................................................................................................ 9 
2.2.1 Biology and microbiology ............................................................................................. 9 
2.2.2 Epidemiology ............................................................................................................. 13 
2.2.3 Pathogenesis ............................................................................................................. 16 
2.2.4 Neisseria interaction with complement components .................................................. 18 
2.3 Meningococcal vaccines .................................................................................................. 20 
2.3.1 State of the art in developed countries....................................................................... 20 
2.3.2 State of the art in Africa ............................................................................................. 21 
2.3.3 Native outer membrane vesicles (NOMV) and Generalized Modules for Membrane 
Antigens (GMMA) ............................................................................................................... 22 
2.3.3 Factor H binding protein ............................................................................................ 24 
III Aim of thesis .......................................................................................................................... 29 
IV Material and methods ............................................................................................................ 31 
4.1 Bacterial growth conditions .............................................................................................. 31 
4.1.1 Escherichia Coli ......................................................................................................... 31 
4.1.2 Neisseria Meningitidis ................................................................................................ 31 
4.2 Molecular biological DNA techniques ............................................................................... 31 
4.2.1 Polymerase chain reaction (PCR) .............................................................................. 31 
4.2.2 Colony PCR............................................................................................................... 34 
4.2.3 Agarose gel electrophoresis ...................................................................................... 34 
4.2.4 DNA purification and quantitation .............................................................................. 35 
4.2.5 Enzymatic restriction of DNA ..................................................................................... 36 
4.2.6 Gel extraction of DNA ................................................................................................ 36 
4.2.7 Ligation of DNA fragments ......................................................................................... 37 
For ligation reactions T4 DNA Ligase (Invitrogen) was used to ligate DNA fragments. ....... 37 
4.2.8 Neisseria genomic DNA prep .................................................................................... 38 
4.2.9 Plasmidic Miniprep .................................................................................................... 39 
4.2.10 Escherichia Coli transformation ............................................................................... 39 
4.2.11 Neisseria Meningitidis transformation ...................................................................... 40 
  
4.2.12 Preparation of bacterial glycerol stocks for long term storage .................................. 40 
4.3 Generation of Neisseria Meningitidis mutants .................................................................. 40 
4.3.1 Overview of definitions and objectives of mutations in Neisseria meningitidis genome
 ........................................................................................................................................... 40 
4.3.2 Plasmids and primers ................................................................................................ 41 
4.4 Determination of protein concentration by Lowry assay ................................................... 47 
4.5 SDS-Polyacrylamid gel electrophoresis of proteins .......................................................... 47 
4.6 Western Blotting............................................................................................................... 47 
4.7 Dot blotting....................................................................................................................... 48 
4.8 Coomassie blue stain of proteins ..................................................................................... 48 
4.9 FACS analysis of fHbp surface expression on live bacteria .............................................. 49 
4.10 Preparation and purification of GMMA ........................................................................... 49 
4.11 Characterization and quality control of GMMA ............................................................... 50 
4.11.1 Negative Staining Trasmission Electron Microscopy ................................................ 50 
4.11.2 Monocyte Activation Test (MAT) .............................................................................. 50 
4.11.3 MALDI-TOF and MS/MS analysis on lipid A ............................................................ 51 
4.11.4 HPLC-SEC MALLS analysis of GMMA samples ...................................................... 52 
4.12 Mice immunization ......................................................................................................... 55 
4.13 Characterization of immune responses by Serum Bactericidal Assay (SBA) .................. 55 
4.14 FHbp sequence diversity analysis by pairwise amino acid comparison .......................... 56 
V – Results ................................................................................................................................ 59 
5.1 Generation and characterization of GMMA from a serogroup W strain with over-expressed 
fHbp v.2 ................................................................................................................................. 59 
5.1.1 Over-expression of native fHbp variant 2 in MenW .................................................... 60 
5.1.2 Deletion of capsule in MenW strains over-expressing fHBp v.2, ................................ 62 
5.1.3 Deletion of lpxL1 ........................................................................................................ 63 
5.1.4 Deletion of gna33 ...................................................................................................... 64 
5.2 Comparative characterization of Group W GMMA over-expressing two different variants of 
fHbp ....................................................................................................................................... 65 
5.2.1 Detection of total protein and fHbp in GMMA by SDS PAGE, Comassie blue and 
western blotting .................................................................................................................. 65 
5.2.2 MALDI-TOF analysis of lipid A from N. meningitidis GMMA lpxL1 knock out ............. 67 
5.2.3 Evaluation of endotoxin activity of Neisseria GMMA after genetic manipulation ......... 68 
5.2.4 Analysis of GMMA samples from group W mutants with over-expressed fHbp fHbp v.2 
by HPLC-SEC MALLS ........................................................................................................ 69 
5.3 Analysis of the breadth of fHbp sequence coverage by antibodies against fHbp in GMMA
 .............................................................................................................................................. 71 
5.3.1 Structure and sequence analysis of fHbp v.1, v.2 and v.3 .......................................... 72 
  
5.3.2 Investigation of functional activity of antibodies against fHbp on a strain panel 
expressing highly diverse fHbp sequences ......................................................................... 80 
VI Discussion ............................................................................................................................ 95 
VII Reference List .................................................................................................................... 101 
Ringraziamenti ........................................................................................................................ 115 
 
  
 
1 
 
Summary 
 
FHbp sequence diversity expressed by African isolates is limited among currently 
circulating strains in sub-Saharan Africa but could change in the future. 
The primary aim of the project was to systematically investigate and dissect the breadth 
and nature of fHbp sequence coverage irrespective of the fHbp sequence prevalence. 
This was obtained by using a combination of bioinformatic tools and analysis of 
functional antibody raised against fHbp over-expressed in meningococcal GMMA from 
an African group W strain. 
The work is divided into three parts: 
1. Comparative structure/sequence analysis of the amino acids involved in factor H 
binding including more than 700 individual existing and published fHbp sequences. The 
results obtained show a differential degree of variability of the factor H binding site 
between fHbp belonging to variant 1 versus those belonging to variant 2 or 3 with 
greater sequence diversification of the factor H binding site in the v.1 group. 
2. Systematic selection of fHbp sequences based on a gradually different number of 
differences in the factor H (fH) binding site compared to fHbp variant 1 ID9 expressed in 
the group W GMMA. Applying these criteria a panel of 11 African and non-African wild 
type strains (belonging to serogroup A, C, W, Y or X) was selected that expressed a 
subset of the identified phylogenetically diverse fHbp sequences. Use of fHbp selection 
criteria to generate a panel of eight genetically defined isogenic strains that were 
engineered to express seven existing diverse fHbp v.1 sequences and one naturally 
existing and published fHbp v.1/2 hybrid protein. The wild type and isogenic strains as 
test strains in serum bactericidal assay to measure functional activity of antibodies 
raised against GMMA from a group W strain with over-expressed fHbp v.1 ID 9. 
The sera had bactericidal activity against 10 out of the 11 diverse wild type strains. 
However, against 8 of the susceptible strains also sera raised against GMMA that did 
not contain fHbp were bactericidal suggesting that other yet unknown target(s) 
contribute to the generation of bactericidal antibodies.The sera raised in mice against 
the group W GMMA with over-expressed fHbp v.1 also had bactericidal activity against 
the panel of eight isogenic strains engineered to express diverse fHbp sequences 
including the strain engineered to express the natural fHbp v.1/2 hybrid sequence. The 
results with the isogenic strains expressing diverse fHbp sequences suggest that 
differences in the fH binding site contribute to susceptibility of the isolate to killing by anti 
fHbp antibodies but also overall sequence diversity plays a role. 
3. As proof of principle to broaden coverage of GMMA from a group W strain with over-
expressed fHbp v.1 a mutant group W strain engineered to over-express the native fHbp 
v.2 sequence, which is predominant among African group W isolates was generated. 
GMMA from the mutant had approximately 10-fold higher amount of fHbp than in GMMA 
from wild type meningococcus; penta-acylation of lipidA after inactivation of lpxL1 was 
confirmed by MALDI-TOF analysis and Monocyte-Activation Test (MAT) assay showed 
an approximately 100-fold decreases ability of GMMA from the mutant to activate 
cytokine release from human blood cells. By HPLC-SEC MALLS integrity, size and 
impurities of the vesicles were characterized. 
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Riassunto 
 
Introduzione 
 
La meningite causata dal batterio Neisseria meningitidis si verifica in tutto il mondo sia in 
forma endemica che epidemica. Infetta soltanto esseri umani; non esiste un portatore 
animale. N. meningitidis appartenente ai gruppi capsulari A, C, W e X è responsabile 
delle epidemie di meningite nella “cintura meningococcica africana” (un‟area che si 
estende dall‟Etiopia al Senegal) e sono necessari vaccini a buon mercato che possano 
garantire una ampia protezione contro i ceppi epidemici africani. 
I moduli generalizzati per gli antigeni di membrana (GMMA) da ceppi di N. meningitidis 
geneticamente ingegnerizzati sono in fase di studio come potenziali candidati vaccini. 
Le GMMA sono vescicole della membrane esterna, rilasciate da batteri geneticamente 
modificati, che possono essere usate come vettori di antigeni. 
In topo, le GMMA meningococciche inducono prevalentemente una risposta anticorpale 
diretta versa antigeni proteici. 
La proteina di legame al fattore H (fHbp) è un antigene chiave del meningococco. 
Si tratta di una lipoproteina presente sulla superficie della membrane esterna e può 
essere divisa in tre varianti antigeniche. Ogni variante può essere ulteriormente divisa in 
sub-varianti che differiscono da pochi amminoacidi e finora più di 900 sub-varianti sono 
state identificate, distinguibili da un‟unica sequenza definita ID. Una delle funzioni di 
fHbp è legare il fattore umano H, un regolatore negative della cascata del complemento. 
Ogni variante fHbp si lega al fattore H mediante una regione della proteina detta sito di 
legame al fattore H. 
Gli anticorpi elicitati contro una particolare variante fHbp sono in generale funzionali 
contro i ceppi di N. meningitidis che esprimono la stessa variante di fHbp. 
Ad ogni modo, differenze nella sequenza di fHbp entro ogni variante possono incidere 
sulla suscettibilità di un ceppo alla lisi mediata da anticorpi anti-fHbp. 
E‟ stato osservato che GMMA derivanti da un ceppo di serogruppo W overesprimente 
fHbp v.1 inducevano in topi anticorpi contro fHbp. In saggi gli anticorpi avevano la 
capacità di uccidere un pannello di ceppi africani di serogruppo A, W e X esprimenti 
fHbp v.1. Il pannello includeva ceppi rappresentativi esprimenti sequenze di fHbp che 
sono prevalenti tra gli attuali ceppi africani epidemici. La diversità della sequenza di 
fHbp è limitata tra gli isolati africani invasivi attualmente circolanti e poche sub-varianti di 
fHbp sono espresse dalla maggior parte dei ceppi. L‟epidemiologia è dinamica e I ceppi 
con diverse sequenze di fHbp potrebbero diventare predominanti in future nella cintura 
meningococcica Africana. Un‟analisi sistematica può fornire indicazione sull‟ampiezza 
della copertura delle sequenze di fHbp che può emergere in future nell‟Africa sub-
Sahariana. 
 
Scopo 
 
Lo scopo primario del progetto è investigare ed esaminare sistematicamente l‟ampiezza 
e la natura della copertura delle sequenza di fHbp mediata dagli anticorpi contro fHbp. 
Ciò è ottenuto usando una combinazione di strumenti bioinformatici come base per 
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analizzare l‟attività funzionale degli anticorpi. L‟analisi può supportare la selezione di 
sequenze di fHbp da includere in vaccini basati su fHbp per l‟Africa sub-Sahariana. 
 
Metodi 
 
Ho messo a punto un‟analisi comparativa di struttura/sequenza di più di 700 sequenze 
fHbp ID esistenti e pubblicate, appartenti alla variante 1 (N=383), variante 2 (N=151) e 3 
(N=149). In particolare, ho comparato il livello di diversità degli amminoacidi in contatto 
col fattore H tra varianti diverse e entro la stessa variante nelle diverse sequenze di 
fHbp. Essendo accessibili in quanto di superficie ci si aspetta che tali amminoacidi siano 
sotto pressione immunitaria. Usando fHbp variante 1 come modello ho usato i risultati 
ottenuti mediante analisi bioinformatica per applicare nuovi criteri per la selezione di un 
pannello di diverse sequenze di fHbp a esprimere in N. meningitidis con l‟obiettivo finale 
di studiare la copertura della sequenza di fHbp. Le sequenze di fHbp sono state 
selezionate sulla base di un livello di differenze nel sito di legame al fattore H 
gradualmente differente. Entro ogni livello una sequenza è stata selezionata sulla base 
della percentuale di identità più bassa comparata con l‟fHbp inclusa nel vaccine. 
1. Applicando questi criteri, ho selezionato un pannello di ceppi wild type 
(appartenenti ai sierogruppi A, C, W, Y e X) che esprimevano un sottoinsieme 
delle sequenze di fHbp selezionate. 
2. Ho applicato i criteri di selezione per generare, partendo da un ceppo parente, un 
pannello di 8 ceppi isogenici geneticamente definiti che sono stati ingegnerizzati 
per esprimere 7 sequenze fHbp v.1 diverse esistenti e un ibrido fHbp v.1/v.2. I 
mutanti sono stati generati usando un ceppo parente resistente all‟uccisione 
mediante siero contro GMMA senza fHbp. Le sequenze di fHbp selezionate sono 
state integrate nel genoma ed espresse sotto il controllo di un promotore 
inducibile da IPTG. Il vantaggio di questo pannello è che esso ha permesso di 
investigare in modo specifico l‟attività funzionale di anticorpi contro fHbp dato che 
i mutanti differivano soltanto per la sequenza di fHbp che essi esprimevano. Ho 
usato i ceppi come ceppi test negli SBA (saggi per investigare la battericidia dei 
sieri) per misurare l‟attività funzionale di anticorpi elicitati contro GMMA derivanti 
da un ceppo di sierogruppo W con fHbp v.1 overespressa in presenza di 
complemento umano e di coniglio. 
Come prova di principio, ho generato un ceppo mutante di sierogruppo W (basato sullo 
stesso ceppo parente wild type che è stato usato per generare il mutante 
overesprimente fHbp v.1) e ingegnerizzato per overesprimere fHbp v.2 nativa, che è 
predominante tra gli isolati africani di sierogruppo W. Le GMMA dai mutanti generati 
sono stati caratterizzati dal punto di vista della forma tramite microscopia elettronica a 
colorazione negativa, dal punto di vista dell‟espressione di fHbp tramite western blotting, 
dal punto di vista della reattogenicità tramite analisi del lipide A per MALDI-TOF e test di 
attivazione dei monociti (MAT) e dal punto di vista della dimensione, del contenuto di 
acido nucleico e di proteine solubili tramite HPLC-SEC. 
 
Risultati 
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Dal confronto tra le sequenze del sito di legame al fattore H è risultato che per la 
variante 1 tra i 54 amminoacidi in contatto con il fattore H, 29 (55%) delle posizioni sono 
variabili. Al contrario, entro i gruppi relativi alla variante 2 e 3 rispettivamente soltanto 13 
e 10 dei 54 residui in contatto con il fattore H sono variabili (24% e 18% rispettivamente). 
Un confronto a coppie del numero dei differenti residui tra ogni sequenza ID ha rivelato 
che entro il gruppo variante 1, il sito di legame al fattore H tra le sequenze individuali 
può differire in più di 13 posizioni. Al contrario, il massimo numero di differenze in 
amminoacidi osservato nel sito di legame al fattore H tra coppie di peptidi ID 
appartenenti alla variante 2 è stato 5 (osservato per 4 paia di sequenze) e 6 per la 
variante 3. Quando abbiamo comparato i residui in contatto con il fattore H tra variante 2 
e 3, 125 peptidi IDs differivano per 5 o 6 amminoacidi, mentre all‟interno di entrambe le 
varianti da 96 a 107 sequenze hanno lo stesso sito di legame al fattore H.  
Le sequenze diverse di fHbp v.1 selezionate per essere espresse nei ceppi usati negli 
SBA avevano tra 0 e un massimo di 10 di differenze in amminoacidi nel sito di legame a 
fattore H comparati all‟fHbp usata nel vaccino un‟identità di sequenza complessiva tra 
89.6% e 94.9%. Tramite SBA usando complemento di coniglio contro il pannello di ceppi 
wildtype esprimenti le diverse sequenze di fHbp, 10 su 11 ceppi si sono rivelati sensibili 
all‟uccisione mediata da siero elicitato contro GMMA con fHbp v.1 over-espressa (media 
geometrica dei titoli osservati > 1000 contro 8 ceppi). Ad ogni modo, contro 8 su 11 
ceppi anche i topi immunizzati con le GMMA controllo (senza fHbp) hanno sviluppato 
una risposta anticorpale battericida indicando la presenza di anticorpi contro target 
ancora sconosciuti. Tramite FACS, è stato osservato che l‟espressione superficiale di 
fHbp è stata similare negli 8 diversi ceppi isogenici. Quando pool di sieri elicitati contro 
GMMA con fHbp over-espressa sono stati testati in presenza di complemento di coniglio 
(ricordando che il fattore H di coniglio non lega fHbp) contro il pannello di ceppi isogenici 
i titoli battericidi sono stati alti indipendentemente dall‟fHbp espressa dal ceppo. Quando 
gli stessi sieri e isolati sono stati testati in presenza di complemento è stato osservato 
un trend secondo cui titoli battericidi più alti erano ottenuti quando il numero di 
differenze nel sito di legame al fattore H di fHbp espresse nel ceppo test era basso, 
comparato con il sito di legame al fattore H di fHbp usata nel vaccino. I risultati 
suggeriscono che le differenze nel sito di legame al fattore H sono cruciali rispetto a 
differenze osservate sull‟intera sequenza. 
I risultati della caratterizzazione delle GMMA derivanti dal ceppo Men W OE nativa fHbp 
v.2 ID23 ΔcpsΔlpxL1Δgna33 hanno rivelato, tramite western blotting, più di 10 volte 
maggiore l‟espressione di fHbp nelle GMMA dai ceppi mutanti rispetto a quella 
osservata nelle GMMA derivanti dal ceppo wild type e un pattern proteico nei mutanti 
similare a quello osservato in Men W wild type tramite SDS PAGE/Coomassie blue. 
Tramite MAT assay, è stato osservato che mentre le GMMA non detossificate iniziavano 
a indurre il rilascio di interleuchina 6 (IL-6) già a basse concentrazioni (10-2ng/mL), 
quelle detossificate iniziavano a rilasciarla a concentrazioni 100 volte maggiori 
(101ng/mL). Dopodichè, i ceppi di sierogruppo W, wild type e mutanti, aventi una 
differente combinazione delle mutazioni descritte in precedenza, sono stati analizzati, 
come già anticipato, tramite HPLC-SEC per valutare la dimensione e la presenza di 
proteini solubili e acido nucleico. In tutti i campioni analizzati mediante il canale della 
fluorescenza non c‟era presenza dei picchi corrispondenti a proteine solubili, in genere 
eluenti a tempi differenti rispetto alle GMMA. Tramite il canale UV, in base al rapporto 
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ABS260/ABS280, è stata valutata l‟assenza di acidi nucleici indipendentemente dal 
trattamento con la benzonasi. Questi risultati suggeriscono che le GMMA sono state 
purificate bene mediante filtrazione attraverso filtro da 0.22 µm. 
 
Conclusioni 
 
L‟approccio basato sull‟utilizzo di una matrice per l‟analisi comparative del sito di legame 
al fattore H nelle tre varianti di fHbp v.1, v.2 e v.3 ha rivelato un grado di variabillità 
differenziale di tale sito, in particolare con una maggiore diversificazione osservata 
relativamente alla variante 1, rispetto alle alter due varianti di fHbp analizzate. La 
matrice è stata utilzzata come nuovo approccio per selezionare in modo razionale 8 
diverse sequenze di fHbp appartenenti alla variante 1 così da analizzare l‟ampiezza 
della protezione e della copertura che la sequenza di fHbp potrebbe garantire, indotta 
da GMMA derivanti da meningococco di sierogruppo W contenente fHbp v.1. Ciò che è 
stato osservato è stato che MenW GMMA overesprimenti fHbp v.1 inducevano anticorpi 
battericidi (in presenza di complemento umano) contro i ceppi isogenici test esprimenti 
tutte le diverse sequenze di fHbp. L‟attività battericida è risultata quindi dipendente 
dall‟espressione di fHbp nelle GMMA. I risultati hanno indicato che gli anticorpi indotti da 
MenW GMMA con over-espressa fHbp v.1 potrebbero garantire protezione contro 
un‟ampia varietà di sequenze di fHbp. 
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II Introduction 
 
2.1 Neglected diseases 
 
The neglected tropical diseases (NTDs) are a group of chronic, disabling, and disfiguring 
conditions that occur most commonly in the setting of extreme poverty, especially 
among the rural poor and some disadvantaged urban populations (1, 2). Today, the 
world's greatest concentration of poverty occurs in sub-Saharan Africa (SSA). According 
to a recent World Bank analysis, 51% of the population of SSA lives on less than 
US$1.25 per day, and 73% of the population lives on less than US$2 per day (Errore. 
L'origine riferimento non è stata trovata.) (1, 3). 
 
Table 1: World Bank data related to poverty in Sub-Saharan Africa. 
 
 
Gram-negative bacteria, as invasive Salmonella, Shigella and Meningitis, are the major 
causes of neonatal sepsis in developing countries, causing a wide range of diarrheal, 
respiratory and invasive diseases (3). Together these diseases are responsible for well 
in excess of 160 million clinical cases per year with more than 1 million deaths. 
Besides the progressive improvement of basic hygienic and sanitary conditions, 
immunization still represent the most cost effective and efficient way to control and 
possibly defeat infectious diseases. Unfortunately, vaccines are not yet available to 
prevent many major bacterial infections especially affecting developing countries. 
An ideal vaccine should be easy to administer, i.e. not requiring high professional skills 
for being administered, well tolerated, formulated for protecting against multiple 
pathogens (both for reducing cost and the number of injections per child), easy to 
manufacture, low cost (ideally lower than 1 $ per dose) and able to induce long-term 
protection. 
 
2.2 Meningitis 
 
Meningitis is inflammation of the meninges. The meninges is the collective name for the 
three membranes that envelope the brain and spinal cord (central nervous system), 
called the dura mater, the arachnoid mater, and the pia mater (Figure 1). The meninges' 
main function, alongside the cerebrospinal fluid is to protect the central nervous system.  
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Figure 1: Meningitis is an infection and inflammation of the fluid and three membranes (meninges) protecting 
the brain and spinal cord. The tough outer membrane is called the dura mater, and the delicate inner layer is 
the pia mater. The middle layer is the arachnoid, a web-like structure containing the fluid and blood vessels 
covering the surface of the brain. 
 
Meningitis is generally caused by infection of viruses, bacteria, fungi and parasites. 
Anatomical defects or weak immune systems may be linked to recurrent bacterial 
meningitis. 
Although viral meningitis is the most common, it is rarely a serious infection. It can be 
caused by a number of different viruses, such as mosquito-borne viruses. There is no 
specific treatment for this type of meningitis. In the vast majority of cases the illness 
resolves itself within a week without any complications. 
Bacterial meningitis is generally a serious infection. It is caused by four types of bacteria: 
 Haemophilus influenzae type b (Hib) was once the leading cause of bacterial 
meningitis in children, but new Hib vaccines have greatly reduced the number of 
cases of this type of meningitis. 
 Neisseria meningitidis (meningococcus) causes a blood and/or brain infection 
that affects mainly teenagers and young adults.  
 Streptococcus pneumoniae (pneumococcus) is the most common cause of 
bacterial meningitis in infants, young children and adults in the United States (5). 
 Listeria monocytogenes (listeria), found in unpasteurized cheeses, hot dogs 
and luncheon meats, can cross the placental barrier, and infections in late 
pregnancy may be fatal to the baby. 
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2.2 Neisseria meningitidis 
 
Neisseria meningitidis is an exclusively human, obligately aerobic, non sporulating, 
oxidase-positive, encapsulated or not, Gram negative pathogen, often diplococcal in 
form, about 0.6-1.0 µm in diameter (Figure 2) and recognized as the leading cause of 
meningitis and other forms of meningococcal disease such as meningococcemia, a life-
threatening sepsis, in children and young adults. 
 
Figure 2: The micrograph depicts the presence of aerobic Gram-negative Neisseria meningitidis diplococcal 
bacteria; Mag. 1150X. 
 
About 10% of adults are carriers of the bacteria in their nasopharynx (6, 7). 
It causes the only form of bacterial meningitis known to occur epidemically (8), mainly in 
Africa and Asia. 
N. meningitidis is spread through saliva and respiratory secretions for example during 
coughing, sneezing, kissing, and chewing on toys. It infects the cell by sticking to it with 
long thin extensions called pili and the surface-exposed proteins Opa and Opc and has 
several virulence factors. 
 
2.2.1 Biology and microbiology 
 
Neisseria meningitidis virulence depends on several factors as the iron sequestration 
mechanisms, the presence of endotoxin, the expression of surface adhesive proteins 
and of polysaccharide capsule, which is absent from N. gonorrhoeae, even though both 
organisms share about 90% homology at the nucleotide level. 
N. meningitidis strains are primarily classified in serogroups based on capsule type that 
they express (11). Further classification is based on major outer-membrane porins into 
serotypes and serosubtypes as well as LPS (lipopolysaccharide) into immunotypes (12). 
Moreover, MLST (multi-locus sequence typing) classifies strains into STs (sequence 
types) based on variations among seven housekeeping genes (13). 
Based on the sequencing of several genomes including those of strains MC58 
(serogroup B, ST-32) (14), Z2491 (serogroup A, ST-4) (15), FAM18 (serogroup C, ST-11) 
and NMB-CDC (serogroup B, ST-8), it has been discovered that the chromosome is 
between 2.0 and 2.2 megabases in size and contains 2,000 genes (16). The core 
meningococcal genome, encoding for essential metabolic functions, represents about 70% 
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of the genome, while large genetic islands are predicted to encode hypothetical surface 
proteins and virulence factor. 
N. meningitidis strains causing invasive disease are characterized almost always by the 
presence of a capsule, which is essential for the survival of the organism in the blood as 
it provides resistance to antibody/complement-mediated killing and inhibits phagocytosis 
(17). 
Genes responsible for generation of the capsule are located in a single chromosomal 
locus cps that is divided in three regions A, B and C. Region A encodes enzymes for the 
biosynthesis and polymerization of the polysaccharide, and regions B and C carry the 
genes responsible for its translocation from the cytoplasm to the cell surface (18). 
“Capsule switching” can occur and is the result of horizontal gene exchange and 
recombination in the locus of serogroup specific capsule biosynthesis genes (19) and is 
one of the mechanism of escape from vaccine-induced or natural protective immunity 
and a virulence mechanism shown by other encapsulated bacterial pathogens (e.g., 
Streptococcus pneumoniae). 
Although 13 meningococcal serogroups have been described (A, B, C, D, 29E, H, I, K, L, 
Y, W, X and Z), the majority of diseases is caused by organisms expressing one of six 
capsule types namely A, B, C, Y, W135 (described in Errore. L'origine riferimento non 
è stata trovata.) and X, differently distributed. 
 
Table 2: Predominant meningococcal serogroups with respective capsular structures and operon 
compositions. 
 
 
As reported in the table above, the main meningococcal capsular polysaccharides 
associated with invasive disease contain sialic acid [NANA (5-N-acetylneuramic acid) 
and cps region A of these serogroups harbours a set of conserved genes siaA, siaB and 
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siaC, responsible for the synthesis of sialic acid in the form of CMP-NANA, required for 
incorporation into the capsular polysaccharide. The fourth gene in this region, siaD, 
encodes a serogroup-specific polysialyltransferase involved in capsule polymerization 
(20, 21). In serogroup A, the locus contains four genes named mynA–D (22) responsible 
of biosynthesis of repeating units of N-acetyl-mannosamine-1-phosphate. The 
incorporation of Neu5Ac into meningococcal capsules allows the meningococcus to 
become less visible to the host immune system (23, 24) because of molecular mimicry. 
The most striking example is observed in the serogroup B capsule (25), an α(2–8)-linked 
sialic acid homopolymer identical in structure to the human fetal neural cell-adhesion 
molecule (NCAM). Such identity is responsible for the particularly poor immune 
response generated against serogroup B capsule by humans (26). 
The subcapsular cell envelope of N. meningitidis consists of an outer membrane (OM), a 
peptidoglycan layer, and a cytoplasmic or inner membrane (Figure 3). 
 
 
Figure 3: Cross-sectional view of the meningococcal cell membrane. 
 
The OM has an outside layer primarily composed of lipopolysaccharide (LPS), proteins 
and an inside layer composed of phospholipids (27) that contains proteins primarily 
responsible for regulating the flow of nutrients and metabolic products. The structure of 
peptidoglycan, recognizable by components of the innate immune system (28), consists 
of two layers (29) with different variations in the degree of cross-linking and O-
acetylation in the different strains of N.meningitidis. 
Meningococcal LPS (also referred to as LOS, lipo-oligosaccharide) (30, 31) has a 
conserved region (the inner core) composed of heptose (Hep) and 2-keto-3-deoxy-D-
manno-2-octulosonic acid (Kdo) attached to a lipid A moiety embedded in the outer 
membrane. Attached to Hep2Kdo2-Lipid A are variable sugar residues (the 
heterogeneous outer core), including the α-chain, which, in N. meningitidis and 
N.gonorrhoeae, is composed of glucose (Glc), galactose (Gal), N-acetylglucosamine 
(GlcNAc), N-acetylgalactosamine (GalNAc), and N-acetylneuraminic acid (NeuNAc), 
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added by glycosyltransferases encoded by Igt genes (32, 34) (Figure 4). Meningococci 
have been classified into 12 immunotypes based on the expression of LOS antigens 
detected by solid-phase radioimmunoassay, passive hemaglutination methods (36-38), 
and mobility on SDS-PAGE gels (36, 39). The α-chains of neisserial LOS mimics many 
human glycosphingolipids (40-42). Of the 12 LOS immunotypes expressed by 
meningococci (43), eight contain the lacto-N-neotetraose structure (Galβ1-4GlcNAcβ1-
3Galβ1-4Glc), which is common to the human I erythrocyte antigen. 
 
 
Figure 4: Schematic diagram showing structural organization of N. meningitidis LPS and some important 
determinants of immunotypes. The membrane-located part of meningococcal LPS comprises lipid A bound to two 
KDO and two heptose (HepI and HepII) moieties. Extended from the membrane are the structurally variable α- and β-
chains of LPS. The different immunotypes of LPS are determined by variations both in the HepI α-chain extensions 
(Glc, Gal, GlcNAc, Gal and sialic acid) and the HepII β-chain extensions (GlcNAc, PEA and Glc). These arise as a 
result of phase variation in a number of genes shown and account for the antigenic variation of meningococcal LPS 
(34). Phosphatidylethanolamine (PEA) may be added at position 3 or 6 on HepII by two distinct enzymes encoded by 
lpt3 and lpt6 (35). The α-chain structures of the L3, L7 and L8 immunotypes are indicated. LNnT and sialylation: the 
immunotypes L7/L9, L2/L4/L5 contain identical α-chains terminating in LNnT (Gal-GlcNAc-Gal-Glc structure bound to 
HepI) which can be sialylated. The L7 immunotype, found in serogroup B and C isolates, refers to the immunotype 
lacking sialic acid, whereas L3 is sialylated. Phase variation of the lgtA gene gives rise to the immunotype L8, which 
cannot be sialylated (34). 
 
Meningococcal LOS plays a role in the adherence of the meningococcus (32) and in 
activation of the innate immune system (33). It binds to a series of host transfer 
molecules and receptors on monocytic and dendritic cells of the innate immune system, 
including LPS-binding protein (LBP), CD14, and myeloid differentiation protein 2 (MD2), 
part of the Toll-like receptor 4 (TLR4) (44, 45) complex. This triggers the secretion of 
various cytokines (46) (including IL-6 and TNF-α ). There is a direct correlation between 
LPS levels and severity of meningococcal disease (47, 48). In addition, LOS also plays 
an important role in resistance to other host defenses. Meningococci are resistant to 
cationic antimicrobial peptides (CAMPs) due to the lipid A phosphoethanolamine 
structures present on lipid A head groups. CAMPs, present in macrophages and 
neutrophils, are key components of the innate immune responses through their 
nonoxidative killing action and their signaling functions (49). 
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N. meningitidis strains express a number of surface and secreted proteins that bind to 
human molecules. The adhesive properties of capsulate N. meningitidis are mediated by 
major and minor adhesins. The first group is characterized by pili and opacity proteins, 
Opa and Opc. Meningococcal pili (50), composed of two major pilin families, undergo 
both phase and antigenic variation and extend several thousand nm beyond the capsule 
initiating the binding to epithelial cells (51). Opc is only expressed by N. meningitidis and 
encoded by a single gene. Opa proteins, expressed by both meningococci and 
gonococci, encoded by multiple genes and interact with multiple members of the 
CEACAM (carcinoembryonic antigen-related cell-adhesion molecule) family (52) that, 
during inflammation, are expressed at high level, facilitating Opa interactions and 
therefore cellular attachment and invasion. 
Minor adhesion are molecules expressed at low levels in vitro, but that may be 
upregulated in vivo but their potential roles in pathogenesis remain to be fully defined: 
NadA (neisserial adhesinA), NhhA (Neisseria hia homologue A), App (adhesion and 
penetration protein), and MspA (meningococcal serine protease A) (53). 
Iron-binding proteins (HmbR (hemoglobin), TbpA and TbpB (transferrin), HbpA and 
HbpB (lactoferrin), HpnA and HpnB (hemoglobin-haptoglobin complex)) enable 
meningococci to acquire iron, a crucial growth factor during colonization and disease (54, 
55). 
Neisserial porins, PorA and PorB, although not considered adhesins, interact with 
numerous human cells and proteins. Through them small hydrophilic nutrients diffuse 
into the bacterium via cation or anion selection. PorB is a major OM porin that inserts in 
membranes, induces Ca2+ influx and activates TLR2 and cell apoptosis (56). PorA is a 
major component of OM vesicle-based vaccines and a target for bactericidal antibodies 
(57). 
 
2.2.2 Epidemiology 
 
The global incidence of meningococcal disease changes in relation to geographical 
areas; worldwide, 500,000-1,200,000 invasive meningococcal diseases (IMD) occur 
each year, with 50,000-135,000 deaths (58, 59). Low socioeconomic status and immune 
deficiencies contribute to meningococcal infection, especially in infants and adolescents, 
particularly vulnerable because of the disappearance of maternal antibodies early in life 
and the high rate of nasopharyngeal colonization (60, 61). The serogroups causing IMD 
vary geographically for differences in population immunity and environmental factors 
(Figure 5). Before introduction of the MenA conjugate vaccine (2010) meningococcus 
serogroup A (MenA) occurred in Africa with incidence ranges between 10 and 1000 
cases per 100,000 inhabitants and year during epidemics, whereas serogroups B 
(MenB), C (MenC) and Y (MenY) are predominant in the other continents, including 
Europe, North America and Australia (60, 62) with incidence ranges between 0.3 and 3 
cases per 100,000 inhabitants/year (61). 
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Figure 5: Global N. meningitidis serogroup distribution. 
 
N. meningitidis is unique among the major bacterial agents of meningitis in that it causes 
epidemic as well as endemic (sporadic) disease. The area which extends from Ethiopia 
to Senegal, described by Lapeyssonnie as the African “meningitis belt” (63) (Figure 6) 
continues to have major outbreaks of meningococcal disease (200, 201). During African 
epidemics, attack rates can reach 1 000 cases/100 000 population (202). In the largest 
meningococcal epidemic outbreak recorded, over 300 000 cases and 30 000 deaths 
occurred in sub-Saharan Africa in 1996–97 due to serogroup A N. meningitidis (200). 
MenA was responsible for the majority of cases until the introduction of the group A 
conjugate vaccine in 2010, while meningococcus serogroup W (MenW) predominated 
between 2010 and 2014 (62). Although cases caused by MenC were rare in Africa, in 
2013 and 2014 two outbreaks due to a novel strain of MenC were reported in Nigeria 
and Kebbi, respectively and it was identified among the majority of disease causing 
isolates in 2015 (64). Moreover, during 2006-2010 outbreaks of MenX were described in 
Niger, Togo, Kenya, Uganda, and Burkina Faso (65). 
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Figure 6: A. The sub-Saharan African meningitis belt. Source: CDC website, NCID, Travelers’ health. B. The 
sub-Saharan serogroup distribution (circle diameter is proportional to the number of cases identified). Source 
WHO, weekly meningitis bulletin. 
 
In Europe, MenB is the main cause of IMD, followed by MenC and MenY (62). In 
countries with established MenC vaccination programs, the incidence of MenC disease 
has significantly declined (60, 62). In comparison with the US, IMD caused by MenY is 
rare in Europe. However, an increase in this serogroup has been reported in recent 
years, particularly in the Nordic European countries (66). 
The dynamic nature of meningococcal epidemiology is due to a variety of factors: age, 
with the highest rates occurring in infants (67); lack of serum bactericidal antibodies 
(SBA) (68, 69); low socioeconomic status (67,70–72); asplenia, genetic polymorphisms 
or deficiencies in components of the innate immunesystem, and HIV infection (73–81); 
environmental and behavioral risk factors such as active and passive smoking, bar and 
pub patronage, intimate kissing, and university dormitory attendance (82-91); recent or 
concomitant upper respiratory infection, including influenza (92-97); climactic conditions 
(98) and crowding (99). 
Other factors involved in dynamics of meningococcal epidemiology are related to the 
antigenic variability that occurs mainly through horizontal gene transfer, which allows the 
organism to acquire large DNA sequences. The meningococcus also uses gene 
conversion, which is autologous recombination and does not require the acquisition of 
DNA from another strain (100, 101). N. meningitidis is also capable of varying its 
antigenic profile through variable gene expression and phase variation, which can occur 
through slipped-strand mispairing of variable number tandem repeats, variation in poly-C 
tracts, and use of insertion sequences (102-106). Capsular switching is the mechanism 
by which N. meningitidis can change its capsular phenotype. It occurs through horizontal 
gene transfer and is detected by identifying strains that are related genetically as 
defined by, for example, MLST (multi-locus sequence typing) but express different 
capsular polysaccharide. Capsular switching is presumed to occur during co-
colonization of the pharynx with at two or more meningococcal strains (203, 204). 
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Meningococcal outbreaks can be started or sustained by capsular switching, which is 
believed to allow immunologic escape from the original serogroup (107-110). Capsular 
switching is believed to have been at least in part responsible for a serogroup W 
outbreak that occurred in 2000 in Mecca, Saudi Arabia, with subsequent global spread 
of the epidemic strain (111). 
 
2.2.3 Pathogenesis 
 
Meningococci that are transmitted by aerosol or contact with secretions colonize upper 
respiratory mucosal surfaces (e.g., the nasopharynx), may spread to adjacent mucosal 
surfaces (e.g., lower respiratory tract), and may invade epithelial surfaces and gain 
access to the bloodstream to produce systemic and focal infections (112). Acquisition of 
meningococci can lead to colonization (carriage), and under certain circumstances result 
in invasive disease (113-118). 
Carriage is an immunising event leading to protective immunity against the organism 
(119). N. meningitidis colonises 8–25% of healthy individuals; the duration of 
meningococcal carriage can vary from days to many months (115-117). Adhesion to 
mucosal surface is an essential step in the establishment of a carrier state. Once 
meningococci penetrate the mucus barrier of the upper respiratory tract and attach to 
human epithelial cells, a series of interactions take place that result in a microcolony 
formation (114) (Figure 7). 
 
 
Figure 7: Events in acquisition and carriage of N meningitidis (A), N meningitidis attachment (B), microcolony 
formation (C), and colonisation (D) at nasopharyngeal mucosal surfaces. 
 
Adhesion to epithelial cells of the nasopharynx is mediated by Type IV pili (120). They 
are multimeric proteins, with PilE and PilV that are involved in adhesion to host cells and 
recently shown to activate β2-adrenergic receptor (β2-AR), promoting the endothelial 
signaling events enabling Neisseria meningitidis translocation through the brain 
endothelium (121, 122). The mechanism of Type IV pili adhesion has been further 
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elucidated by Bernard et al. who identified CD147, a member of the immunoglobulin (Ig) 
superfamily, as receptor for PilE and PilV-mediated adhesion to human brain or 
peripheral endothelial cells and shown the role of CD147 in vascular colonization by 
meningococci (123). 
The second step in meningococcal colonization is mediated by the opacity proteins, 
Opa, and Opc, with a typical integral membrane protein structure, which bind to 
carcinoembryonic antigen cell adhesion molecule (CEACAMs) receptor and extracellular 
matrix components, respectively. Additional antigens having a role in adhesion are 
NhhA (Neisseria hia/hsf homologue), a trimeric autotransporter with homology to Hia 
and Hsf adhesins of Haemophilus influenzae, App (Adhesion and penetration protein, 
homologous to Haemophilus Hap) and NadA (Neisseria adhesin A), a trimeric 
autotransporter belonging to the Oca family (Figure 8). 
 
 
Figure 8: Neisseria meningitidis outer membrane proteins involved in colonization. App (adhesion and 
penetration protein); Type IV pili; Opc (opacity protein C); NhhA (Neisseria hia/hsf homologue); NadA 
(Neisseria adhesin A). 
 
Meningococci can cross mucosal surfaces, enter the bloodstream and produce a 
systemic infection. Once access to the bloodstream is obtained, meningococci may 
multiply rapidly to high levels. Meningococci may also translocate across the blood-
meningeal barrier, proliferate in the CNS and cause meningitis (124). 
Major meningococcal contributors that influence the ability to cause invasive 
meningococcal disease include: capsular polysaccharide, other surface structures [pili, 
OMPs (e.g. PorA, PorB, Opa, Opc), lipooligosaccharide (LOS)] and the genotype. 
Resistance to complement-mediated lysis and phagocytosis is determined by the 
expression of the capsule and lipooligosaccharide (125). Meningococcal endotoxin 
released in outer membrane blebs also plays a major role in the inflammatory events of 
meningococcemia and meningococcal meningitis (126). 
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2.2.4 Neisseria interaction with complement components 
 
Within the blood stream, meningococci produce a strong inflammatory response and 
activate the complement and the coagulation cascades (Figure 9). 
 
 
Figure 9: Meningococcal entry into and survival within the vasculature 
Capillaries in close proximity to mucosal epithelial tissues are a possible point of entry into the blood for N. 
meningitidis. In vivo, meningococci initially encounter the basolateral surface of endothelial cells and need to traverse 
in a basal to apical direction to enter the vasculature. The in vitro studies, however, do not allow easy examination of 
basal interactions as cultured cells present their apical surfaces to the media. Both integrins and HSPGs are known to 
be expressed on the basolateral surface of endothelial cells and, hence, are likely targets for vascular penetration. 
However, it should be noted that these receptors are also expressed apically and are also probably involved in the 
exit from the bloodstream. Once in the blood, only capsulate meningococci appear to survive; whether acapsulate 
bacteria arising naturally can survive in any microenvironment is not known. In addition, meningococci are able to bind 
to a number of negative regulators of complement such as C4bp, factor H and vitronectin. Acquisition of such factors 
could lead to decreased complement-mediated killing in vivo. Interactions with vascular cells via protein adhesins and 
their cognate receptors and via LPS–TLR4 provoke an inflammatory response leading to cytokine release and cellular 
damage. This could increase further cell barrier penetration and leakage, which accounts for the damage and clinical 
symptoms observed during meningococcal sepsis, typified in latter stages by a petechial rash. LPS has also been 
shown to be toxic for human endothelial cells in vitro (145). 
 
The lipid A moiety of LPS is the active component responsible for eliciting the 
inflammatory response associated with meningococcal sepsis. As already described, 
LPS induces the release of several cytokines, including IL-6 and TNF-α (tumour 
necrosis factor-α), as well as chemokines, ROS (reactive oxygen species) and NO, 
acting in part through TLR (Toll-like receptor) 4 (127, 128). Natural LPS variants lacking 
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a single acyl chain engage less well with TLR4, yet can cause clinical disease and so 
may be better placed to evade the innate immune system (129). 
In the blood, N. meningitidis encounters numerous host killing mechanisms, including 
antibody/complement-mediated lysis, as well as opsonophagocytic killing. Disruption of 
genes associated with capsule and LPS synthesis results in an increase in 
meningococcal sensitivity to serum killing, indicating the importance of these 
polysaccharides for survival in the blood (130). 
Negative regulators of complement can be recruited by meningococci to promote their 
survival. Factor H is recruited by fHbp (factor H-binding protein; also named GNA1870), 
a 27 kDa lipoprotein which is expressed by all meningococcal strains and which 
promotes serum resistance (131). The porin PorA of meningococci can also bind a 
complement regulator, C4bp (C4-binding protein), and influence serum resistance. 
However, capsule may inhibit C4bp binding to PorA (132). It has been suggested that 
both PorA and PorB may be involved in bacterial uptake via re-arrangement of the 
cytoskeleton (133). Porins may also act via TLR2 as an adjuvant leading to the 
stimulation of B-cells (134). It has also been demonstrated that PorB has an 
antiapoptotic effect on epithelial cells, by localizing in the mitochondrial compartment, 
enhancing survival of the cell upon apoptotic stimuli (135). Porins therefore appear to 
have multiple roles in meningococci from aiding not only colonization, but also survival in 
the blood. 
Besides facilitating entry into the vasculature, some bacterial adhesins may also function 
directly in resisting complement-mediated killing. Vitronectin inhibits the formation and 
insertion of a MAC (membrane attack complex) into bacterial membranes. In binding 
directly to vitronectin, Opc-expressing bacteria are able to resist serum-mediated killing 
(136). Thus meningococci have the means to interact with several regulators of the 
complement pathways which could lead to increased bacterial survival in the blood. 
N. meningitidis can bind to and influence cells within the vasculature. Peripheral blood 
mononuclear cells from individuals immunized with a range of outer membrane proteins 
of N. meningitidis have a higher proliferative response to Opa than to other neisserial 
proteins (137). 
Another study demonstrated a suppressive effect on T-cell activation and proliferation in 
response to Opa-containing meningococcal OMV preparations (138). However, no such 
deleterious effects of Opa containing OMVs used as vaccines have been reported (139). 
Recent studies have also shown Opa-independent proliferation of T-cells in the 
presence of N. meningitidis (140).Thus the influence of Opa proteins on immune cells is 
unclear and whether the Opa receptor CEACAM1, which is expressed on stimulated T-
cells is involved, remains to be clarified. 
Engagement of CEACAM3 by Opa-expressing N. gonorrhoeae has been postulated to 
result in increased cell death of neutrophils during infection (141). Such interactions of 
N. meningitidis could also lead to evasion of killing by promotion of neutrophil cell death, 
but this remains to be investigated. 
Of the minor adhesins, NadA-expressing Escherichia coli adhere to and activate human 
monocytes and macrophages. 
In addition, purified NadA induced high levels of TNF-α and IL-8 production by these 
cells (142). Recent work has demonstrated that OMVs containing NadA possessed 
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enhanced immune stimulation compared with controls, suggesting an additional role for 
this adhesin in septic shock (143). 
In conclusion, it is widely believed that the key players in meningococcal survival in the 
blood include capsule and LPS. In addition, proteinaceous adhesins also play important 
roles in entry to and exit from the vasculature and may also modulate immune 
responses. 
 
2.3 Meningococcal vaccines 
 
Meningococcal infection continues to be reported worldwide, especially in the poorest 
countries, where universal vaccine coverage is absent and antibiotic resistance 
increasingly more common (9), (10). 
Meningococcal disease has the highest incidence in infants and children aged <4 years 
and adolescents (126). The early stages of disease can mimic viral infections such as 
influenza, but the disease course may be fulminant. Thus, it can be difficult to identify 
and treat the disease quickly. Rapid progression of the disease from bacteremia and/or 
meningitis to life-threatening septic shock syndrome or meningitis can occur within the 
first few hours after initial symptoms appear. Because of these parameters, prevention 
through vaccination is the best option for the control of this disease in a community. 
 
2.3.1 State of the art in developed countries 
 
Capsular polysaccharide vaccines to decrease A, C, Y, and W meningococcal disease 
were introduced in the 1970s and 1980s on the basis of Gotschlich, Gold, 
Goldschneider, and Artenstein‟s classic studies (205-207). These vaccines are safe with 
mild local adverse events, are effective (>85%) in children (older than 2 years) and 
adults, but are less immunogenic (C less than A) in children younger than 24 months, do 
not induce immunological memory and have little or no effect on nasopharyngeal 
carriage. 
A major advance in the prevention of meningococcal disease has been the development 
of meningococcal polysaccharide and protein conjugate vaccines and their introduction 
into the UK, other parts of Europe, Canada, and the USA (208-213). They have been 
shown to be very effective in preventing the disease in all age groups (144). These 
vaccines have been proven to be safe and effective, with infrequent and mild side 
effects, and immunogenic, particularly for children under 2 years of age whereas 
polysaccharide vaccines are not. Moreover they induce immunological memory, and 
decrease nasopharyngeal carriage and hence transmission of meningococci. In the UK, 
introduction of the C conjugate meningococcal vaccines in 2000 to all children and 
young adults greatly reduced the rate of serogroup C disease (90% vaccine eff 
ectiveness at 3 years for patients aged 11–18 years) (208). A major protective effect of 
the C conjugate vaccine is mediated through herd immunity (209, 155). 
The development of vaccines for serogroup B Neisseria meningitidis has been a 
challenge (145) because it is identical to the polysialic acid present in many human 
glycoproteins including the fetal neural cell adhesion molecule. As a consequence the 
serogroup B capsular polysaccharide is poorly immunogenic and safety concerns exist 
because it may induce the production of autoantibodies (146) therefore different 
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approaches based on protein antigens were used for the development of a vaccine 
against serogroup B disease. The first protein based MenB vaccine contained outer 
membrane vesicles (OMVs) which are obtained by detergent extraction of the bacterial 
biomass. They have been shown to be efficacious predominantly against the 
homologous strain that was used to generate the OMV. OMV protective ability resides 
mainly in the PorA antigen, an integral membrane protein with β-barrel structure and 
protruding loops made by variable sequences which constitute the main epitopes and 
which are the driving cause for the OMV vaccine strain specificity (147). This antigenic 
diversity of the meningococcal surface proteins has been the main limitation in the 
design of broadly protective meningococcal vaccines. The challenge of the antigen 
diversity has been addressed by two different approaches. 
The first one has been based on multiple antigens identified by „reverse vaccinology‟. 
The Reverse Vaccinology (RV) approach is one of the most powerful examples of 
biotechnology applied to the field of vaccinology for identifying new protein-based 
vaccines. RV combines the availability of huge amounts of genomic data, the analyzing 
capabilities of new bioinformatic tools, the application of high throughput expression and 
purification systems combined with serological screening assays, for a coordinated 
screening process of the entire genomic repertoire of bacterial pathogens, viruses or 
parasites, for selecting the best vaccine antigens (4). In particular, in silico methods are 
used for selecting surface-exposed or secreted proteins. After antigen selection, great 
effort needs to be applied in amplifying the genes, cloning them in suitable vectors for 
protein expression, purifying the proteins and testing them in vitro for functionality, or in 
vivo for their ability to raise protective antibodies. It is possible to select the best 
antigens on the basis of their ability to induce antibodies by serum bactericidal assay 
(SBA) (150). SBA is an assay for measuring functional quality of antibody (ability to kill a 
strain) and for Neisseria meningitidis it is a predictor for protection against invasive 
disease: specifically when measured with human sera and human complement a 
bactericidal titer of >4 predicts protection against invasive disease 
The application of RV to Neisseria meningitidis serogroup B represents the first success 
of this novel approach and resulted in the development of the first MenB vaccine 
licensed so far in Europe, Australia, Canada and Chile (4CMenB or Bexsero) (148, 149). 
It is a multi-component meningococcal B vaccine containing three surface-exposed 
recombinant proteins (fHbp, NadA and NHBA) and New Zealand strain detergent 
extracted outer membrane vesicles (NZ OMV) with PorA 1.4 antigenicity. The second 
approach has been based on the combination of two variants of the lipidated 
recombinant fHbp, (151). 
 
2.3.2 State of the art in Africa 
 
Quadrivalent conjugate vaccines based on the capsular polysaccharide are available 
against strains with capsular groups A, C, W and Y but are unlikely to be affordable for 
use in Africa. 
The use of unconjugate A, C or A, C, W polysaccharide vaccine has been adopted for 
many years in response to epidemics in the African meningitis belt, but they are not 
effective in children under the age of 2 years and they do not induce immunologic 
memory, so they have not prevented the continuous occurrence of epidemics. 
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In 2010, in Niger, Burkina Faso and Mali, a polysaccharide conjugate vaccine 
(MenAfriVac) has been first introduced for preventive mass immunization in the 
meningitis belt against serogroup A. Where the vaccine has been implemented, the 
number of reported cases caused by serogroup A strains has decreased dramatically, 
but group W and X strains remain a persistent problem because the protection is 
serogroup- specific. This observation underlines the need for an affordable vaccine that 
can provide broad protection against all three main serogroups causing meningitis in 
Africa and potentially against new disease-causing serogroups that may emerge in the 
region in the future (152). 
Vaccines based on GMMA (Generalized Modules for Membrane Antigens) from 
genetically engineered strains are under investigation (153). 
 
2.3.3 Native outer membrane vesicles (NOMV) and Generalized Modules for 
Membrane Antigens (GMMA) 
 
Gram-negative bacteria naturally release blebs from the outer membrane that were 
described as native or spontaneous Outer Membrane Vesicles (nOMV, sOMV) (153) 
and are attractive vaccine candidates as they present surface antigens in their natural 
context. 
While outer membrane vesicles (OMV) are obtained by detergent-extraction of 
homogenized bacteria, NOMV are obtained from culture supernatant and not treated 
with detergent (154). 
NOMV are derived from genetically engineered strains that contain modifications to 
increase immunogenicity by over-expression of antigens, like fHbp, and to increase 
safety, by deletion of lpxL1 in case of N. meningitidis. In detail, NOMV contain 
immunostimulatory components, especially lipopolysaccharide (LPS), so, for vaccine 
use, they need to be genetically detoxified reducing their reactogenicity by modifying 
lipid A, the endotoxic part of LPS, through deletion of late acyltransferase and 
generating a lipid A with a different acylation pattern (a penta-acylated lipid A in place of 
esa-acylated lipid A). 
In contrast, OMV are “detoxified” by the use of the detergent which removes the LOS. 
By avoiding the use of detergent protein, antigens like lipoproteins (as fHbp) that are 
detergent soluble, are maintained in NOMV, while they are also extracted by the 
detergent used to obtain the OMV. 
These NOMV are small spherical structures (Figure 10), 30-250 nm in diameter, which 
protrude from the outer membrane and then are released into the environment (156) 
and have a different composition than OMV (154). 
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Figure 10: Native Outer Membrane Vesicles (NOMV) generation. 
 
NOMV, in general, maintain the structure, composition, and orientation of the outer 
membrane, including the glycerophospholipids, outer membrane proteins and also 
contain soluble periplasmic proteins entrapped in the lumen (157, 158). 
Gram-negative bacteria, both pathogenic and non-pathogenic, secrete NOMV during 
constitutive growth, including E. coli, N. meningitidis, V. cholerae, Pseudomonas 
aeruginosa, Brucella melitensis, and Helicobacter pylori especially during the end of log 
phase growth and at sites of cell division (159). 
For the most part, NOMV are devoid of inner membrane and cytosolic constituents. 
NOMV have been discussed to have different biological roles, e.g. as delivery vehicles 
for active components to host cells, as nucleators in the formation of bacterial 
communities (biofilms) and as contributors to bacterial survival and virulence (158). 
As NOMV represent the envelope of Gram-negative bacteria and, thus, components on 
the NOMV that are recognized by the immune system resemble components on the 
surface of the bacterium (160), they have been tested for use as vaccines. Also, NOMV 
combine both adjuvant and carrier activity, increasing the low immunogenic properties of 
some protein antigens (161). It was also demonstrated that proteins from a foreign 
source can be localized in the outer membrane and periplasm of the parent cell and 
successively internalized into OMVs (162). 
NOMV have been shown to induce protection in mice against multiple pathogens, 
including Salmonella enterica serovar Typhimurium (163), Helicobacter pylori (164), 
Vibrio cholera (165, 166) and Shigella bodyii (167) or to elicit antibodies with in vitro 
bactericidal activity in mice and humans, e.g. for Neisseria meningitidis (168, 169). In 
addition, NOMV have been tested as veterinary vaccine candidate, e.g. against 
Edwardisiella tarda implicated in the death of see water fish (170). 
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The yield of NOMV is usually too low for a practical production. The application of 
NOMV as vaccines requires high production and efficient purification. Various methods 
have been employed to induce and increase blebbing of the outer membrane of Gram-
negative microbes. These techniques include inhibiting protein synthesis, autolytic cell 
wall degradation by lysine starvation, increasing growth temperature (even to 55oC), and 
the addition of sub-lethal doses of antibiotics (158, 161). However, all of these 
conditions alter the composition of OMVs so that they are no longer “native” and have 
not resulted in true high yield production. 
As mentioned above, NOMV preferentially form where the link between the inner and 
outer membrane is weakened. In the case of Shigella and Salmonella, this linkage can 
be genetically disregulated by deletion of tolR, a gene of the Tol-Pal pathway (153, 171). 
The Tol-Pal system is present in most of Gram-negative bacteria and is required to 
maintain outer membrane integrity. Thus, a mutation in any of tol-pal genes, and 
especially on tolR, confers a defect in other membrane integrity, resulting in a major 
release of outer membrane particles (171). In the case of N. meningitidis, which do not 
have a homologue of tolR, deletion of gna33, encoding a membrane bound lipoprotein 
with murein hydrolase activity, has been shown to impair the integrity of the cell 
envelope and increase the release (154). Vesicles derived from bacteria with a 
genetically upregulated outer membrane shedding have been termed generalized 
modules for membrane antigens or “GMMA” (153, 171). 
Widely used methods at research scale is the separation of NOMV from the bacterial 
cells by low speed centrifugation, in which the outer membrane particles remain in the 
culture supernatant, followed by collection of the particles by using ultrafiltration or 
ultracentrifugation (172). Also alternative methods have been tested, e.g. purification 
over a sucrose density gradient or gel filtration chromatography, resulting in vesicles of 
high purity and being relatively homogeneous. Those systems were based on differential 
diffusion and pore size exclusion, but the use of ammonium sulfate in the precipitation of 
OMVs before density gradient centrifugation can lead to artifacts (158). 
A method to collect GMMA from bacterial suspensions has been developed at large 
scale, by using two consecutive Tangential Flow Filtration steps: the first one with 0.22 
µm to separate the biomass from the GMMA, and the second one with a smaller cut-off 
for purifying and concentrating GMMA (153), thus resulting in an high yield process. 
 
2.3.3 Factor H binding protein 
 
One of the main protective meningococcal protein antigens is factor H binding protein 
(fHbp) (173). 
It was identified as a putative surface-exposed lipoprotein during the screening of the 
genome of serogroup B strain MC58, and then referred to as GNA1870 and, once 
purified as recombinant protein, recognized as very effective in inducing bactericidal 
antibodies (174, 175). 
FHbp is a major component of licensed meningococcal vaccines and vaccines under 
development (176-179). As mentioned above, a multicomponent vaccine containing 
fHbp (4CMenB or Bexsero) was approved by the European Medicines Agency (180). 
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FHbp is a 28 kDa surface-anchored lipoprotein that consists of two β-barrels connected 
by a short linker (181), a flexible peptide chain connects these domains to the outer 
membrane, to which it is anchored by an N-terminal lapidated cysteine (182-184). 
It is expressed by almost all N. meningitidis strains and all serogroups, even though the 
level of expression can significantly vary between different strains (175). 
Based on amino acid alignments, fHbp can be divided into three variant groups (v.1, 2 
and 3) (175) or, into 2 sub-families, with subfamily A corresponding to v.2 and v.3, and B 
corresponding to v.1 (185) (Figure 11). 
 
 
Figure 11: Phylogenetic tree showing the two different classifications of fHbp. Based on amino acid 
alignments, fHbp can be divided into three variant groups (v.1, 2 and 3) or, according to Pfizer nomenclature, 
into 2 sub-families, A corresponding to v.2 and v.3, and B corresponding to v.1. 
 
Variant 1 fHbps are expressed by approximately 60% of invasive meningococcal 
serogroup B isolates in North America and Europe, while variant 2 and variant 3 fHbps 
are present in around 30% and 10% of the isolates, respectively (186-188). 
Immunological cross-reactivity between these variant groups is limited, although cross-
reactivity is observed between v.2 and v.3 fHbps (175, 189). 
The % identity within each variant is between 89% and 100% for variant 1, and between 
variants like v.1 versus v.2 is around 60%, whereas the sequence identity between v.2 
and v.3 is around 80 %. 
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Each variant can be further divided into sub-variants, with small differences in their 
aminoacid sequence; each sub-variant is identified by a specific ID number. As reported 
by the public fHbp allel and peptide database on http://pubmlst.org/neisseria/fHbp/, the 
subvariant identified to date are 535 for variant 1, 196 for variant 2 and 187 for variant 3. 
Immunogenicity studies in mice conducted with recombinant fHbp showed that even 
within the same variant, different fHbp subvariants induce antibodies that have highest 
serum bactericidal activity against strains expressing the same subvariant (190). 
Furthermore, fHbp binds the negative human complement regulator factor H (fH) at high 
affinity, with a dissociation constant (Kd) for v.1, 2 and 3 fHbps with fH in the nanomolar 
range (181). Factor H is an abundant complement component (191) and the main 
negative regulator of the alternative complement pathway by acting as a cofactor for 
Factor I cleavage of C3b, and by accelerating the decay of the alternative pathway C3 
convertase, C3bBb (192). Recruitment of fH to the surface of N. meningitidis reduces 
complement activation and promotes immune evasion by the bacterium (193, 194). 
Antibodies raised against fHbp have two modes of action: first, they block factor H 
binding, so that the bacterium is no longer able to escape complement-mediated killing; 
second, antibodies bound to the surface of meningococcus activate the classical 
complement pathway (193). Factor H consists of 20 complement control protein 
domains (CCPs), and it has been shown that CCPs 6 and 7 (fH6-7) are sufficient for 
high affinity interactions between fHbp and factor H (181). The interaction between fHbp 
and factor H could have consequences for fHbp-based vaccines and affect their efficacy 
and immunogenicity. As factor H engages a large area of fHbp, immunogenic epitopes 
on fHbp might be hidden. Indeed, several bactericidal mAbs raised against fHbp 
recognise epitopes that include the factor H binding site (195-197), suggesting that 
some important epitopes might be concealed when factor H is bound to fHbp. For this 
reason, current vaccine candidates under investigation are fHbp mutant proteins that do 
not bind factor H. 
Also, down-regulation of complement activation by locally recruited factor H could impair 
antibody production and hence reduced immunogenicity. 
African strains currently express a limited number of fHbp peptides: a study analyzing 
106 invasive isolates from sub-Saharan Africa has shown that 100% of serogroup A 
isolates express fHbp v.1, peptide ID 4 or 5 that differ by one amino acid; the majority of 
X strains express fHbp v.1, and among them 63% express ID 74; fHbp v.1 ID9 is 
expressed by 20 % of serogroup W strains (190). However, among serogroup W strains 
the distribution of fHbp variants is quite heterogeneous (34% for v.1; 58% for v.2 and 8% 
for v.3); on the other hand, almost all W strains isolated in Africa express PorA subtype 
P1.5,2 (190). PorA is one of the main outer membrane porins in N. meningitidis. It is 
able to induce a strong and protective antibody response in the host but antibody 
responses are specific for the PorA subtype (Figure 12). 
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Figure 12: FHbp and PorA distribution in African strains. 
 
A single GMMA vaccine has been investigated for use against African strains from an 
African group W strain with PorA P1.5,2, engineered to over-express fHbp v.1. To 
increase safety of the vaccine strain, capsule biosynthesis genes have been deleted. In 
order to increase the tolerability of the vaccine, the genetic modification of 
Lipooligosaccharide (LOS) is necessary. The lipid A, portion of the LOS is responsible 
for the endotoxin activity of LOS. Inactivation of lpxL1 gene that encodes for late-
functioning acyltransferases of lipid A biosynthesis results in a penta-acylated lipid A, 
instead of the wild type hexa-acylated lipid A with lower toxicity, but retaining the 
adjuvant activity (198). To increase blebbing gna33 has been deleted (199). In mice, 
GMMA from this mutant elicited bactericidal antibodies against the homologous W strain 
and also cross protective antibodies against a panel of genetically diverse African A and 
X strains expressing fHbp v.1 sequence IDs that are predominant among current African 
isolates.  
This vaccine approach is promising and has the potential to provide protection against 
the majority of current invasive A, W and X strains circulating in sub-Saharan Africa, but, 
such a vaccine, it would not be expected to cover strains with a heterologous PorA 
compared to that included in the vaccine and expressing fHbp v. 2 or 3. 
The dynamic nature of meningococcal epidemiology in Africa and the resulting goal to 
expand protection have been the rational for test, as proof of concept, of over-
expression of a fHbp v.2 in serogroup W strain. Despite a relatively high conservation 
and small number of fHbp sequences expressed by current invasive strains from Africa, 
the distribution and prevalence may change in the future. Therefore an analysis of 
sequence coverage and of functionality of anti-fHbp antibodies induced by a GMMA 
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containing fHbp v.1, against strains expressing a broad panel of highly diverse fHbp 
sequences IDs, independent of their prevalence among existing isolates was performed. 
In order to reach this aim we first performed a comparative sequence/structure analysis 
of fHbp v.1, 2 and 3 analyzing the factor H binding site. Being a surface exposed portion 
of the molecule, the factor H binding site is subject to a balance between immunological 
selection and functional activity. Variations in the amino acids characterizing the factor H 
binding site could have a greater impact on the ability of antibodies to kill a particular 
strain than variations of amino acids that are “hidden” in the molecule and not accessible 
to antibodies Moreover, we selected as model a panel of diverse fHbp sequences based 
on diversity in the factor H binding site and overall diversity. On the basis of the first 
sequences selection we chose a panel of wild type strains (NOT serogroup B) that 
expressed a subset of the selected sequences and a panel of isogenic strains. To 
generate the last panel we selected one parent strain and generated eight mutants that 
we engineered to express eight highly diverse fHbp sequences. The advantage of this 
panel is that it allowed us to specifically investigate functional activity of antibodies 
against fHbp because the mutants only differed by the fHbp sequence that they 
expressed. The work demonstrate that fHbp expression level, fHbp sequence diversity 
and intrinsic susceptibility of killing play a key role contributing to susceptibility of strain 
killing by anti fHbp antibodies. 
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III Aim of thesis 
 
Current african A, W and X strains causing diseases are relatively conserved in terms of 
the fHbp variant and fHbp sequence that they express. Meningococcal epidemiology is 
dynamic and fHbp sequences that are expressed by African isolates could change in the 
future. The primary aim of the project is to systematically investigate and dissect the 
breadth and nature of fHbp sequence coverage by antibodies against fHbp. This is 
obtained by using a combination of bioinformatic tools as the basis to analyze functional 
antibody activity. The analysis can support the selection of fHbp sequences to be 
included in fHbp based vaccines for sub Saharan Africa. 
In detail, in order to reach this objective, by a comparative structure/sequence analysis 
of >700 existing and published individual fHbp IDs belonging to three variants, we 
selected fHbp sequences based on a gradually different level of differences in the factor 
H binding site. Applying these criteria, we selected a panel of wild type strains 
(belonging to serogroup A, C, W, Y or X) that expressed a subset of the selected fHbp 
sequences. Moreover, we applied the selection criteria to generate, starting from one 
parent strain, a panel of eight genetically defined isogenic strains that were engineered 
to express seven existing diverse fHbp v.1 sequences and one fHbp v.1/2 hybrid 
protein. The selected fHbp sequences were integrated into the genome and expressed 
under control of an IPTG inducible promoter. The advantage of this panel is that it 
allowed to specifically investigate functional activity of antibodies against fHbp because 
the mutant only differed by the fHbp sequence that they expressed. We used the strains 
as test strains in serum bactericidal assay to measure functional activity of antibodies 
raised against GMMA from a group W strain with over-expressed fHbp v.1 in the 
presence of baby rabbit or human complement. As proof of principle, We generated a 
mutant group W strain (based on the same parent wild type strain that was used for the 
mutant to over-express fHbp v.1) and engineered it to over-express the native fHbp v.2, 
which is predominant among African group W isolates, with deletion of capsule 
biosynthesis gene to increase safety of the vaccine strain, with deletion of lpxL1 to 
obtain strains with a reduced endotoxin activity and with deletion of gna33 to increase 
the release of GMMA. The vesicles obtained were then characterized based on the fHbp 
expression by western blotting, on reactogenicity by MALDI-TOF analysis of LipidA and 
Monocyte-Activation Test (MAT) assay, and on size, nucleic acid and soluble proteins 
content by HPLC-SEC MALLS. 
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IV Material and methods 
 
4.1 Bacterial growth conditions 
 
4.1.1 Escherichia Coli 
 
Escherichia Coli DH5α competent cells (Invitrogen) were used for plasmid cloning. 
Bacteria were grown at 30 or 37°C in Luria-Bertani Broth (LB) or LB agar plates with the 
addition of required antibiotics. Antibiotics used for selection were: ampicillin (100 
µg/mL); chloramphenicol (20 µg/mL); kanamycin (20 µg/mL); erythromycin (20 µg/mL); 
spectinomycin (50 µg/mL). 
 
4.1.2 Neisseria Meningitidis 
 
Parent wild type strain used for generating Neisseria meningitidis mutants is a 
serogroup W meningococcus, “NVGH 0385”, an ST11 strain isolated in 2004 in Ghana; 
the native fHbp expressed belongs to variant 2, and PorA subtype is P1.5,2. 
Neisseria meningitidis strains were grown at 37°C on GC agar plates or in liquid medium 
containing yeast extract, casaminoacids, and lactic acid, in a humid atmosphere 
containing 5% CO2. 
When required, antibiotics were added to plates and liquid medium at concentration of 5 
µg/mL for chloramphenicol, 80 µg/mL for kanamycin, 5 µg/mL for erythromycin, 60 
µg/mL for spectinomycin. 
 
4.2 Molecular biological DNA techniques 
 
4.2.1 Polymerase chain reaction (PCR) 
 
The Polymerase Chain Reaction (PCR) is used to amplify a gene or DNA fragment of 
interest. For subsequent cloning of the amplified fragment, restriction sites were added 
to the 5‟ end of both PCR primers. In addition, 6 bases were added at the 5‟ end of the 
primer. These additional bases provide an overhang for the restriction enzyme to bind 
the recognition site and cut efficiently. When selecting a restriction site(s) to add to the 
primers, it is important to determine which site(s) will be compatible with the selected 
vector, whether directional cloning is desired and, confirm that the recognition site(s) 
does not occur within the gene or DNA fragment. Primer sequences of 18 to 22 
nucleotides were created on the base of the template sequence, taking note of the 
melting temperatures. The optimal annealing temperature was initially determined by 
using a gradient between 55°C and 65°C for the annealing step. Lyophilized primers 
were obtained from Sigma Aldrich and dissolved with sterilediH2O to a final stock 
concentration of 100 μM. For use in a PCR a primer stock of 10 μM diluted in diH2O was 
used. The polymerases used were TAQ, Deep Vent and Pfu obtained from New 
England Biolabs. 
 
Taq DNA Polymerase (New England BioLabs) is a thermostable DNA polymerase that 
possesses a 5´→3´ polymerase activity and a 5´ flap endonuclease activity. 
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The conditions for PCR amplification with Taq DNA Polymerase are shown in Table 3. 
 
Table 3: Conditions for PCR amplification with Taq DNA Polymerase. 
Component 25 μl reaction 50 μl reaction Final Concentration 
10X ThermoPol Reaction Buffer 2.5 µl  5μl 1X 
10 mM dNTPs (NEB) 0.5 µl  1μl 200μM  
10 µM Forward Primer 0.5 µl  1 μl  0.2 µM (0.05–1 µM) 
10 µM Reverse Primer  0.5 µl  1 μl  0.2 µM (0.05–1 µM) 
Template DNA  variable variable  <1 µg 
Taq DNA Polymerase 0.125 µl 0.25 µl 1.25 units/50 µl  
Nuclease-free water to 25 µl  to 50 µl  
 
The thermal cycling conditions adopted for Taq DNA Polymerase-mediated PCR 
amplification are reported in Table 4. 
 
Table 4: Thermal cycling conditions for Taq DNA polymerase-mediated PCR. 
Step Temperature Time Number of Cycles 
Initial Denaturation 95°C  30 seconds 1 cycle 
Denaturation 95°C 15-30 seconds  
30 cycles Annealing 45-68°C 15-60 seconds 
Extension 68°C 1 minute per kb 
Final Extension 68°C  5 minutes 1 cycle 
Hold 4-10°C Indefinite 1 cycle 
 
Deep VentR DNA Polymerase (New England BioLabs) is a high-fidelity thermophilic 
DNA polymerase. The fidelity of Deep VentR DNA Polymerase is derived in part from an 
integral 3´→ 5´ proofreading exonuclease activity. Deep VentR is even more stable than 
VentR at temperatures of 95 to 100°C. 
Both Taq and Deep Vent polymerase were supplied with 10X ThermoPol Reaction 
Buffer, which contains a nonionic detergent to increase enzyme stability during longer 
incubations. 
The conditions for PCR amplification with Deep Vent DNA Polymerase are shown in 
Table 5. 
 
Table 5: Conditions for PCR amplification with Deep Vent DNA Polymerase. 
Component Volume(μl) Final Concentration 
ThermoPol Reaction Buffer (10X) 5μl 1X 
Deoxynucleotide (dNTP) (NEB) Solution Mix 
(10 mM) 
1μl 200μM 
Upstream Primer (10 μM stock) 0.5-2.5 μl 0.1-0.5 μM 
Downstream Primer (10 μM stock) 0.5-2.5 μl   0.1-0.5 μM 
DNA template variable  <1 µg 
Deep Vent DNA Polymerase 0.25-0.5 μl   0.5-1 unit 
Nuclease-Free Water to final volume of 50μl  
 
The thermal cycling conditions adopted for Deep Vent DNA Polymerase-mediated PCR 
amplification were reported in Table 6. 
 
Table 6: Thermal cycling conditions for Deep Vent DNA polymerase-mediated PCR. 
Step Temperature Time Number of Cycles 
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Initial Denaturation 95°C  2-5 minutes 1 cycle 
Denaturation 95°C 15-30 seconds  
20–30 cycles Annealing 55-65°C 15-30 seconds 
Extension 72°C 1 minute per kb 
Final Extension 72°C  5 minutes 1 cycle 
Hold 4-10°C Indefinite 1 cycle 
 
Pfu DNA Polymerase (Promega) is a thermostable enzyme that replicates DNA at 75°C. 
It catalyzes the polymerization of nucleotides into duplex DNA in the 5´→3´ direction in 
the presence of magnesium. The enzyme has a molecular weight of approximately 
90,000 daltons as estimated from the predicted amino acid sequence and exhibits 
3´→5´ exonuclease (proofreading) activity. Pfu DNA Polymerase is recommended for 
use in PCR and primer extension reactions that require high fidelity and it was used for 
self-priming PCR (Figure 13). In this reaction two DNA fragments were used as template 
that overlap for 30 bp. This allows the generation of a full-length DNA fragment by a self-
priming PCR followed by a PCR with primers annealing at the ends of the two fragments. 
 
Figure 13: Example of a SELF-PRIMING PCR. The two DNA pieces used as template in the PCR reaction 
overlap for 30 bp of N-term fHbp. This allows the generation of a full-length DNA fragment by a self-priming 
PCR followed by a PCR with primers (schematically represented by the black arrows) annealing at the 
external extremities of the DNA fragments 
 
The conditions for PCR amplification with Pfu DNA Polymerase are shown in Table 7. 
 
Table 7: Conditions for PCR amplification with PFU DNA Polymerase. 
Component Volume(μl) Final Concentration 
Pfu DNA Polymerase 10X Buffer with MgSO4  5μl 1X 
dNTP mix (NEB),10mM each 1μl 200μM each 
Upstream primer 5–50pmol  0.1–1.0μM 
Downstream primer 5–50pmol  0.1–1.0μM 
DNA template variable  <0.5μg/50μl 
Pfu DNA Polymerase (2–3u/μl) variable  1.25u/50μl 
Nuclease-Free Water to final volume of 50μl  
 
The thermal cycling conditions adopted for Pfu DNA Polymerase-mediated PCR 
amplification were reported in  
Table 8. 
 
Table 8: Thermal cycling conditions for PFU DNA polymerase-mediated PCR. 
Step Temperature Time Number of Cycles 
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Initial Denaturation 95°C  1–2 minutes 1 cycle 
Denaturation 95°C 0.5–1 minute  
25–35 cycles Annealing 42–65°C 30 seconds 
Extension 72–74°C 2–4 minutes 
Final Extension 72–74°C 5 minutes  1 cycle 
Soak 4°C Indefinite 1 cycle 
 
4.2.2 Colony PCR 
 
The colony PCR (for screening of E. coli colonies after transformation for uptake of 
plasmid with the correct insert(s) was performed using the same protocol as described 
for Deep VentR DNA Polymerase (New England BioLabs). A tiny part of the colony was 
picked using a pipette tip and place in the PCR tube. In PCR block to heat to 92°C for 1 
minute helps break open the cells and kills DNAses. The PCR reactions were separated 
by agarose gel electrophoresis. 
 
4.2.3 Agarose gel electrophoresis 
 
Gel electrophoresis is the standard lab procedure for separating DNA by size (e.g. 
length in base pairs) for visualization and purification. Electrophoresis uses an electrical 
field to move the negatively charged DNA toward a positive electrode through an 
agarose gel matrix. The gel matrix allows shorter DNA fragments to migrate more 
quickly than larger ones. Thus, it is possible accurately determine the length of a DNA 
segment by running it on an agarose gel alongside a DNA ladder (a collection of DNA 
fragments of known lengths). For a standard 1.2% Agarose Gel, 1.2 g of agarose were 
measured and agarose powder was poured into microwavable flask along with 100mL of 
1X Tris Acetate EDTA buffer (TAE) and heated for 1-3min (until the agarose is 
completely dissolved). Agarose solution was let cool down for 5min. 10 μL of 10,000X 
SYBR® Safe stain concentrate was added to 100 mL of agarose solution and mixed well. 
SYBR® Safe stain has been specifically developed for reduced mutagenicity, making it 
safer than ethidium bromide for staining DNA in agarose or acrylamide gels and the 
detection sensitivity with SYBR® Safe stain is comparable to that obtained with ethidium 
bromide. 
The gel was placed into a gel tray with the well comb in place and let solidify for 30 
minutes at roome temperature or at 4°C for 10-15 minutes. The gel and staining solution 
were covered from light by covering it with aluminum foil or by placing it in the dark. The 
gel was run using a running buffer appropriate to the SYBR® Safe gel stain formulation. 
No post-staining or destaining is required. GelPilot Loading Dye was added to each 
sample. 
It contains three tracking dyes (xylene cyanol, bromophenol blue, and orange G) for two 
purposes: 1) it provides a visible dye that helps with gel loading and will also allows to 
gauge how far the gel has run while you are running your gel; and 2) it contains a high % 
glycerol, so after adding it your sample is heavier than water and will settle to the bottom 
of the gel well, instead of diffusing in the buffer. 
Once solidified, the agarose gel was placed into the gel box (electrophoresis unit) and 
gel box was filled with 1xTAE until the gel was covered. A molecular weight ladder was 
loaded into the first lane of the gel. Samples were loaded into the additional wells of the 
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gel. The gel was run at 80-150V until the dye line was approximately 75-80% of the way 
down the gel (a typical run time is about 1-1.5 hours, depending on the gel concentration 
and voltage). DNA bands stained with SYBR® Safe DNA gel stain can be detected 
using a standard UV transilluminator, a visible-light transilluminator such as the Safe 
Imager™ blue-light transilluminator from Molecular Probes (S37102), or a laser-based 
scanner. Bound to nucleic acids, SYBR® Safe stain has fluorescence excitation maxima 
at 280 and 502 nm, and an emission maximum at 530 nm. 
In case of purification of DNA away from the agarose gel by Gel extraction kit (Qiagen) 
for later use, wavelength UV exposure should be for as short a time as possible to 
minimize damage to the DNA. 
For further manipulation, such as molecular cloning, the PCR reactions were purified 
using the PCR purification kit (Qiagen). 
 
4.2.4 DNA purification and quantitation 
 
The QIAquick PCR Purification procedure removes primers, nucleotides, enzymes, 
mineral oil, salts, and other impurities from DNA samples. Using a microcentrifuge or 
vacuum manifold, DNA ranging from 100 bp to 10 kb is purified. 
DNA fragments purified with the QIAquick system are ready for direct use in all 
applications, including sequencing, microarray analysis, ligation and transformation, 
restriction digestion, labeling, microinjection, PCR, and in vitro transcription. 
In detail, 5 volumes of PB (Binding Buffer: 5 M Gu-HCl and 30% isopropanol) were 
added to 1 volume of the PCR reaction and mix. 
A QIAquick column was placed in a provided 2 ml collection tube or into a vacuum 
manifold. To bind DNA, the sample was applied to the QIAquick column and centrifuged 
for 30–60 s. Flow-through was discarded and the QIAquick column was placed back in 
the same tube. To wash, 0.75 ml PE (Washing Buffer: 10 mM Tris-HCl pH 7.5 and 80% 
ethanol) were added to the QIAquick column and centrifuged for 30–60 s. The flow-
through was discarded and the QIAquick column was placed back in the same tube. The 
QIAquick column was centrifuged once more in the provided 2 ml collection tube for 1 
min to remove residual wash buffer. Each QIAquick column was placed in a clean 1.5 ml 
microcentrifuge tube. To elute DNA, 50 μl Buffer EB (10 mM Tris·Cl, pH 8.5) or water 
(pH 7.0–8.5) were added to the center of the QIAquick membrane and centrifuge the 
column for 1 min. For increased DNA concentration, 30 μl elution buffer were added to 
the center of the QIAquick membrane, the column is let stood for 1 min, and then 
centrifuged. 
The NanoDrop ND-1000 spectrophotometer uses a patented sample retention system 
that holds 1 µl of sample without the need for traditional containment devices such as 
cuvettes and capillaries. Using fiber optic technology and surface tension, the sample is 
held in place between two optical surfaces that define the pathlength in a vertical 
orientation. Direct coupling of the sample to the optics of the spectrophotometer 
removes interference caused by incident light and transmitted light passing through 
containment walls of traditional cuvettes, microcell cuvettes, and capillaries. Total 
measurement cycle time, including preparation and removal of the sample, is ~ 30 sec. 
The measurement and subsequent concentration calculation is volume independent. 
Once the instrument lever arm is lowered, the upper optical surface engages with the 
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sample, forming a liquid column with the path length defined by the gap between the two 
optical surfaces. During each measurement, the sample is assessed at both a 1-mm 
and 0.2-mm path, providing a large dynamic range of nucleic acid detection. The 
software automatically calculates the nucleic acid concentration. All measurements are 
automatically normalized to 340 nm. 
 
4.2.5 Enzymatic restriction of DNA 
 
Preparation of DNA for cloning is dependent upon restriction enzyme digestion to 
generate compatible ends. DNA templates used for restriction were plasmids or PCR 
fragments. In all cases, one or more restriction enzymes are used to digest the DNA 
resulting in either non-directional or directional insertion into the target vector. 
Enzymatic digestions were performed for 2 hours or overnight at 37°C using 1 μl 
enzyme/500-1000 ng DNA. Enzymes from New England Biolabs, were used at 
conditions reported in Table 9. 
 
Table 9: NEBuffer Activity/Performance Chart with Restriction Enzymes. 
Enzyme 
 
Recognition 
Sequence 
 
Supplied 
NEBuffer 
% Activity in 
NEBuffer 
Heat 
Inactivation 
Incubation 
Temperature 
XmaI C/CCGGG  CutSmart® Buffer 100 65°C  37°C 
XbaI T/CTAGA  CutSmart® Buffer 100 65°C  37°C 
NsiI ATGCA/T  NEBuffer 3.1 100 65°C  37°C 
NdeI CA/TATG  CutSmart® Buffer 100 65°C  37°C 
SpeI A/CTAGT  CutSmart® Buffer 100 80°C  37°C 
BamHI G/GATCC  NEBuffer 3.1 
CutSmart® Buffer 
100 No 37°C 
 
After restriction of the DNA, the fragments were purified using the PCR purification kit (Qiagen) 
or fragmehts were separated by Agarose gel electrophoresis and purified from the gel using the 
gel extraction kit (Qiagen). 
 
4.2.6 Gel extraction of DNA 
 
The QIAquick Gel Extraction Kit enables removal of nucleotides, enzymes, salts, 
agarose, ethidium bromide, and other impurities from samples, ensuring up to 80% 
recovery of DNA. Using a microcentrifuge or vacuum manifold, DNA ranging from 70 bp 
to 10 kb is purified from 1–24 samples. Purified DNA can be used, for example, in 
sequencing. 
DNA fragments purified with the QIAquick system are ready for direct use in all 
applications, including sequencing, ligation and transformation, restriction digestion, 
labeling, microinjection, PCR, and in vitro transcription. 
The DNA fragment was excised from the agarose gel with a clean, sharp scalpel. 
The gel slice was weighed in a colorless tube. 3 volumes Buffer QG (5.5 M guanidine 
thiocyanate (GuSCN) and 20 mM Tris HCl pH 6.6) were added to 1 volume gel (100 mg 
gel ~ 100 μl). The maximum amount of gel per spin column is 400 mg. For >2% agarose 
gels, 6 volumes Buffer QG were added and incubate at 50°C for 10 min (or until the gel 
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slice has completely dissolved). The tube was vortexed every 2–3 min to help dissolve 
gel. 
1 gel volume isopropanol was added to the sample and mixed. 
A QIAquick spin column was placed in a provided 2 ml collection tube or into a vacuum 
manifold. To bind DNA, the sample was applied to the QIAquick column and centrifuged 
for 1 min. The flow-through was discarded and the QIAquick column was placed back 
into the same tube. 
If DNA will subsequently be used for sequencing, in vitro transcription, or microinjection, 
500 μl Buffer QG were added to the QIAquick column and centrifuged for 1 min. 
The flow-through was discarded and the QIAquick column was placed back into the 
same tube. 
To wash, 750 μl Buffer PE (Washing Buffer: 10 mM Tris-HCl pH 7.5 and 80% ethanol) 
were added to QIAquick column and centrifuged for 1 min. 
The flow-through was discarded and the QIAquick column was placed back into the 
same tube. 
If the DNA will be used for salt-sensitive applications (e.g., sequencing, bluntended 
ligation), the column is let stand 2–5 min after addition of Buffer PE. 
The QIAquick column was centrifuged in the provided 2 ml collection tube for 1 min to 
remove residual wash buffer. 
The QIAquick column was placed into a clean 1.5 ml microcentrifuge tube. 
To elute DNA, 50 μl Buffer EB (10 mM Tris·Cl, pH 8.5) or water were added to the 
center of the QIAquick membrane and the column was centrifuged for 1 min. For 
increased DNA concentration, 30 μl Buffer EB were added to the center of the QIAquick 
membrane, the column was let stand for 1 min, and then centrifuged for 1 min. After the 
addition of Buffer EB to the QIAquick membrane, increasing the incubation time to up to 
4 min can increase the yield of purified DNA. 
 
4.2.7 Ligation of DNA fragments 
 
For ligation reactions T4 DNA Ligase (Invitrogen) was used to ligate DNA fragments. 
T4 DNA Ligase catalyzes the formation of phosphodiester bonds in the presence of ATP 
between double-stranded DNAs with 3´ hydroxyl and 5´ phosphate termini. The unique 
T4 DNA Ligase buffer optimizes ligation, which can be performed in 5 minutes. The 
conditions adopted for cloning are reported in Table 10. 
 
Table 10: Conditions adopted for the reaction of ligation. 
Component Blunt ends 
5X Ligase Reaction Buffer 4 μl 
Insert: Vector Molar Ratio 3:1 
Vector Ends 15-60 fmol 
Insert Ends 45-180 fmol 
Total DNA 0.1-1.0 μg 
Autoclaved distilled water to 20 μl 
Temperature 14°C 
Time 16-24 h 
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4.2.8 Neisseria genomic DNA prep 
 
Sigma‟s GenElute Bacterial Genomic Kit is used as a simple and convenient technique 
to isolate high quality DNA from Gram negative bacteria, as Neisseria meningitidis. 
The GenElute kit combines the advantages of a silica-based system with a microspin 
format and eliminates the need for expensive resins, alcohol precipitation, and 
hazardous organic compounds such as phenol and chloroform. Bacteria are first 
incubated with the appropriate enzymes to ensure efficient cell lysis and DNA release 
from the cells. The bacteria are lysed in a chaotropic salt-containing solution to ensure 
the thorough denaturation of macromolecules. The addition of ethanol causes the DNA 
to bind when the lysate is spun through a silica membrane into a microcentrifuge tube. 
After washing to remove the contaminants, the DNA is eluted in 200 μL of a Tris-EDTA 
solution. The expected yield of genomic DNA will vary depending on the cell density of 
the bacterial culture and the bacterial species and strain used. 
DNA purified with the GenElute kit has an A260/A280 ratio between 1.6 and 1.9 and can 
be up to 50 kb in length. An absorbance of 1.0 at 260 nm corresponds to approximately 
50 mg/mL of double-stranded DNA. 
This DNA purified in this way is ready for downstream applications such as restriction 
endonuclease digestions, PCR, and Southern blots. 
In detail, 1.5 mL of Neisseria meningitidis cells pellet of an overnight bacterial broth 
culture was harvested by centrifuging for 2 minutes at 12,000–16,000 × g. The culture 
medium was completely removed and discarded. The pellet was resuspended 
thoroughly in 180 μL of Lysis Solution T. 
If RNA-free genomic DNA was required, 20 μL of RNase A Solution were added, mixed 
and incubated for 2 minutes at room temperature. 
20 μL of the Proteinase K solution were added to the sample, mixed and incubated for 
30 minutes at 55 °C. 200 μL of Lysis Solution C were added and vortexed thoroughly 
(about 15 seconds), and incubated at 55 °C for 10 minutes. 
A homogeneous mixture is essential for efficient lysis. 
500 μL of the Column Preparation Solution were added to each pre-assembled 
GenElute Miniprep Binding Column seated in a 2 mL collection tube and centrifuged at 
12,000 × g for 1 minute. The eluate was discarded. 200 μL of ethanol (95–100%) were 
added to the lysate and mixed thoroughly by vortexing for 5–10 seconds. A 
homogeneous mixture is essential. The entire contents of the tube was transferred into 
the binding column and centrifuged at ≥ 6500 × g for 1 minute. Discard the collection 
tube containing the eluate was discarded and the column was placed in a new 2 mL 
collection tube. 500 μL of Wash Solution 1 were added to the column and centrifuged for 
1 minute at ≥ 6500 × g. The collection tube containing the eluate was discarded and the 
column was placed in a new 2 mL collection tube. 500 μL of Wash Solution were added 
to the column and centrifuged for 3 minutes at maximum speed (12,000–16,000 × g) to 
dry the column. The column must be free of ethanol before eluting the DNA. The column 
was centrifuged for an additional 1 minute at maximum speed if residual ethanol is seen. 
Finally, the collection tube containing the eluate was discarded and the column was 
placed in a new 2 mL collection tube. 
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200 μL of the Elution Solution were pipetted directly into the center of the column and 
centrifuged for 1 minute at ≥ 6500 × g to elute the DNA. To increase the elution 
efficiency, the sample was incubated for 5 minutes at room temperature after adding the 
Elution Solution and then centrifuged. 
The yield can be improved by 20–50% when performing a second elution. 
The eluate contains pure genomic DNA. For short-term storage of the DNA, 2–8 °C is 
recommended. For longer-term storage, –20 °C is recommended. Avoid freezing and 
thawing, which causes breaks in the DNA strand. The Elution Solution will help stabilize 
the DNA at these temperatures. 
 
4.2.9 Plasmidic Miniprep 
 
The protocol of Plasmid DNA Purification using the QIAprep Spin Miniprep Kit and a 
Microcentrifuge is designed for purification of up to 20 μg of high-copy plasmid DNA 
from 1–5 ml overnight cultures of E. coli in LB medium. 
The pelleted bacterial cells were resuspended in 250 μl Buffer P1 (50 mM Tris-HCl pH 
8.0, 10 mM EDTA and 100 μg/ml RNaseA) and transferred to a microcentrifuge tube. 
250 μl Buffer P2 (200 mM NaOH and 1% SDS) were added and the tube was mixed 
thoroughly by inverting 4–6 times. 350 μl Buffer N3 (4.2 M Gu-HCl and 0.9 M potassium 
acetate pH 4.8) were added and the tube was mixed immediately and thoroughly by 
inverting 4–6 times. The samples were centrifuged for 10 min at 13,000 rpm (~17,900 x 
g) in a table-top microcentrifuge. 800 μl of the supernatant were added to the QIAprep 
2.0 spin column by pipetting. The samples were centrifuged for 30–60 s and the flow-
through was discarded. The QIAprep 2.0 spin column was washed by adding 0.5 ml 
Buffer PB (Binding Buffer: 5 M Gu-HCl and 30% isopropanol) and centrifuged for 30–60 
s. The flow-through was discarded. The QIAprep 2.0 spin column was washed by 
adding 0.75 ml Buffer PE (Washing Buffer: 10 mM Tris-HCl pH 7.5 and 80% ethanol) 
and centrifuging for 30–60 s. The flow-through was discarded and the sample was 
centrifuged at full speed for an additional 1 min to remove residual wash buffer. The 
QIAprep 2.0 column was placed in a clean 1.5 ml microcentrifuge tube. To elute DNA, 
50 μl Buffer EB (10 mM Tris·Cl, pH 8.5) or water were added to the center of each 
QIAprep 2.0 spin column, let stand for 1 min, and centrifuged for 1 min. Plasmid DNA 
was stored at -20°C for long term or 4°C for short term. 
 
4.2.10 Escherichia Coli transformation 
 
The transformation of E. coli is performed using chemically competent cells (subcloning 
efficient E.coli DH5α, Invitrogen). The appropriate amount of competent cells was 
thawed on ice. 50 µl aliquots of cells were put into pre-chilled tubes. 5-10 µl of a ligation 
reaction mix or 5 ng of pure plasmid DNA were added to each tube and mixed gently. 
The tubes were incubated on ice for 30 minutes. The cells were heat shocked for 45 
seconds at 42°C. The tubes were placed immediately on ice for 2 min. 950 µl of LB 
medium were added to each tube and incubate for 1 hour at 37°C.The cultures were 
transferred to 1.5 ml microcentrifuge tubes and centrifuged for 1 min at 6000 rpm. 950 µl 
of the supernatant were removed and the pellet was resuspended. The suspension was 
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suspended on a LB agar plate containing the appropriate antibiotic. The plates were 
incubated overnight at 37°C.  
 
4.2.11 Neisseria Meningitidis transformation 
 
The meningococcus strain to be transformed was plated on a GC agar plate from a 
glycerol stock kept at -80°C. After ON growth at 37°C, 5% CO2, 5 to 10 single colonies 
were transferred onto a fresh GC agar plate in a single spot. 1-3 µg of DNA in a 
maximum volume of 20 µL used to transform meningococcus was directly dropped onto 
bacteria, and then mixed with a 1µL loop. The plate was incubated at 37°C, 5% CO2 for 
5-6 hours. After incubation bacteria were collected, resuspended in 100 µL of PBS 1X, 
plated onto a fresh GC agar plate containing the appropriate antibiotics to select the 
colonies that have taken up the DNA and express the appropriate resistance. Plates 
were incubated at 37°C, 5% CO2 for 18-36 hours, or until transformants appeared big 
enough to be subcultures. Single colonies were subcultured on fresh GC agar plates 
with antibiotics and incubated at at 37°C, 5% CO2 for 18-36 hours. Glycerol stocks of 
the colonies were prepared. 
 
4.2.12 Preparation of bacterial glycerol stocks for long term storage 
 
For a Glycerol stock preparation, sterile pipet tips and sterile microfuge tubes were 
used. Few colonies of the clone of interest were picked off the plate and added to a 
sterile 1.5 ml microfuge tube containing 0.5 ml of sterile liquid meningococcal growth 
mediun with 20% (v/v) glycerol solution. The solution was mixed by inversion and 
freezed on dry ice or directly placed into the -80°C freezer. The tube was labeled with 
clone informations. 
To recover the bacteria the frozen surface of the culture was scraped with a sterile 
inoculating needle, and then the bacteria that adhere to the needle were immediately 
streaked onto the surface of the plate. The glycerol stocks should not freeze/thaw too 
many times. Placing the glycerol stock on dry ice while streaking onto the plate will 
prevent it from thawing completely and will improve the shelf life. 
 
4.3 Generation of Neisseria Meningitidis mutants 
 
4.3.1 Overview of definitions and objectives of mutations in Neisseria meningitidis 
genome 
 
Gene to delete Aim of mutation Reference 
gna33 To improve the production of outer 
membrane vescicules production, interfering 
with biosynthesis of cell wall 
Adu Bobie et al. Infect. 
Immun. 2004, 72(4);  
1914-1919 (214) 
lpxL To remove an enzyme responsible of last 
step of lipopolysaccaride synthesis, reducing 
its tossicity 
Koeberling et al. 2008. J 
Infect Dis 19:262-70 
(215) 
Genes 
responsible of 
To make the strain sensitive to serum and 
human blood and so non-virulent 
Kahler et al. 1998; 
Mackinnon et al. 1993 
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capsule 
biosynthesis  
(syn or ctr) 
(216) 
Vogel et al. 1996, 1997 
(217) 
Gene to 
overexpress 
  
fHbp To increase fHbp expression on outer 
membrane in order to improve the 
immunogenicity of outer membrane 
vescicules vaccine 
Koeberling et al., CVI 
2011(218) 
 
Inserts and plasmids used to generate modifications in the host 
 
Inserts  Plasmids 
Spectinomycin resistance 
(spec) 
pSL1190 
Erythromycin resistance (erm) pBluescript 
Kanamycin resistance (kan) pUC18 or pUC19 
Chloramphenicol resistance 
(cat) 
pSL1190 or pBluescript 
Factor H binding protein (fHbp) pSL1190 or pBluescript 
 
4.3.2 Plasmids and primers 
 
Table 11: List of plasmids used in this study. 
Plasmid name Resistance Description Reference 
psynX Chloramphenicol 
and ampicillin 
This plasmid is an 
expression vector that 
contains an upstream 
flanking region that 
allows homologous 
recombination with 
genes of the capsule 
biosynthesis locus 
and a portion of fHbp 
gene that allows 
recombination with 
fHbp in Neisseria 
genome under the 
control of a strong 
synthetic promoter 
designed at GSK 
Vaccines Siena 
This study 
psynX_nmb1869 Chloramphenicol 
and ampicillin 
psynX containing an 
upstream flanking 
region that allows 
recombination with 
the gene nmb1869, 
located upstream of 
fHbp in the genome of 
This study 
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Neisseria Meningitidis 
serougroup B 
Plasmid used for 
deletion of the group 
W capsule 
biosynthesis genes 
(without replacement 
with fHbp) 
Spectinomycin and 
ampicillin 
This plasmid is an 
expression vector that 
contains flanking 
regions that allow the 
capsule biosynthesis 
gene deletion in place 
of spectinomycin 
resistance cassette by 
allelic exchange in the 
genome of Neisseria 
Meningitidis 
Personel 
communication 
pLpxL1kan Kanamycin and 
chloramphenicol 
This plasmid is an 
expression vector that 
contains flanking 
regions that allow 
lpxL1 gene deletion in 
place of kanamycin 
resistance cassette by 
allelic exchange in the 
genome of Neisseria 
Meningitidis 
Koeberling et al. 
2008. J Infect Dis 
19:262-70 (215) 
pBSUDGNA33ERM Erythromycin and 
ampicillin 
This plasmid is an 
expression vector that 
contains flanking 
regions that allow 
gna33 gene deletion 
in place of 
erythromycin 
resistance cassette by 
allelic exchange in the 
genome of Neisseria 
Meningitidis. 
Adu Bobie et al. 
Infect. Immun. 2004, 
72(4); 1914-1919 
(214) 
pComPind Chloramphenicol 
and ampicillin 
This plasmid is an 
expression vector that 
allows the integration 
of a target gene into 
the Neisseria 
chromosome into a 
non coding region 
between nmb1428 
and nmb1429. 
Expression of the 
inserted gene is under 
control of an IPTG 
inducible promoter. 
This plasmid was 
used as the parent 
plasmid to generate a 
Iewa et al., J 
Bacteriology 
2005(219) 
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set of derivative 
constructs that 
contain different full 
length fHbp IDs under 
IPTG inducible control 
pCompind fHbp ID5 Chloramphenicol 
and ampicillin 
pComPind containg 
the gene encoding the 
full length fHbp ID 5 
This study 
pCompind fHbp ID15 Chloramphenicol 
and ampicillin 
pComPind containg 
the gene encoding the 
full length fHbp ID 15 
This study 
pComPind fHbp ID55 Chloramphenicol 
and ampicillin 
pComPind containg 
the gene encoding the 
full length fHbp ID 55 
This study 
pComPind fHbp 
ID359 
Chloramphenicol 
and ampicillin 
pComPind containg 
the gene encoding the 
full length fHbp ID 359 
This study 
pComPind fHbp 
ID283 
Chloramphenicol 
and ampicillin 
pComPind containg 
the gene encoding the 
full length fHbp ID 283 
This study 
pComPind fHbp 
ID473 
Chloramphenicol 
and ampicillin 
pComPind containg 
the gene encoding the 
full length fHbp ID 473 
This study 
pComPind fHbp 
ID306 
Chloramphenicol 
and ampicillin 
pComPind containg 
the gene encoding the 
full length fHbp ID 306 
This study 
pComPind fHbp 
ID419 
Chloramphenicol 
and ampicillin 
pComPind containg 
the gene encoding the 
full length fHbp ID 419 
This study 
pBSUDgna1870ERM  Erythromycin and 
ampicillin  
This plasmid is an 
expression vector that 
contains flanking 
regions that allow 
fHbp v.1 gene 
deletion in place of 
erythromycin 
resistance cassette by 
allelic exchange in the 
genome of Neisseria 
Meningitidis 
 
This study 
 
Table 12: List of primers used in this study. Fw means forward and rev means reverse. 
Primer name Primer sequence 5’>3’ Primer use 
nmb1869 fw CCCCCCGGGGCCTGTAAACAAAATGCC
G 
Amplification of the portion 
of the gene nmb1869 
located upstream of fHbp in 
the genome of Neisseria 
Meningitidis serogroup B 
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and used as flanking region  
nmb 1869 rev GCTCTAGAGCATACCGCATCAATGAGG Amplification of the portion 
of the gene nmb1869 
located upstream of fHbp in 
the genome of Neisseria 
Meningitidis serougroup B 
and used as flanking region 
nmb1869 fw2 CCCCCCGGGCCCGCGCAAATACCTGAG
C 
Amplification of the portion 
of the gene nmb1869 
located upstream of fHbp in 
the genome of Neisseria 
Meningitidis serougroup B 
and used as flanking region 
CpsUp-fw TCCCCCCGGGTATCGCCAACAAACGGC
ACAG 
Amplification of a fragment 
of the group W capsule 
biosynthesis locus used as 
upstream recombination 
site in plasmid that allows 
the capsule biosynthesis 
gene deletion in place of 
spectinomycin resistance 
CpsDo-rev GGACTAGTGTTTGTTTGCCGCATGCTAA
TGCC 
Amplification of a fragment 
of the group W capsule 
biosynthesis locus used as 
downstream recombination 
site in plasmid that allows 
the capsule biosynthesis 
gene deletion in place of 
spectinomycin resistance 
REVcpsUP_rev GCTCTAGATTTCGATTAAGTGCTATAATT
AGGCC 
Amplification of a fragment 
of the group W capsule 
biosynthesis locus used as 
upstream recombination 
site in plasmid that allows 
the capsule biosynthesis 
gene deletion in place of 
spectinomycin resistance 
FWcpsDO_fw GCCAATGCATCAATATGCTGCCATTACT
CC 
Amplification of a fragment 
of the group W capsule 
biosynthesis locus used as 
downstream recombination 
site in plasmid that allows 
the capsule biosynthesis 
gene deletion in place of 
spectinomycin resistance 
fHbpID5_fw CGCGGATCCCATATGAATCGAACTGCCT
TCTGCTGCC 
Amplification of the full 
length fHbp gene ID 5 from 
genomic DNA of Neisseria 
meningitidis serogroup A as 
template 
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fHbpID5_rev AACTGCAGAACCAATGCATTGGCTGCTT
GGCGGCAAGAC 
Amplification of the full 
length fHbp gene ID 5 from 
genomic DNA of Neisseria 
meningitidis serogroup A as 
template 
fHbpID9_fw CGCGGATCCCATATGAACCGAACTACCT
TTTTCTGCC 
Amplification of the full 
length fHbp gene ID 9 from 
genomic DNA of Neisseria 
meningitidis serogroup W 
as template 
fHbpID9_rev AACTGCAGAACCAATGCATTGGCTGCTT
GGCGGCAAGAC 
Amplification of the full 
length fHbp gene ID 9 from 
genomic DNA of Neisseria 
meningitidis serogroup W 
as template 
fHbp-f41_fw  GGATCAGTCCGTCAGTAAAAACGAGAAA
C 
Insertion of the mutation 
R41S by site directed 
mutagenesis (using the 
Q5® Site-Directed 
Mutagenesis Kit, NEB) in 
the plasmids where the 
different fHbp genes were 
added 
fHbp-r41_rev GTTTCTCGTTTTTACTGACGGACTGATC
C 
Insertion of the mutation 
R41S by site directed 
mutagenesis (using the 
Q5® Site-Directed 
Mutagenesis Kit, NEB) in 
the plasmids where the 
different fHbp genes were 
added 
lpxL1up-fw GCATTTGTATTTTGCCGTCTG Amplification of a fragment 
of lpxL1 gene used as 
upstream recombination 
site in plasmid that allows 
the lpxL1 gene deletion in 
place of kanamycin 
resistance 
lpxL1do-fw ATGCATGCCCCGATTTTTACTGACTACG Amplification of a fragment 
of lpxL1 gene used as 
downstream recombination 
site in plasmid that allows 
the lpxL1 gene deletion in 
place of kanamycin 
resistance 
lpxl1do-rev CGCCATTTTCTACGCTTTGCCAAG Amplification of a fragment 
of lpxL1 gene used as 
downstream recombination 
site in plasmid that allows 
the lpxL1 gene deletion in 
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place of kanamycin 
resistance 
lpxL1up-rev GCTCTAGAGCCGTCTGAACGTAGTCAGTA
AAAATCGGGGC 
Amplification of a fragment 
of lpxL1 gene used as 
upstream recombination 
site in plasmid that allows 
the lpxL1 gene deletion in 
place of kanamycin 
resistance 
GNA33_R1 CGGGAAAGAGCTGTATGTCGAACG Amplification of a fragment 
of gna33 used as 
downstream recombination 
site in pBsudGNA33ERM 
that allows the gna33 gene 
deletion in place of 
kanamycin resistance 
GNA33_R2 GGCGGTTTGAAGCCGAGTTTGACG Amplification of a fragment 
of gna33 used as 
downstream recombination 
site in pBsudGNA33ERM 
that allows the gna33 gene 
deletion in place of 
kanamycin resistance 
GNA33_R3 GCACAGGCATACCGCGACGCGCG Amplification of a fragment 
of gna33 used as 
downstream recombination 
site in pBsudGNA33ERM 
that allows the gna33 gene 
deletion in place of 
kanamycin resistance 
ERM_fw1 CTAGTCTAGATTTGTGTATAATAGG Amplification of the full 
length erm gene from the 
full length erm synthesized 
and present in 
pBsudGNA33ERM 
ERM_rev1 CGCGGATCCTTATTTCCTCCCG Amplification of the full 
length erm gene from the 
full length erm synthesized 
and present in 
pBsudGNA33ERM 
ERM_fw2 CTAGTCTAGAGAGTGTGTTGATAGTGCAG Amplification of the full 
length erm gene from the 
full length erm synthesized  
and present in 
pBsudGNA33ERM 
ERM_rev2 CGCGGATCCCTTTAGTAACGTGTAACTTTCC Amplification of the full 
length erm gene from the 
full length erm synthesized 
and present in 
pBsudGNA33ERM 
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fHbp f1 CGCGGATCCCATATGAATCGAACTGCCT
TCTGCTGCC 
Amplification of the full 
length fHbp gene ID5, 15, 
55 and 306 from genomic 
DNA of Neisseria 
meningitidis serogroup C as 
template or the full length 
fHbp gene ID283, 359, 473 
and 419 synthesized 
(Invitrogen)  
fHbp r1 GCCAATGCATGCGGTTGGCCTGAAAATA
GGG 
Amplification of the full 
length fHbp gene ID5, 15, 
55 and 306 from genomic 
DNA of Neisseria 
meningitidis serogroup C as 
template or the full length 
fHbp gene ID283, 359, 473 
and 419 synthesized 
(Invitrogen)  
 
4.4 Determination of protein concentration by Lowry assay  
 
Standard curve for the assays were prepared with bovine serum albumin (Pierce) in the 
range 4-50 µg. Detergent Compatible (DC) Protein assay (Bio-Rad) is used following the 
producers specifications. Different quantities of GMMA were adjusted to a final volume 
of 25 µL with water. 125 µL of Reagent A‟ (prepared adding 20 µL of reagent S to every 
mL of reagent A) were added and samples were vortexed. 1 mL of reagent B was added 
and absorbances were read at 750 nm after 15 minutes incubation. 
 
4.5 SDS-Polyacrylamid gel electrophoresis of proteins 
 
Whole cell lysates samples were prepared by centrifuging 1 mL of bacteria liquid culture 
(OD 1) at 13000 rpm for 10 minutes, and resuspending the pellet in 200 µL sample 
buffer 2X (NuPAGE® Sample Reducing Agent (10X) plus NuPAGE® LDS Sample 
Buffer (4X) to final concentration 2X); samples were then boiled for 10 minutes. 
GMMA samples were prepared by mixing equal volumes of GMMA and sample buffer 
2X (NuPAGE® Sample Reducing Agent (10X) plus NuPAGE® LDS Sample Buffer (4X) 
to final concentration 2X); samples were then boiled for 10 minutes. Both whole cell 
lysates and GMMA samples were separated by SDS-PAGE using NuPAGE® Novex® 
12% Bis-Tris Protein Gels; gels were run in NuPAGE® MOPS SDS Running Buffer, at 
200V for 1 hour. 
 
4.6 Western Blotting 
 
The term "blotting" refers to the transfer of biological samples from a gel to a membrane 
and their subsequent detection on the surface of the membrane. Western blotting (also 
called immunoblotting because an antibody is used to specifically detect its antigen) was 
introduced by Towbin, et al. in 1979 and is now a routine technique for protein analysis. 
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The specificity of the antibody-antigen interaction enables a target protein to be 
identified in the midst of a complex protein mixture. Western blotting can produce 
qualitative and semiquantitative data about that protein. 
It was performed using the iBlot system (Invitrogen). Protein transfer on nitrocellulose 
membrane was performed as per instruction of the manufacturer. The membrane was 
blocked in PBS 3% milk for 2 hours at room temperature, washed in PBS-Tween 0.1%, 
and incubated with primary antibody. For fHbp detection, primary antibody was a mouse 
anti-fHbp v.1 (or anti-fHbp v.2) polyclonal (or monoclonal used at 1 µg/mL final 
concentration) antibody, diluted 1:2000 in PBS-Tween 0.1%; secondary antibody was an 
anti-mouse IgG conjugated with horseradish peroxidase (Sheep anti-mouse IgG – HRP, 
GE Healthcare, diluted 1:10000 in PBS-Tween 0.1%). After 1 hour incubation with 
secondary antibody, membranes were washed with PBS-Tween 0.1%. 4 mL of ECL 
(Pierce ECL Western Blotting Substrate, Thermo Scientific) were added to the 
membranes for 1 minute; membranes were removed from the substrates and placed in 
plastic sheet protectors, exposed to Amersham Hyperfilm ECL film (GE Healthcare) and 
developed. 
 
4.7 Dot blotting 
 
Dot blotting is a technique for detecting, analyzing, and identifying proteins, similar to the 
western blot technique but differing in that protein samples are not separated 
electrophoretically but were spotted directly onto the membraneusing a dot blot devide 
that allowed spotting of 96 samples. 
20 to 50 uL of samples were spotted onto the nitrocellulose membrane. Vacuum was 
applied to spot the sample on the membrane.. The membrane was removed from the 
blotting device and let dry for a few minutes. Non-specific sites were blocked by soaking 
in PBS 3% milk for 2 hours at room temperature, washed in PBS-Tween 0.1%, and 
incubated with primary antibody. For fHbp detection, primary antibody was a mouse 
anti-fHbp v.1 (or anti-fHbp v.2) polyclonal (or monoclonal used at 1 µg/mL final 
concentration) antibody, diluted 1:2000 in PBS-Tween 0.1%; secondary antibody was an 
anti-mouse IgG conjugated with horseradish peroxidase (Sheep anti-mouse IgG – HRP, 
GE Healthcare, diluted 1:10000 in PBS-Tween 0.1%). After 1 hour incubation with 
secondary antibody, membranes were washed with PBS-Tween 0.1%. 4 mL of ECL 
(Pierce ECL Western Blotting Substrate, Thermo Scientific) were added to the 
membranes for 1 minute; membranes were removed from the substrates and placed in 
plastic sheet protectors, exposed to Amersham Hyperfilm ECL film (GE Healthcare) and 
developed. 
 
4.8 Coomassie blue stain of proteins 
 
For Comassie staining, after run gels were washed with distilled H2O and stained with 
Coomassie Blue Stain (Sigma-Aldrich) following the data sheet‟s procedures for 
proteins. 
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4.9 FACS analysis of fHbp surface expression on live bacteria 
 
Surface expression of fHbp in strains that were engineered to express fHbp under the 
control of IPTG-inducible promoter  was measured on live bacteria by FACS-Scan flow 
cytometer. Antibody binding was detected using a secondary antibody anti-mouse 
(whole molecule) FITC-conjugated (Sigma). 
Neisseria Meningitidis strain to test in the assay was subculture from glycerol stock on 
GC agarplate and incubate O/N at 37°C, 5% CO2. 
7 ml of Mueller-Hinton Broth (MHB) (DIFCO, #275730) were inoculated with single cells 
to OD600 = 0.12 to 0.15. Bacteria were incubated on a shaker at 37%, 5% CO2 until 
OD600 reached 0,6 - 0,65. 1 mL of culture were then transferred into 6 mL warm MHB + 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) at concentrations adopted in this work 
(0.05 mM or 0.5 mM). Bacteria were incubated at 37%, 5% CO2. When the culture 
reached the target OD 600 = 0.6 to 0.65, it was transferred into 50 mL Falcon tube, and 
washed with PBS + 1%BSA, centrifuged for 10 minutes at 3500 rpm, RT. After another 
washing in PBS + 1%BSA, the supernatant was discarded and pellet resuspended in 
DPBS + BSA to OD600 = 0.6 to 0.7. 80 µl of bacterial suspension (OD 0.6) were 
incubated with 20 µl of polyclonal sera (1:100 final dilution) at room temperature for 60 
minutes. After a centrifugation at 13,400 RCF for 3 minutes at room temperature, the 
bacterial pellets were washed once with 1 mL PBS + 1%BSA and after a second 
centrifugation step the pellets were resuspended in 100 µl PBS + 1%BSA containing 
1:300 dilution anti-mouse-FITC and incubated for 30 minutes RT. After a centrifugation 
at 13,400 RCF for 3 minutes, the pellet of bacteria were washed as described above 
and resuspended in 1 ml filter sterilized freshly made 0.5% formaldehyde in 1X PBS. 
Samples (10-20 µl) were transferred to FACS tubes, adding 500 µl of sterile PBS. 
Fluorescence was measured using a FACS machine. 
 
4.10 Preparation and purification of GMMA 
 
Strains were subcultured on GC agar plates with antibiotics if required and incubate for 
18 to 24 hours at 37°C, 5% CO2. 25 mL of complete medium (Table 13) was inoculated 
with single colonies to O.D. = 0.1 and incubated on shaker at 37°C, 5% CO2 150 rpm for 
12 +/- 2 hours. 
 
Table 13: Complete medium. The medium was adjusted to pH 7.2 with NaOH and filter sterilized. 
Composition of complete medium (g/L) 
L-glutamic acid 1  
L-cystein hydrochloride 0.03 
Na
2
HPO4 x 7 H
2
O 3.25 
KCl 0.09 
MgSO
4
 x 7 H
2
O 0.6 
Yeast extract 5 
Casamino acids 10 
Lactic acid 7.5 
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200 ml of medium (in 1 L baffled flask, vented) was inoculated with over-night culture to 
O.D. = 0.15 and incubate for 8 to 10 hours at 37°C, 150 rpm. O.D. was measured every 
two hours to generate growth curve (end O.D. should be around 7 to 8). The cultures 
were centrifuged and the supernatants were sterilized by filtration through a 0.22 µm 
filter. To collect the GMMA the sterile culture supernatants were centrifuged (186,000 g, 
2 hours, 4°C), the membrane pellets were washed once with PBS and after a second 
centrifugation step the GMMA pellets were resuspended in 1X PBS and were sterilized 
by filtration through a 0.22 µm filter. 
 
4.11 Characterization and quality control of GMMA 
 
4.11.1 Negative Staining Trasmission Electron Microscopy 
 
A drop of 5 µL of GMMA suspension prediluted 100 µg/mL was placed onto 300 mesh 
copper formvar/carbon-coated grids and adsorbed for 5 min. Grids were then washed 
with few drops of distilled water and blotted with a Whatman filter paper. For negative 
staining, grids were treated with 2% uranyl acetate in ddH2O for 1 min, blotted with 
Whatman filter paper and air-dried and observeded with a Tecnai 2 Spirit transmission 
electron microscope (FEI, Eindoven, the Netherlands) operating at 80 kV. Electron 
micrographs were recorded at a nominal magnification of 87,000 – 105,000 X. 
 
4.11.2 Monocyte Activation Test (MAT) 
 
PBMC isolation and freezing 
 
Buffy coat from different donors were used to isolate PBMC by Ficoll (Amersham 
Pharmacia Biotec, cat N° 17-1440-03) density centrifugation and following protocol 
reported in (220, 221). 
PBMC were frozen resuspending in freezing medium (heat-inactivated FBS (Fetal 
Bovine Serum), 10%DMSO) at a concentration of 5x107 cells/cryovial. Cryovials were 
prepared dispensing 1 mL aliquots of cell suspension in pre-cooled 2 mL cryovials 
marked with subject‟s code and were immediately transferred into the Cell Freezing Box 
(Nalgene) and stored at –80°C for 24-48h and then transfered in Liquid Nitrogen tank. 
 
PBMC thawing and stimulation 
 
For thawing, each cryovial conserved in liquid nitrogen was warmed at 37C in water 
bath gently shaking until a small, pea-sized pellet of ice remained. 1 mL of thawing 
medium (PBS without Ca2+ and Mg2+, with 2.5 mM EDTA and 20 µg/mL DNAse (Sigma, 
20 mg/mL stock) warmed at 37°C was added directly into each cryovial; thus, the cell 
suspension was added to a 40 mL of warm thawing medium. Each cryovial was rinsed 
with 1 mL of fresh thawing medium to collect residual cells and samples were 
centrifuged at 320 g for 10 minutes at room temperature. Supernatants were discarded 
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by gently inverting the tube and the pellet of cells were washed with 40 mL of pre-
warmed thawing medium and centrifugation and discarding of supernatants were 
repeated. Pellet containing PBMCs was diluted in adequate volume of medium RPMI-
1640 complete (with 25 mM HEPES, glutamine, 10% Fetal Bovine Serum (FBS) + 1% 
Antibiotics Penicilline-Streptomicine (InvitroGen)). 
For the stimulation PBMC were cultured at a density of 2 x 105 cells/well with 180 µL of 
medium RPMI-1640 complemented with 25 mM HEPES, 2 mM glutamine, 10% FBS,  
1% Pen-Strep (InvitroGen) in 96-well round bottom plates. After incubation at 37°C for 
30 min, 20 µL of 10-fold serial dilutions of in PBS (0.0001-1,000 ng/mL final 
concentration in the assay) were added. 
 
Cytokine analysis by ELISA  
 
For IL-6 detection by ELISA Nunc MaxiSorp 96-well plates were coated overnight at 4°C 
with 2 µg/mL human IL-6 capture antibody (eBioscience 14-7069) in PBS, subsequently 
washed with PBS with 0.05% Tween 20 (PBS-T), blocked for 1 h with PBS with 1% BSA 
at room temperature (RT) and washed 3-times with PBS-T. 50 µL of supernatants from 
PBMC experiments, diluted 1:4 with PBS, were incubated for 2 h at RT. A two-fold 
dilution series of recombinant human IL-6 (eBioscience 39-8069) of 31.24 pg/mL to 
4,000 pg/mL in RPMI with 10% FBS was included as standard curve on each plate (in 
duplicate). Plates were washed with PBS-T. Bound IL-6 was detected using 2 µg/mL of 
biotin-conjugated anti-human IL-6 (e-Bioscience 13-7068) in PBST with 0.1% BSA for 2 
h at RT, followed by 3 washes with PBS-T, 20 min incubation at RT with streptavidin-
horse radish peroxidase (R&D Systems, DY998) diluted 1:200 in PBS-T with 0.1% BSA, 
3 washes with PBS-T, and a color reaction with 100 µL/well of substrate (R&D Systems, 
DY999) for 8 min at RT in the dark. The reaction was stopped by adding 50 μL/well of 
12.5% sulfuric acid. The plates were read at 450 nm and 630 nm and the OD450nm-630nm 
was determined. IL-6 concentrations in the samples were calculated in comparison to 
the IL-6 standard using a four parameter logistic curve and plotted against the amount of 
GMMA in the sample. Results below the detection limit were assigned half of the 
detection limit. The average of the IL-6 release at the lowest concentration of GMMA 
that did not trigger activation was defined as background level. For comparison of the 
stimulatory activity of GMMA, the amounts of GMMA needed to obtain a 10-fold 
increase of IL-6 release over background were determined from the generated curves. 
 
4.11.3 MALDI-TOF and MS/MS analysis on lipid A 
 
Lipid A was precipitated from GMMA using mild acid hydrolysis with 1 % acetic acid for 2 
h at 100°C (222). Samples were centrifuged at 14,000 g for 15 min, the pellets 
resuspended in water, and washed twice with water. The pellets were dried overnight 
using a speedvac and resuspended in chloroform-methanol 4:1 and mixed with an equal 
volume of Super DHB solution (Sigma-Aldrich). 2 µL of the mixture were loaded to the 
target plate (MTP 384 target plate ground steel BC, Bruker Daltonics) and analyzed by 
Ultraflex MALDI-TOF (Bruker Daltonics) in reflectron ion-negative mode. A Peptide 
Calibration Standard (Bruker Daltonics), mixed with the Super DHB solution, was 
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included in each analysis. For MS/MS analysis of lipid A, main peaks from the linear 
mode analysis were selected for Collision Induced Dissociation (CID) and resulting 
fragments were detected by MALDI-TOF-TOF in ion negative mode. For each sample, 
spectra represent the integration of the analysis of 20 different areas of the spot by 50 
single laser shots. The m/z rations were determined by Flex Analysis software in 
comparison to the Peptide Standard.  
 
4.11.4 HPLC-SEC MALLS analysis of GMMA samples 
 
The GMMA have a size range that allows to enter in the pore of the Size Exclusion High 
Pressure Liquid Chromatography (HPLC-SEC) eluting as entire vesicles. The procedure 
was used to analyze GMMA samples and evaluate their soluble protein content, the radii 
populations and the presence of a relevant amount of nucleic acids. 
In particular the detectors adopted were: 
 UV, 280/260 ratio to detect DNA presence and its MW 
 Fluorimeter, ex280/em336 to detect protein related to GMMA particles and free 
soluble proteins 
 Multi Angle Laser Light Scattering (static scattering) for particle sizing 
GMMA ultracentrifuged pellets, resuspended in 1X PBS and sterilized by filtration 
through a 0.22 µm filter as described in the paragraph 4.10, were diluted in PBS 1X to a 
final concentration 150 µg/mL in a final volume for injection of 80 µL. 
To clarify how MALLS works in Figure 14 is reported the chromatogram related to an 
injection of 80 µL of sample. The HPLC system used is SEPAX 2000A+1000A column in 
series while the eluent used is PBS 0.5 ml/min. 
 
Figure 14: Chromatogram related to an injection of 80 µL of GMMA sample (150 µg/mL). The HPLC system 
used is SEPAX 2000A+1000A column in series while the eluent used is PBS 0.5 ml/min for a 70 min run time. 
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In the chromatogram reported above is possible to check the peak related to the GMMA 
and the absence of the peak related to the soluble free proteins, generally located on 
the right in the chromatogram because of their smaller size that delayed their time of 
elution in respect to the bigger GMMA samples. 
The size determination by MALLS was performed by the following detector flow cell 
scheme (Figure 15). 
 
 
Figure 15: Detector flow cell scheme for size determination in MALLS analysis. 
Then a multiple chromatogram was acquired (18, one for each angle) as reported in 
Figure 16. The analysis performed was in function of Light Scattering intensity = f (angle, 
MW, Particle size). 
 
Figure 16: Multiple chromatogram in function of Light Scattering intensity related to one of the GMMA sample 
analyzed in this work (GMMA deriving from Neisseria Meningitidis serogroup W wild type strain). 
 
Successively, it was chosen the best fitting model and the fit degree for the data to 
achieve, from LS equations, the particles radius. Each model, in theory, works better 
with a different range of MW / radius, but it depends also on the product to characterize. 
For this reason they have to be tried on each peak. 
In Figure 17 it is reported, as example, trials on first LS peak. 
In this case the model/fit degree was applied on data obtained from: 
54 
 
• retention time (RT) corresponding to the top of the peak 
• averaging for the whole peak  
The parameters considered were: 
• RMS (root mean square radius) 
• Peak Rn (average radius) 
• Peak Rw (mass weighted average radius) 
• Peak Rz (mass
2 weighted average radius) 
The criteria to evaluate the method were based on: 
• R2 for fitting on RT 
• Errors on the RMS of the whole peak 
 
 
Figure 17: Analysis of first LS peak reported in Figure 16. 
The configuration of MALLS is reported in Figure 18. 
 
Figure 18: Typical MALLS configuration. 
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4.12 Mice immunization 
 
In order to obtain serum samples for analysis, mouse immunization studied were carried 
out previously at the Toscana Life Science animal facility, according to formal approved 
GVGH protocols. Female CD-1 mice (4 to 6 weeks old) were obtained from Charles 
River Laboratories (Wilmington, MA, USA). 
Eight mice per group were immunized intraperitoneally two times with 4 weeks intervals. 
Serum samples were obtained 2 weeks after the second dose. Mice were immunized 
with the following antigens: 0.5 or 2.5 µg “native outer membrane vescicles” (nOMV) 
from a serogroup W mutant with deleted capsule, deleted lpxL1 and over-expressed 
fHbp ID5; 1 or 5 µg GMMA from a serogroup W mutant with deleted capsule, deleted 
lpxL1, deleted gna33 and over-expressed fHbp ID9 R41S A control vaccine consisted of 
5 µg GMMA from a serogroup W mutant with deleted capsule, deleted lpxL1, deleted 
gna33. All vaccines were adsorbed on 3 mg/mL Aluminium hydroxide in a 200 μL 
formulation containing 10 mM Histidine and 0.9 mg/mL NaCl. Sera were stored at 
−80 °C until use. All animal work was approved by the Italian Animal Ethics Committee. 
 
4.13 Characterization of immune responses by Serum Bactericidal 
Assay (SBA) 
 
Neisseria Meningitidis strain to test in the assay was subculture from glycerol stock on 
GC agarplate and incubate O/N at 37°C, 5% CO2. 
7 ml of Mueller-Hinton Broth (MHB) (DIFCO, #275730) supplemented with 0.25% 
glucose were inoculated with single cells to OD600 = 0.12 to 0.15. Bacteria were 
incubated on a shaker at 37%, 5% CO2 until OD600 reached 0,6 - 0,65. 1 mL of culture 
were then transferred into 6 mL warm MHB (+ 0.25% glucose and 0.02 mM CMP-NANA 
and Isopropyl β-D-1-thiogalactopyranoside (IPTG) at concentrations adopted in this 
work (0.05 mM or 0.5 mM)). Bacteria were incubated at 37%, 5% CO2 until OD 600 = 
0.6 to 0.65. Culture was then transferred into 50 mL Falcon tube, and washed with 
Dulbecco‟s saline phosphate buffer (Sigma #D8662) supplemented with BSA 1% 
(DPBS+BSA), centrifuged for 10 minutes at 3500 rpm, RT. The supernatant was 
discarded and pellet resuspend in DPBS + BSA to OD600 = 0.6 to 0.7. Bacteria were 
diluted in DPBS+BSA to a final working dilution of 1:12,500. 
The assay was done in sterile 96 well plates in a final volume of 40 µl per well. In a 
separate plate (“dilution plate”), sera dilutions were performed, starting from a 1:10 
dilution, followed by 7 serial dilutions 1:4. 10 µL of serum sample were added from the 
dilution plate into the assay plate. In control wells were added wither DPBS + BSA only, 
or active complement, or heat-inactivated complement without serum. These controls 
were used to calculate the average of colonies at time zero (T0). 10 µL of bacteria 
working dilution were added to each well of the assay plate containing buffer only or 
diluted sera. Active and inactivated complement were added to control wells. 12 µL of 
controls were plated on square GC agar plate, loading 12 uL on top of the plate, and 
letting the drops run down to bottom of plate. Active complement was added to all the 
assay wells. Plate was sealed and incubated (37°C, 5% CO2) for 60 min. After 60 
minute (T60) 12 µL of each well were plated on GC agarplate (as before) and incubated 
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O/N at 37°C, 5% CO2. 1. Colonies were counted on T0 plates and T60 plates. The 
bactericidal titer is defined as the serum dilution that results in 50% decrease of CFU at 
T60, compared to the average number of CFU at T0 in the six control wells that did not 
contain the test serum. 
 
4.14 FHbp sequence diversity analysis by pairwise amino acid 
comparison 
 
A matrix approach was adopted in order to analyze sequence diversity in the factor H 
binding sites in an existing and published panel of fHbp v.1, 2 and 3 sequence IDs.. 
Starting from the crystal structure of fHbp variant 1 and 3 from NCBI‟s Entrez Structure 
database, the amino acids that are in contact with factor H has been identified. Selection 
criteria were amino acid residues in fHbp that are in a maximum distance of 5Å to factor 
H. Factor H binding  site sequence used for the analysis was characterized by 48 out 
255 amino acids (full length fHbp v.1 ID1, published crystal structure) and 54 out 262 
amino acids (full length fHbp v.3 ID28, published crystal structure). The factor H binding 
site for variant 2 has been obtained by alignment of sequence fHbp ID 28 (published 
crystal structure of the v.3 protein, as reported previously) and fHbp ID 16 (variant 2). 
Factor H binding sites in the other published fHbp IDs  belonging to fHbp v.1 (N= 382), 2 
(N= 150) and 3 (N= 148) have been identified by alignment with the reference sequence 
for fHbp variant 1 (ID1), variant 2 (ID16) and variant 3 (ID28). A snapshot of the pairwise 
comparison of the fH binding site sequences using the matrix shown in Figure 19. 
 
 
Figure 19: Screenshot of matrix used to compare Factor H binding sites in fHbp v.2. Each variant can be 
divided into sub-variants (each one identified by a specific ID  number) differing in their amino acid sequence. 
The numbers on the left and top correspond to the numbers of ID compared. Numbers in matrix from 0 to 2, in 
this case, correspond to the differences in aminoacid sequence between each ID pair. 
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It is possible to observe on the left and top the numbers of IDs compared, while the 
numbers within the matrix correspond to the numbers of differences in terms of 
aminoacid residues between the factor H binding sites of each ID. The darker colour is 
proportional to the increase of number of differences.  
By matrix it was possible to calculate the number of positions of a sequence that were 
different from those of another sequence, as reported in the following equation. 
 
 
 
  
 
Number of differences = n° ij= 
number of aminoacids differences 
comparing sequence i and sequence j 
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V – Results 
 
5.1 Generation and characterization of GMMA from a serogroup W 
strain with over-expressed fHbp v.2 
 
The majority of current African invasive group A and X isolates express fHbp variant 1. 
Current African serogroup W strains are more heterogeneous and strain have been 
identified that express fHbp v.1, 2 or 3. However, the majority of group W strains 
express a single subtype of the porin protein PorA. Antibodies against PorA provide 
subtype specific protection. Therefore, GMMA from a group W strain expressing the 
PorA subtype common among W strains and over-expressed fHbp variant 1 have the 
potential to provide protection against the majority of the current invasive African strains. 
However they are not expected to cover strains with a different PorA subtype and 
expressing fHbp variant 2 or 3. As a proof of principle I generated and characterized a 
GMMA from an African group W strain engineered to over-express fHbp v.2 (Figure 20). 
The approach was to use a group W wildtype strain that naturally expresses fHbp v.2 
(ID23) and upregulate the native fHbp v.2 expression by replacing the native promoter 
with a strong promoter and leaving the fHbp in its native site. 
Additional mutations that were introduced in the strain were: 
 Deletion of capsule biosynthesis gene to increase safety of the vaccine strain. In 
fact, strains without capsule were not infectious (223) and allowed to present 
better antigens like fHbp known to be protective and avoided potential generation 
of serogroup specific antibodies 
 Deletion of lpxL1 (224) to obtain strains with a reduced endotoxin activity 
 Deletion of gna33 (225) to increase the release of GMMA (Figure 20). 
 
 
Figure 20: One GMMA from a serogroup W strain with over-expressed native fHbp v.2. 
The initial selection of ID belonging to v.2 chosen to overexpress was based on current 
epidemiology and, as shown in the chart (Figure 21), among the invasive MenW strains 
that express fHbp v.2 or 3, ID22 and 23, differing by only one aminoacid (Figure 22), are 
represented in 74% of W strains. 
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Figure 21: FHbp variant 2 (ID22, ID23, ID151, ID21) and 3 (ID351, ID349) distribution among the invasive MenW 
strains. 
 
Figure 22: FHbp variant 2 ID22 and ID23 (most prevalent among the invasive MenW strains) differ by only one 
aminoacid as checked by ClustalW Bioinformatics software. 
5.1.1 Over-expression of native fHbp variant 2 in MenW 
 
The plasmid used to generate N. meningitidis mutants with over-expressed native fHbp 
(Figure 23) contains the upstream recombination site that allows homologous 
recombination with genes of the capsule biosynthesis locus (capsW up), a 
chloramphenicol resistance gene (cm), a portion of fHbp that allows recombination with 
fHbp (fHbp Nterm) and a strong synthetic promoter. By homologous recombination in 
Neisseria the native fHbp promoter will be replaced with the strong synthetic promoter. 
 
 
Figure 23: Schematic representation of the plasmid psynX containing the cps upstream flanking region, the 
chloramphenicol resistance cassette, a portion of fHbp gene downstream a strong synthetic promoter. 
The first step has been the replacement (by enzymatic digestion and ligation) of the 
upstream recombination site (capsW up) with a flanking region that allows 
recombination with the gene nmb1869, located upstream of fHbp in the genome of 
 
 
capsW up cm 
Promoter 
XmaI XbaI BamHI NdeI SpeI 
 
fHbp Nterm 
Pajon et al., 2011 
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Neisseria Meningitidis. To do this, a portion of the gene nmb1869 was amplified by PCR 
from the genome of Neisseria meningitidis group W. 
 
 
Figure 24: Substitution of the recombination site in the plasmid used for over-expression of fHbp v.2 in native 
site of MenW strain. 
The recombination site the chloramphenicol resistance gene, the strong promoter and 
the downstream recombination site fHbp ID16 N-terminal was amplified by PCR (Figure 
25). 
 
Figure 25: PCR product used for Neisseria Meningitidis transformation. 
The primers used allowed the amplification of the portion of the gene located upstream 
of fHbp in the genome of Neisseria Meningitidis serougroup B and used as flanking 
region and were designed to add two restriction sites for XmaI upstream and XbaI 
downstream of the gene of interest (nmb1869). The PCR product was used for 
transformation of Neisseria Meningitidis. Homologous recombination of the PCR 
fragment with the chromosome is represented in  
Figure 26. Chloramphenicol resistant clones were selected. 
  
Figure 26: Homologous recombination of the PCR fragment with the chromosome. 
 
Neisseria meningitidis serogroup W was transformed with the PCR product previously 
described resulting in 40 chloramphenicol resistant colonies. Whole cell lysates was 
prepared and analyzed by SDS-PAGE and western blotting detecting with an antibody 
 
 
capsW up cm 
Promoter 
XmaI XbaI BamHI NdeI SpeI 
 
fHbp Nterm 
 
nmb1869 cm 
Promoter 
XmaI XbaI BamHI NdeI SpeI 
 
fHbp Nterm 
 
nmb 1869 cm 
Promoter 
XmaI Xba BamH Nde Spe
fHbp Nterm 
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specific for fHbp variant 2. Seven colonies out of 40 colonies screened showed over-
expression of fHbp v.2 ID23 (Figure 27) which was approximately 10-fold above native 
fHbp expression in this strain. 
 
Figure 27: FHbp v.2 expression in whole cell lysates from 40 colonies obtained after transformation with the 
PCR fragment containing th strong promoter. Number of cells loaded was normalized based on optical 
density of the cell suspension. Wt = expression of fHbp in the respective wildtype strain. 
 
5.1.2 Deletion of capsule in MenW strains over-expressing fHbp v.2,  
 
The primers used for amplification of the fragment containing the recombination site 
allow the capsule biosynthesis gene deletion by replacement with a spectinomycin 
resistance and were designed to add two restriction sites for each recombination site: 
XmaI upstream and XbaI downstream of the gene of interest (cps up); NsiI upstream 
and SpeI downstream of the gene of interest (cps down). 
The mutation generated was the deletion of capsule biosynthesis genes in group W 
strain over-expressing fHbp v.2. The analysis of colonies obtained after transformation 
with the DNA fragment was carried out by dot blot with whole cell lysates and using a 
monoclonal antibody against group W capsule polysaccharide. The deletion of capsule 
was observed in all 3 colonies selected on spectinomycin. Control wild type gave a 
strong signal while mutants capsule KO were negative (Figure 28). 
 
63 
 
 
Figure 28: Deletion of capsule biosynthesis genes in group W strain over-expressing fHbp v.2 as determined 
by dot blot with heat killed bacteria and using a groupW monoclonal antibody for detection. Wild type = 
parent group W wild type strain expressing the capsule and used to generate the mutants. Capsule KO = 
Three out of 3 clones obtained after transformation with the plasmid used to delete the capsule. 
 
5.1.3 Deletion of lpxL1 
 
The lipid A, portion of the LOS is responsible for the endotoxin activity of LOS. 
Inactivation of lpxL1 gene that encodes for a late-functioning acyltransferases of lipid A 
biosynthesis results in a penta-acylated lipid A, instead of the wild type hexa-acylated 
lipid A with lower toxicity, but retaining the adjuvant activity (226). 
A plasmid containing kanamycin resistance cassette and the flanking regions of lpxL1 
gene was used (Figure 29). The deletion of lpxL1 gene was obtained by allelic exchange 
with kanamycin resistance cassette. 
 
Figure 29: Plasmid pLpxL1kan used to delete lpxL1 gene. 
 
The primers used for amplification of lpxL1 recombination sites were designed to add 
two restriction sites for each recombination site: XmaI upstream and XbaI downstream 
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of the gene of interest (lpxL1 up); NsiI upstream and SpeI downstream of the gene of 
interest (lpxL1 down). 
The insertion of kanamycin resistance gene and so the deletion of gene lpxL1 in capsule 
KO mutants, over-expressing fHbp v.2 was verified by PCR. The positive result occurred 
in all 7 colonies selected previously on kanamycin (Figure 30). 
 
Figure 30: Deletion of lpxL1 in  capsule KO mutant, over-expressing fHbp v.2. LpxL1 wild type = parent group 
W wild type strain used to generate the mutants. LpxL1 KO = one out of 7 clones obtained after the 
transformation with the plasmid used to delete gene lpxL1 by the insertion of kanamycine resistance gene. 
Transformats were tested by PCR using genomic DNA as template and primers LpxL1forHindIII and 
LpxL1revXba. The higher band in the mutant results from integration of the kanamycin gene. 
 
5.1.4 Deletion of gna33 
 
Mutants obtained so far were further mutated for gene gna33 deletion To delete the 
gene gna33 a plasmid containing erythromycin cassette and the flanking region of 
gna33 gene was used in order to obtain in removing gna33 and integrating in place of it 
the erythromycin cassette resistance by homologous recombination. The insertion of 
erythromycin resistance gene and the deletion of gene gna33 in capsule KO, lpxL1 KO 
mutants, over-expressing fHbp v.2 was confirmed by PCR. The positive result occurred 
in 7 out of 16 colonies screened on erythromycin (Figure 31). 
 
Figure 31: Deletion of gene gna33 in capsule and lpxL1 KO mutants, over-expressing fHbp v.2. Plasmid used 
for deletion of gna33. transformation is reported as positive control.Transformats having the gna33 deletion 
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were verified by PCR with chromosomal DN Aas template and primers annealing in the recombination site 
and the inserted erythromycin gene. 
 
5.2 Comparative characterization of Group W GMMA over-expressing 
two different variants of fHbp 
 
GMMA were generated from Men W strains cpslpxL1gna33 over-expressing the 
native fHbp variant 2, described in the previous paragraph. 
In this section it is report a comparative characterization between GMMA obtained from 
Men W strains cpslpxL1gna33 over-expressing native fHbp v.2 ID23. 
GMMA from Men W strains cpslpxL1gna33 over-expressing native fHbp v.2 were 
obtained by ultracentrifugation (186,000 g, 2 hours, 4°C) of the sterile culture 
supernatants (200 mL supernatant/strain), a washing with 1X PBS, a second 
ultracentrifugation step (186,000 g, 1 hours, 4°C) and resuspension in 1X PBS (~ 5 
mL/strain) and sterilization by filtration through a 0.22 µm filter and quantitation by Lowry 
assay. 
The GMMA characterization was based on: 
 Total protein composition by separation with SDS PAGE and staining with 
coomassie blue 
 FHbp expression by western blotting 
 Lipid A analysis by MALDI-TOF in order to detect the effect of lpxL1 knock out 
 Endotoxin activity evaluation by MAT assay 
 DNA, protein related to GMMA particles and free soluble proteins presence and 
particle sizing by HPLC-SEC MALLS, before and after benzonase treatment 
 
5.2.1 Detection of total protein and fHbp in GMMA by SDS PAGE, Comassie blue 
and western blotting 
 
In Figure 32 is shown the total protein composition of vesicle preparations from the 
group W wild type, from a mutant derived from the wild type over-expressing the native 
fHbp v.2 and from a mutant with over-expressed fHbp v.2 and deleted cps, lpxL1 and 
gna33 genes (3 different clones) after separation by SDS PAGE and staining with 
coomassie blue. 
As shown, the protein pattern of mutants is similar to that of Men W wild type and Men 
W overexpressing fHbp v.2, which was used as parent strain for the subsequent genetic 
modifications. Bands show the typical pattern of major proteins present in 
meningococcal outer membrane preparations including Opa (ca. 27 kDa), RmpM (ca. 34 
kDa), PorB (ca. 38 kDa) and PorA (ca. 42 kDa). -Fhbp cannot be separately visualized 
by 1D gelelectrophoresis and coomassie stain because the band is at the same level as 
the Opa protein. 
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Figure 32: Total protein content of GMMA from MenW cpslpxL1gna33 over-expressing native fHbp as 
detected by SDS PAGE and coomassie blue stain. This protein pattern was compared with that deriving from 
MenW wild type and from MenW overexpressing fHbp v.2, strain used then for the deletion of the capsule 
biosynthesis genes, lpxL1 and gna33. 5 ug GMMA based on total protein were loaded per lane. 
 
In Figure 33 it is reported the detection of fHbp in GMMA prepared from the same 
strains analyzed after separation by SDS PAGE and staining with coomassie blue (group 
W wild type; a mutant derived from the wild type over-expressing the native fHbp v.2; 3 
clones of a mutant with over-expressed native fHbp v.2 ID23 and deleted cps, lpxL1 and 
gna33 genes). The over-expression of native fHbp v.2 ID23 was detected by western 
blotting using a monoclonal antibody raised against fHbp v.2. It was approximately 10-
fold above native fHbp expression in the mutants with over-expressed fHbp and capsule, 
lpxL1 and gna33 KO. Expression of fHbp in these mutants was similar to the amount of 
fHbp in GMMA from OE v.2. 
 
Figure 33: Detection of fHbp in GMMA from MenW cpslpxL1gna33 over-expressing the native fHbp v.2 
ID23 using a monoclonal antibody raised against fHbp v.2. 
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5.2.2 MALDI-TOF analysis of lipid A from N. meningitidis GMMA lpxL1 knock out 
 
The lipid A, portion of the LOS is responsible for the endotoxin activity of LOS. 
Inactivation of lpxL1 gene that encodes for an enzyme responsible of last step of 
lipopolysaccaride synthesis (late-functioning acyltransferases) results in a penta-
acylated lipid A, instead of the wild type hexa-acylated lipid A with lower toxicity, but 
retaining the adjuvant activity. To prove the correct deletion of the fatty acyl chain lipid A 
from GMMA with lpxL1 KO, lipid A from the various mutants has been extracted from 
GMMA, analyzed by MALDI-TOF and compared with GMMA from the wild type strain. 
The obtained spectra and Neisseria lipid A species corresponding to the observed m/z 
(227) are reported in Figure 34.  
The main peaks in the mass spectra obtained by MALDI-TOF in ion-negative reflectron 
mode from GMMA purified from lipid A unmodified strains of Neisseria, present two main 
peaks; the first one has an m/z correspondent to the theoretical mass (1838 Da, 1837 
m/z) of an hexa-acylated lipid A that present a phosphoethanolamine attached on the 
phosphate 1‟ due to the action of transferases encoded by eptA, instead the second 
ones is correspondent to an hexa-acylated lipid A without the phosphoetanolamine 
(1715 Da, 1714 m/z). It was possible observe that the two peaks corresponded to the 
same two lipid A molecules described before but that had lost a phosphate in 4‟ position, 
most likely during the analysis. 
 
 
 
Figure 34: MALDI-TOF spectra obtained analyzing lipid A extracted from N. meningitidis GMMA lpxL1 knock 
out and wild type. Spectra were acquired in reflectron ion-negative mode. 
 
In the lipid A purified from GMMA from lpxL1 mutant strains two populations were 
observed, with and without phosphoetanolamine, with a shift of exactly 182 Dalton 
corresponding to the lack of a lauroyl (-C12 fatty acid chain), from the two lipid A species 
observed in GMMA purified from lipid A WT strain, consisting in a lpxL1 knock out. The 
discrepancy between the theoretical m/z and the observed ones is only 1 Dalton and it 
was due to calibration (the discrepancy was the same for all the peaks observed). In 
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fact, the m/z shift was perfect at Dalton level in chemical shift due to the lack of fatty acid 
chains and/or phosphoethanolamine. 
 
5.2.3 Evaluation of endotoxin activity of Neisseria GMMA after genetic 
manipulation 
 
In order to directly detect the reduction of reactogenicity after lipid A modifications in N. 
meningitidis, GMMA from strains with wild type (Men W wt; Men W OE native fHbp v.2 
ID23; Men W OE fHbp v.1 ID5, fHbp v.2 and cps) and modified lipid A (Men W OE 
native fHbp v.2 ID23, cpslpxL1gna33; Men W OE fHbp v.1 ID5, fHbpcpslpxL1; 
Men W OE fHbp v.1 ID5 cpslpxL1gna33) were tested by MAT to measure the ability 
of the preparations to induce the release of IL-6 from human peripheral blood 
mononuclear cells. 
As shown in Figure 35, the concentration of GMMA with wildtype lipidA required to 
induce a 10 fold increase of IL6 was 10-1 ng/mL for GMMA from the wild type and a 
mutant over-expressing fHbp v.1 (ID5). GMMA from a mutant with wild type lipid A and 
overexpressed fHbp v.2 had a 10 fold lower ability to induce IL-6 release. GMMA from 
mutants containing the lpxL1 KO mutation had an approximately 100 -fold decreased 
ability to stimulate Il-6 release from human PBMC and the relative decrease was similar 
for GMMA from strains that over-express fHbp v.1 or v.2. 
 
Figure 35: Evaluation of endotoxin activity in Neisseria GMMA by measuring IL-6 release by human PBMC: 
PBMC were stimulated for 4 hours with different concentration of GMMA (0,001-1000 ng/mL, 10-fold steps 
dilutions). 
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5.2.4 Analysis of GMMA samples from group W mutants with over-expressed fHbp 
fHbp v.2 by HPLC-SEC MALLS 
 
Outer membrane preparations from serogroup W wild type and mutants having a 
different combination of mutations resulting in deletion of the capsule biosynthesis 
genes, lpxL1, gna33 and over-expressed fHbp were analyzed by HPLC-SEC in order to 
evaluate their soluble protein content, the size and the presence of nucleic acids before 
and after benzonase treatment (2 µL benzonase/2 mL sample diluted in buffer 20 mM 
Tris-HCl, 2 mM MgCl2). Benzonase is a nuclease that effectively remove nucleic acids. 
Soluble proteins presence is assessed using the fluorescence channel (336 nm) (Figure 
36). In all samples analyzed except for MenW GMMA OE native fHbp v.2 cps KO, lpxL1 
KO, gna33 KO. It is possible to observe for all the samples detected one distinct peak at 
27 min corresponding to the GMMA. Moreover there was a loss of proteins after 
benzonase treatment, as shown in the graph below, more evident in GMMA from 
wildtype strains. 
 
Figure 36: Evaluation of outer membrane preparations from different serogroupW mutants by HPLC-SEC. 
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GMMA radii were evaluated by MALLS). In particular, the parameters adopted were the 
following: 
 Peak Rn (average radius): (Ʃni*Ri)/Ri 
 Peak Rw (mass weighted average radius): (Ʃni*Ri*Ri)/Ri 
 Peak Rz (mass2 weighted average radius): (Ʃni*Ri
2*Ri)/Ri 
Ri is the radius calculated while ni is the number of particles detected. 
The values of Rn, Rw and Rz reported in the Table 14 allow to calculate the index of 
polydispersivity (Rw/Rn). If the values of the three radii are similar and if the index of 
polydispersivity is ~ 1, so if the value of Rw is similar to the value of Rn, it means that 
there aren‟t polydisperse populations as resulted in the case of samples indicated by the 
arrows (GMMA deriving from Men W wild type before and after benzonase treatment; 
GMMA deriving from Men W cps KO, lpxL1 KO and gna33 KO OE heterologous fHbp 
v.1 ID5 before and after benzonase treatment; GMMA deriving from Men W OE native 
fHbp v.2 ID23 and GMMA deriving from Men W cps KO, lpxL1 KO and gna33 KO OE 
native fHbp v.2 ID23, after benzonase treatment). These populations of GMMA were 
therefore homogeneus and monodisperse in respect to GMMA deriving from Men W cps 
KO, before and after benzonase treatment and in respect to GMMA deriving from Men 
W cps KO and lpxL1 KO both OE heterologous fHbp v.1 ID5, before and after 
benzonase treatment.  
The results indicate that the monodispersivity of vesicles is particularly evident in wild 
type strains and in strains characterized by all the mutations described previously. It is 
wortwhile to characterize and to detect the index of polydispersivity in GMMA deriving 
from different Men W strains, anyone with a single mutation in order to understand if any 
mutation is crucial affecting the GMMA radii or if it is the combination of all mutations, in 
a synergistic way, to play a role in the dispersivity observed. 
 
Table 14: Evaluation of GMMA radii and relative uncertainty by MALLS detection. 
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Nucleic acid presence in the preparations was assessed on the ABS260/ABS280 ratio 
on the UV channel (Figure 37). In general, whennucleic acids are present, soluble 
proteins and GMMA are not separated by ultracentrifugation.  
In the first group of samples analyzed nucleic acid and soluble proteins weren‟t present 
more than GMMA proteins, independently of benzonase treatment, while the second 
group of samples showed DNA and soluble proteins, also after benzonase treatment. 
 
Figure 37: Evaluation of nucleic acid presence by UV channel in GMMA from different strains pre and post 
benzonase treatment. 
 
5.3 Analysis of the breadth of fHbp sequence coverage by antibodies 
against fHbp in GMMA 
 
As described in the introduction, fHbp can be divided into 3 variants. Each variant 
contains many subvariants that differ by few amino acids. Each subvariant sequence is 
identified by an individual identification number (sequence ID). A sequence analysis of 
fHbp in more than 100 invasive serogroup A, W and X isolates from 11 countries and 
collected between the 1980‟s and 2010 revealed a small number of predominant fHbp 
sequences expressed in these strains. As a consequence, the analysis of coverage by 
antibodies raised against fHbp containing vaccines was previously performed on 
invasive wild type strains expressing one of the predominant fHbp sequence IDs. In the 
case of strains expressing fHbp variant 1, serogroup A strains with ID 5 were selected 
(100% of strains expressed either ID4 or ID5 that differ be one amino acid). In the case 
of serogroup W strains, about one third expressed fHbp variant 1 and the majority had 
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ID 9. The serogroup X strain tested expressed one of the prevalent variant 1 ID 73 or 
74. A recent serogroup C outbreak in Niger (group C outbreaks have not been observed 
since the 1980s) demonstrates that the epidemiology is dynamic and the possibility 
exists that fHbp sequences which are underrepresented or currently do not occur will be 
expressed by African isolates and become predominant in the future. Antibodies raised 
against a particular fHbp variant induce antibodies that in general are bactericidal 
against strains expressing the same variant. However, a systematic analysis of the 
breadth of fHbp sequence ID coverage independent of the predominance in current 
strains has not been performed. 
I therefore performed a systematic fHbp structure sequence analysis of existing 
published sequence IDs belonging to variant 1, 2 and 3 taken from the Neisseria MLST 
database http://pubmlst.org/neisseria/. Using fHbp variant 1 as a model I used the 
bioinformatic data to rationally select a panel of phylogenetically highly diverse fHbp 
sequences. To test fHbp sequence coverage I tested serum bactericidal activity of sera 
made in mice against GMMA with over-expressed fHbp. Test strains was a panel of 11 
invasive wildtype N. meningitidis strains expressing the selected diverse fHbp 
sequences. I also generated a panel of eight isogenic strains that were obtained by 
engineering a parent strain to express selected diverse fHbp sequences and were used 
as test strains to measure serum bactericidal antibody responses.  
 
5.3.1 Structure and sequence analysis of fHbp v.1, v.2 and v.3 
 
A structure/sequence analysis of 683 fHbp IDs belonging to fHbp v.1, 2 and 3 was 
carried out.  
The amino acids in the different fHbp sequences that are in contact with factor H were 
analyzed. Being accessible for a soluble complement factor of the host these amino 
acids must be exposed on the surface of the bacterium and likely to be target of 
antibodies and under immune selection pressure. In fact, previous studies with anti fHbp 
monoclonal antibodies indicate that some of them have the ability to block binding of 
factor H to fHbp. Our hypothesis was that variations in these amino acids have a greater 
impact on the ability of antibodies to kill a particular strain than variations of amino acids 
that are “hidden” in the molecule and not accessible to antibodies. 
Starting from molecular model of fHbp v.1 and v.3 in complex with factor H from NCBI‟s 
Entrez Structure database, we identified the amino acids that are in contact with factor 
H. We included residues in fHbp that are at a calculated distance of ≤ 5Å to factor H 
indicating an interaction (Figure 38, yellow residues). 
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Figure 38: Molecular model of fHbp in complex with factor H. Left panel: fHbp v.1 (grey); right panel fHbp v.3 
(blue). The model of the portion of factor H that binds to fHbp is shown in purple. The structures were 
generated using Cn3D from the published model on NCBI’s Entrez Structure database. Amino acids on fHbp 
that are at a distance of ≤ 5Å to factor H presumably being involved in factor H binding are highlighted in 
yellow. 
 
There is no publically available structure of fHbp v.2 in complex with factor H. However, 
because fHbp v.2 and 3 are closely related (around 80% sequence identity), I used the 
fHbp v.3 sequence to identify the factor H binding site in fHbp v.2 using ID16 as 
reference sequence. Successively, by sequence alignment, I identified the amino acids 
in contact with factor H in the published fHbp sequences belonging to v.1, 2 and 3. 
I have systematically analyzed the amino acid diversity involved in factor H binding in 
683 published fHbp peptide sequences belonging to variant 1 (N=383), 2 (N=151) and 3 
(N=149). 
The analysis of polymorphic sites in factor H binding site using ID9 as reference 
sequence for variant 1 and ID28 for variant 2 and 3 revealed how many variable 
positions are present in terms of chemical-physical features and how many of these 
variable positions are conservative or not conservative substitutions (Figure 39 and 
Figure 40). 
74 
 
 
Figure 39: Structure-sequence comparison of fHbp variant 1, 2 and 3. Molecular model of fHbp showing 
physico chemical features of amino acids included in the site that is involved in factor H binding. Factor H 
binding site amino acids are coloured in relation to their charge (positively charged residues in blue, negative 
in red and neutral in gray) and to their hydrophobicity (standard hydrophobicity scale to draw the most 
hydrophobic residues in red and the least hydrophobic (most hydrophilic) in blue). Chemical properties of the 
amino acid residues in the factor H binding site of fHbp variant 2 are shown on the model publically available 
for fHbp v.3. 
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Figure 40: Structure-sequence comparison of fHbp variant 1, 2 and 3. Sequence and polymorphic sites of the 
amino acids of fHbp variant 1, 2 and 3 involved in binding of factor H. Starting from the molecular model the 
amino acid residues that are involved in factor H binding were mapped and extracted from the linear 
sequence of the full length fHbp. Factor H binding site amino acids are coloured in relation to their chemical-
physical features (hydrophile in blue black, hydrophobe in red, acidic in yellow, basic in green, aromatic 
hydrophile in blue, aromatic hydrophobe in orange) and to their level of conservation ((*) identical residues, (:) 
highly conserved, (.) weakly conserved). 
 
A summary of the structure-sequence comparison of fHbp variant 1, 2 and 3 looking at 
variable positions in the factor H binding site is reported in  
Table 15. 
For variant 1, 48 amino acids out of 255 (full length of the reference sequence ID1) were 
in contact with factor H, characterizing the factor H binding site. Among them 30 
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positions out of 48 (length of factor H binding site of the reference sequence ID1) were 
variable. Among the 30 variable positions 21 were not conservative substitutions. For 
variant 2, 54 amino acids out of 254 (full length of the reference sequence ID16) were in 
contact with factor H, characterizing the factor H binding site, and among them 31 
positions out of 54 (length of factor H binding site of the reference sequence ID16) were 
variable and among them 19 out of 31 were not conservative substitutions. For variant 3, 
54 amino acids out of 262 (full length of the reference sequence ID28) were in contact 
with factor H, characterizing the factor H binding site, and among them 9 positions out of 
54 (length of factor H binding site of the reference sequence ID28) were variable and 
among them 19 out of 31 were not conservative substitutions. 
 
Table 15: Analysis of the factor H binding site of fHbp variant 1, 2 and 3. Reference sequences for the 
analysis were ID1 for variant 1, ID16 for variant 2 and ID28 for variant 3. 
fHbp Number of amino 
acids involved in 
factor H binding (% 
of full length fHbp) 
Number (%) of 
variable positions in 
the factor H binding 
site of fHbp 
Number (%) of not conservative 
substitutions in the variable positions 
of the factor H binding site 
Variant 1 48 (18.8%) 30 (62.5%) 21 (43.8%) 
Variant 2 54 (21.2%) 31 (57.4%) 19 (35.2%) 
Variant 3 54 (20.6%) 9 (16.6%) 6 (11.1%) 
 
A matrix approach previously performed on fHbp v.1 was adopted in order to analyze 
sequence diversity in the factor H binding sites in an existing and published panel of, 
fHbp 2 and 3 sequence IDs and compared with fHbp v.1. A snapshot of the pairwise 
comparison of the factor H binding site sequences using the matrix is shown in Figure 
41. 
 
Figure 41: Matrix used to compare factor H binding sites in fHbp v.2. Each variant can be divided into sub-
variants (each one identified by a specific ID number) differing in their amino acid sequence. The numbers on 
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the left and top correspond to the numbers of ID compared. Numbers in matrix from 0 to 2, in this case, 
correspond to the differences in aminoacid sequence. 
As shown in the magnified section of the matrix each row and column corresponds to 
the individual ID compared. The numbers in the matrix correspond to the numberof 
differences in terms of aminoacid residues between the factor H binding sites between 
each ID. A darker colour reflects an increase of number of differences. 
In Figure 42 is shown the pairwise comparison of factor H binding sites in fHbp variant 1, 
2 and 3. In this format, the fHbp IDs were sorted by increasing number of differences in 
order to better appreciate the difference in conservation between v1 and v.2/3. In the 
figure it is also shown the comparison of factor H binding sites in fHbp v.2 and v.3 
together, in order to demonstrate the presence of two branches, one related to v.2 and 
one other related to v.3. 
 
Figure 42: Pairwise comparison of factor H binding site using a matrix approach. Each matrix obtained was 
characterized on the left and top by the number of fHbp ID compared, while the numbers in the matrix 
Increasing number of fHbp sequence ID 
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corresponded to the numbers of differences in terms of amino acid residues between each ID. The 
differences were shown also in terms of colour: the darker colour was proportional to the increase of number 
of differences. IDs in the matrices in the left are sorted by the increasing ID sequence number. IDs in the 
matrices on the right are the same ID but sorted by number of differences. 
 
In detail, for variant 1, the factor H binding sites in 383 different fHbp IDs were compared. 
The highest number of IDs that share the same sequence of the factor H binding site is 
81 (21%). 
while the maximum number of amino acids differences observed between pairs of 
peptide IDs is 11 observed for 31 pairs of IDs. 
For variant 2, the factor H binding sites in 151 different fHbp IDs were compared. The 
highest number of IDs that share the same sequence of the factor H binding site is 106 
(69%) while the maximum number of amino acids differences observed between pairs of 
peptide IDs is 5 observed for 4 pairs of IDs. 
For variant 3, the factor H binding sites in 149 different fHbp IDs were compared. The 
highest number of IDs that share the same sequence of the factor H binding site is 99 
(66%) while the maximum number of amino acids differences observed between pairs of 
peptide IDs is 6 observed for 8 pairs of IDs. 
When we compared in the matrix factor H binding sites deriving from the two variants, 
v.2 and v.3, together, 300 different fHbp IDs were compared. We observed the 
conserved clusters represented by a clear colour, one regard v.2 comparison, the 
second one regard v.3 (within the same variants) In contrast we could observe lower 
conservation and bigger differences for most of IDs analyzed between the variants, as 
reflected by the darker color. The highest number of IDs that share the same sequence 
of the factor H binding site is 107 while the maximum number of amino acids differences 
observed between pairs of peptide IDs is 6 observed for 125 IDs. The results observed 
by the pairwise comparison by matrix approach are reported in Table 16. 
 
Table 16: Highest number of IDs sharing the same sequence of factor H binding site and maximum number of 
amino acids differences observed between IDs in the factor H binding site of the three variants of fHbp 
detected by matrix approach. 
fHbp Highest number (%) of IDs 
sharing the same sequence of 
factor H binding site 
Maximum number of amino acids 
differences observed between 
IDs or pairs of peptide IDs in the 
factor H binding site 
Variant 1 81 (21%) 11 for 31 pairs of IDs 
Variant 2 106 (69%) 5 for 4 pairs of IDs 
Variant 3 99 (66%) 6 for 8 pairs of IDs 
Variant 2 + 3 107 (36%) 6 for 125 IDs 
 
In conclusion we can assert that has been observed a similarity in factor H binding site 
between v.1 and v.2 in terms of number of variable positions, not observed between v.1 
and v.3, while the matrix showed that there is lower variability overall in factor H binding 
site v.2 and v.3, compared with v.1. A possible explanation of it is that few sequences in 
v.2 analysis are characterized by this variability. When we compared the factor H binding 
site sequences between fHbp v.2 and 3, most of the pairs of IDs differed by 5 or 6 amino 
acids as reflected by the darker color. However, there were 4 IDs, 67, 175, 339, 381 that 
had from 0 to 3 differences compared to 236 out of 300 IDs including v.2 and 3. These 
results suggest that these IDs could be phylogenetically located between the two 
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variants. To further test it we compared v.2 and v.3 factor H binding site by a 
phylogenetic analysis (Figure 43). The tree obtained revealed the results obtained by 
matrix because we could observe the presence of two branches, one related to v.2 and 
one other related to v.3. Moreover the 4 IDs described previously are effectively located 
at the conjunction of the two branches. 
 
 
Figure 43: Phylogenetic analysis of factor H binding site of IDs belonging to v.2 or 3. The red circle indicate 
IDs located at the conjunction of the two branches. The tree was generated by seaview that drives the PhyML 
v3.1 program to compute maximum likelihood phylogenetic trees. 
 
We also looked at full sequences of fHbp v.2 and v.3 and the tree obtained revealed the 
results obtained by matrix and by the phylogenetic analysis of factor H binding site of 
IDs belonging to v.2 or 3. Also in this case we could observe the presence of two 
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branches, one related to v.2 and one other related to v.3. Moreover the 4 IDs described 
previously (67, 408, 339 and 381, in red circle) were phylogenetically located at the point 
of separation of the two branches (Figure 44). 
 
Figure 44: Phylogenetic analysis of full length fHbp IDs belonging to v.2 or 3. The tree was generated by 
seaview that drives the PhyML v3.1 program to compute maximum likelihood phylogenetic trees. 
 
5.3.2 Investigation of functional activity of antibodies against fHbp on a strain 
panel expressing highly diverse fHbp sequences 
 
Using fHbp variant 1 as model, the results from the bioinformatic analysis of the fHbp 
sequence IDs was used to rationally select diverse fHbp sequences for the analysis of 
functional activity of antibodies. The criteria for fHbp sequence selection were: 
1. Different levels of differences in the factor H binding site of the fHbp ID to be 
tested in comparison with the fHbp expressed in the GMMA vaccine 
2. Within each level of difference in the factor H binding site select an ID with a low 
% identity of the whole sequence compared with the fHbp expressed in the 
GMMA 
3. Broad fHbp distribution in the phylogenetic tree 
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Test N. meningitis for the functional analysis of antibody activity by complement 
mediated serum bactericidal assay was: 
1. A panel of wild type strains belonging to serogroup A, C, W, Y and X that 
expressed a subset of the selected sequences 
2. A panel of isogenic strains based on one parent strain that was used to generate 
eight mutants engineered to express eight highly diverse selected fHbp 
sequences 
The advantage of the latter panel was that it allowed to specifically investigate functional 
activity of antibodies against fHbp because the mutants only differed by the fHbp 
sequence that they expressed and the parent strain was resistant to killing by antibodies 
raised against GMMA without fHbp. 
The test animal sera for the analysis were obtained from mice immunized with: 
1. GMMA from a serogroup W mutant with deleted capsule, deleted lpxL1, deleted 
gna33 and over-expressed fHbp ID9 R41S 
2. “Native OMV” from a serogroup W mutant with deleted capsule, deleted lpxL1 
and over-expressed fHbp ID5 
 
5.2.3.1 Selection of a panel of wild type strains with phylogenetically diverse fHbp 
sequences for the analysis of functional activity of antibodies raised against 
GMMA with over-expressed fHbp 
 
FHbp sequences IDs of N. meningitidis non serogroup B strains present at GVGH and in 
the GSK Siena Molecular Epidemiology Database were analyzed and strains with 44 
different fHbp v.1 IDs have been identified using fHbp variant 1 as reference in matrix 
from variant 1. As reported in Table 17, the selection of fHbp sequences was performed 
considering a maximum of 7 to 0 as number of differences in the factor H binding site 
and a maximum of 99% to 89% as range of highest overall sequence diversity. The fHbp 
sequences selected for the study were highlighted in yellow. 
 
Table 17: % overall identity and number of differences in factor H binding site of fHbp sequences IDs of N. 
meningitidis A, C, W, Y and X  strains analyzed and identified using fHbp variant 1 as reference in matrix from 
variant 1. 
fHbp % overall identity to ID 9 Number of differences  
Sequence ID   in fH binding site compared to ID9 
1 94.35 4 
2 94.76 2 
3 95.16 1 
4 95.97 2 
5 95.56 2 
6 96.0 2 
8 97.6 0 
9 100.0 0 
10 97.2 0 
11 96.4 0 
12 98.0 0 
13 98.0 0 
14 94.4 5 
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15 89.1 6 
37 94.4 3 
38 93.2 6 
73 94.0 5 
74 94.0 6 
78 94.4 2 
126 99.6 0 
130 94.4 3 
213 91.1 4 
254 95.2 5 
258 96.4 0 
299 97.6 0 
303 96.4 2 
306 95.2 0 
321 93.6 6 
328 94.0 2 
369 95.97 2 
391 93.55 7 
445 97.18 0 
447 93.95 5 
449 96.77 0 
456 96.37 0 
457 95.16 5 
462 97.98 0 
465 96.37 1 
490 96.37 2 
513 95.56 2 
514 94.76 3 
515 96.77 2 
516 93.95 4 
517 95.97 1 
 
As reported in Figure 45 and as already described in Table 17, the selection of fHbp 
sequences expressed by the N. meningitidis wild type strains and used for testing in 
serum bactericidal assays (indicated in purple) was performed predominantly on the 
base of: 
 Number of differences in the factor H binding site compared with ID9 
 Differences in the overall % identity compared with ID9 
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Figure 45: Analysis of 44 individual fHbp sequences from a panel of N. meningitidis A, C, W, Y, X strains 
available in the GVGH and GSK vaccines Siena strain collection. FHbp sequences identified for the selection 
of a panel of wild type strains. Each symbol represents an individual fHbp sequence ID belonging to variant 1. 
 
Phylogenetic tree showing broad distribution of the identified sequences is shown in 
Figure 46. 
 
Figure 46: Phylogenetic tree of fHbp v.1 sequences. 380 existing fHbp sequences available on the Neisseria 
MLST database were included in the phylogenetic analysis. The tree was generated with with MAFFT version 
7 The purple dots identify the phylogenetic distribution of the fHbp sequences that expressed by the N. 
meningitidis wild type strains used for testing in serum bactericidal assays. 
 
In detail, we selected one or more fHbp sequence for each degree of difference in factor 
H binding site in respect to fHbp ID9 (reference sequence) as shown in Table 18. 
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Moreover the sequences chosen for the study were the most diverse in respect to fHbp 
ID9 (~95% overall identity) except for ID15 (89%). 
 
Table 18: % overall identity and number of differences in factor H binding site of fHbp sequences IDs selected 
for testing in serum bactericidal assays. 
Number of differences 
in factor H binding 
site compared to ID9 
fHbp Sequence ID 
0 306; 258 
2 5; 328 
3 37 
4 1 
5 14 
6 15; 321; 74 
 
The fHbp expression and the main features of Neisseria meningitidis wild type strains 
used for SBA analysis as serogroup, PorA subtype and sequence type, were reported 
respectively in Figure 47 and in Table 19. 
 
 
Figure 47: FHbp expression of Neisseria meningitidis wild type strains used for SBA analysis. 
Table 19: Characteristics of Neisseria meningitidis wild type strains used for SBA analysis. 
NVGH ID 
Serogroup fHbp variant fHbp ID PorA subtype Sequence type 
NVGH 2383 C 1 1 7-2,16 32 
NVGH 2374 C 1 328 5-1,10-8 11 
NVGH 2372 C 1 303 5-1,10-8 11 
NVGH 2380 C 1 306 5-1,10-8 2994 
NVGH 2378 C 1 306 5-1,10-8 655 
NVGH 2394 Y 1 258 21,16 1466 
NVGH 2381 C 1 14 17,16-4 3346 
NVGH 2379 C 1 1 7, 16 2493 
NVGH 2384 C 1 15 18-1,3 8339 
NVGH 2390 W 1 321 5-2,10-1 6444 
NVGH 2371 C 1 15 5-1,10-8 11 
NVGH 2376 C 1 1 7-2,16 32 
NVGH 2373 C 1 306 5-1,10-8 11 
NVGH 2388 C 1 37 19,15 145 
NVGH 2377 C 1 15 19-1, 15-11 467 
NVGH 2382 C 1 1 5-2, 10-1 8299 
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5.2.3.2 Serum bactericidal antibody responses in sera from mice immunized with 
GMMA with over-expressed fHbp v.1 
 
Serum bactericidal antibodies responses were measured using baby rabbit serum as 
complement source against the invasive wild type strains with diverse fHbp sequences 
and a heterologous PorA compared to that in the vaccine as described in Table 19. 
As reported in Figure 48 high antibodies titers were observed in presence of sera 
against GMMA over-expressing fHbp v.1, except for the strain expressing ID306. 
High antibodies titers that were not significantly different from those induced by GMMA 
with over-expressed fHbp were observed against 8 strains (expressing fHbp ID9, 328, 
15, 258, 37, 321, 5, 1) also with sera against GMMA without fHbp. Two strains 
expressing ID74 and ID14 were resistant to killing by antibodies against GMMA without 
fHbp. While againt these two strains, antibodies against fHbp seem to be responsible for 
bactericidal activity, against the other test strains also antibodies againt other targets 
seem to contribute to bactericidal activity. 
 
Figure 48: Serum bactericidal antibody responses against invasive Neisseria strains with different fHbp IDs. 
The numbers above the graph indicate the fHbp sequence ID expressed by the N. meningitidis wild type 
strain. “OE” indicate sera from mice immunized with 5 ug GMMA with over-expressed fHbp; “KO” indicate 
sera from mice immunized with 5 ug GMMA without fHbp. Each symbol represents the SBA titer measured in 
individual immunized mice. Mice were previously immunized twice four weeks apart with the vaccines over-
expressing variant 1. Serum samples were obtained two weeks after the second dose. A control group of 
mice received GMMA without over-expressed fHbp. All vaccines were adsorbed on Aluminum hydroxide. 
Serum pools containing sera from eight mice immunized with GMMA without fHbp were tested against the 
strains expressing fHbp ID9, 74, 328, 15, 258, 14, 37, 321, 5, 306 and 1. Complement source was 20% baby 
rabbit serum screened to not have bactericidal activity against the test strain. 
 
In addition, we applied the selection criteria adopted previously (described in paragraph 
5.2.3.1), to generate, starting from one parent strain, a panel of eight genetically defined 
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isogenic strains that were engineered to express seven existing diverse fHbp v.1 
sequences and one naturally existing fHbp v.1/2 hybrid protein. The isogenic strains 
were generated using a parent strain resistant to killing by sera against GMMA that did 
not conatin fHbp. After deletion of the native fHbp, the selected “heterologous” fHbp was 
stably integrated into the chromosome using derivatives of the published plasmid 
pComPind that allows controlled expression under control of IPTG. 
As reported in Figure 49 the selection of fHbp sequences to express in isogenic strains 
and used for testing in serum bactericidal assays (coloured symbol) was performed on 
the base of: 
 Number of differences in the surface exposed factor H binding site compared with 
ID9 
 Highest and lowest % overall identity to ID 9 within each level of factor H binding 
site differences 
 
Figure 49: Analysis of fHbp v.1 sequences based on number of differences in fH binding site and % overall 
identity compared to ID 9. Eight candidates IDs were chosen out of 380 individual fHbp v.1 sequences 
analyzed. Among them, ID283 was chosen as hybrid v.1/v.2. Each symbol represents an individual fHbp 
sequence. 
 
Phylogenetic tree showing broad distribution of the identified sequences is shown in 
Figure 50. 
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Figure 50: Phylogenetic tree of fHbp v.1 sequences. 380 existing fHbp sequences available on the Neisseria 
MLST database were included in the phylogenetic analysis. The tree was generated with with MAFFT version 
7 The coloured dots identify the phylogenetic distribution of the fHbp sequences selected to express by 
isogenic strains. 
 
Factor H binding proteins variant 1 selected to be expressed in isogenic strains are 
shown in Table 20 and sorted by the number of differences in factor H binding site 
compared with ID9. In detail, we selected one fHbp sequence for each degree of 
difference in factor H binding site in respect to fHbp ID9 (reference sequence). Moreover 
the sequences chosen for the study were the most diverse in respect to fHbp ID9 (89.6 
to 95.3%overall identity) except for the hybrid v.1/v2 ID283 ID with 75.5 % overall 
identity. Moreover ID 306 was selected because the single wild type strain available with 
this ID was resistant and we wanted to test if this is because of the feature of this 
particular sequence ID or the strain. 
 
Table 20: Number of differences in factor H binding site and % overall identity of candidate fHbp v.1 IDs 
compared with fHbp ID 9 and ID 5 used to over-express in the GMMA vaccine. fHbp ID 283 is a hybrid 
sequence between variant 1 and 2. 
fHbp ID Number of 
differences in 
factor H binding 
site compared 
with ID 9 
% overall 
identity to ID 9 
Number of 
differences in 
factor H binding 
site compared 
with ID 5 
% overall 
identity to ID 5 
419 0 94.2 2 90.6 
306 1 94.9 3 94.9 
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5 2 95.3 0 100 
473 4 94.5 4 92.6 
15 6 89.6 4 89 
55 8 90 8 87.1 
359 10 90 10 87.1 
283*  75.5  74.4 
 
Parent strain selected to generate isogenic strains panel was isolate NVGH2381, which 
is resistant to killing by sera against GMMA without fHbp. The native fHbp v.1 was 
deleted by transformation with plasmid pBSUDgna1870ERM and homologous 
recombination with the erythromycin resistance gene present on the plasmid. Genes 
encoding for fHbp sub-variants (only ID 5, 55 15 and 306 because the other IDs (419, 
473, 359 and 283) were synthesized (Invitrogen)) were amplified by polymerase chain 
reaction (PCR) from different N. meningitidis genomes (all from a C strain) and inserted 
in the genome in a non coding region between the genes nmb1428 and nmb1429 using 
a published plasmid (Figure 51) with a promoter that allows controlled expression of 
fHbp using IPTG. 
 
Figure 51: Plasmid pComPind used for isogenic strains generation. 
Susceptibility to killing has been shown to also be dependent on the level of fHbp 
expression. 
As mentioned previously, by using the isogenic strains we wanted to test susceptibility to 
killing under defined conditions having a combination of the different fHbp ID types and 
different levels of expression, independently of other additional strain specific factors 
that influence susceptibility to killing. The IPTG concentration useful to test the 
contribution of fHbp expression into analysis of functionality of antibodies by SBA was 
initially tested by growing a candidate mutant that was engineered to express fHBp ID 
359 under different concentrations of IPTG and detection of fHbp in whole cell lysates. 
Figure 52. Under the conditions tested, with 0.01 mM IPTG no fHbp was detectable and 
the lowest concentration tested that induced fHbp expression was 0.05 mM. In addition, 
for following experiments also growth conditions with 0.5 m IPTG were selected which 
resulted in higher fHbp expression. 
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Figure 52: Western blotting with whole cell lysate of strain fHbp KO as negative control and of isogenic strain 
expressing ID359. FHbp expression was induced with different IPTG concentrations. 
 
Screening of additional mutants for fHbp expression after transformation with plasmids 
containing fHbp ID 419, 5, 15, 55, 306, 473 and 61 was detected by colony blot. The 
growth conditions of cultures, then pelleted for dot blot, were the same adopted for 
Serum Bactericidal Assay, described in the next paragraph. 7 ml of Mueller-Hinton Broth 
(MHB) were inoculated with single cells to OD600 = 0.12 to 0.15. Bacteria were 
incubated on a shaker at 37%, 5% CO2 until OD600 reached 0,6 - 0,65. 1 mL of culture 
were then transferred into 6 mL warm MHB (+0.02 mM CMP-NANA and Isopropyl β-D-
1-thiogalactopyranoside (IPTG) at concentrations adopted in this work (0.05 mM or 0.5 
mM)). Bacteria were incubated at 37%, 5% CO2 until OD 600 = 0.6 to 0.65. Culture was 
then transferred into 50 mL Falcon tube, and washed with Dulbecco‟s saline phosphate 
buffer supplemented with BSA 1% (DPBS+BSA), centrifuged for 10 minutes at 3500 
rpm, RT. The supernatant was discarded and pellet resuspend in 1XPBS to OD600 = 
0.6 to 0.7. 2 μl of samples were spotted onto the nitrocellulose membrane at the center 
of the grid and then serum anti fHbp v.1 was used to detect fHbp. As shown in Figure 
53, at least one colony out of 4 transformed with the plasmids containing one of the fHbp 
IDs (except for fHbp ID61) expressed fHbp after 0.05 mM IPTG induction (except for 
fHbp ID61). 
 
Figure 53: Colony blot to detect fHbp expression in isogenic strains using as detecting antibody a 
monoclonal antibody against fHbp v.1. The lysate of parent strain (Men C expressing ID14) was used as wild 
type control. 
 
FHbp surface expression in isogenic strains was detected by FACS analysis using a 
polyclonal serum raised in mice against recombinant fHbp v.1 and v.2. The antibody 
was used at 2 dilutions 1:100 and 1:400. No differences in binding were observed 
between the two dilutions and thereforeonly data obtained at 1:100 dilution were shown 
(Figure 54). 
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Figure 54: FHbp surface expression by FACS in isogenic N. meningitidis strains generated. FHbp expression 
was induced with 0.5 or 0.05 mM IPTG for 3 hours. Detecting antibody was a 1:100 dilution of a polyclonal 
serum raised against recombinant fHbp v.1 + v.2. 
 
By FACS analysis FHbp is exposed at same levels on the surface of the mutants 
expressing the eight different fHbp IDs. Therefore, we can control fHbp expression and 
investigate killing of the different mutants depending purely on the fHbp sequence at a 
given IPTG concentration. 
By FACS, it was not possible to appreciate big differences in the surface expression of 
fHbp related to the two different IPTG concentration so IPTG concentrations lower than 
0.05 mM could be a way to regulate better fHbp expression. 
For SBA analysis both rabbit and human complement were used to investigate potential 
breadth of coverage of antibodies induced by GMMA with over-expressed fHbp v.1  
against the panel of the 8 isogenic strains generated and grown at 2 different IPTG 
concentrations.  N. meningitidis only binds human complement factor H and not rabbit 
factor H. Testing both complement sources allows to investigate the potential 
contribution of competition of factor H and the antibody for binding to fHbp and resulting 
consequences for bactericidal activity.  
I tested serum pools containing sera from eight mice from each group per pool. Figure 
55 and Figure 56 shows the SBA titers measured with rabbit and human complement, 
respectively against the panel of isogenic strains. They are sorted by IDs with 
decreasing number of differences in factor H binding site compared with ID9 and by 
overall identity to ID9. 
In presence of rabbit complement (Figure 55), no detectable bactericidal responses 
were obtained in case of control sera against GMMA without fHbp. In contrast, high SBA 
titers were obtained against all mutants expressing the different fHbp sequences 
indicating broad functional activity of anti fHbp antibodies against strains expressing the 
diverse fHbp sequences. Except for one strain (with ID 359 induced with 0.05 mM IPTG) 
titers ranged between 32,000 and 400,000. 
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In most cases SBA titers were similar independent of the IPTG concentration used to 
induce fHbp expression and the dose used for immunization (5 ug or 1.2 ug based on 
total protein). The first observation is in line with the similar fHbp expression levels 
observed by FACS in presence of 0.5 or 0.05 mM IPTG. 
 
Figure 55: Serum bactericidal antibody responses observed against the isogenic strains generated, in 
presence of 20% rabbit complement. Mice were previously immunized twice four weeks apart with the 
vaccines over-expressing variant 1. Serum samples were obtained two weeks after the second dose. A 
control group of mice received GMMA without over-expressed fHbp. All vaccines were adsorbed on 
Aluminum hydroxide. Bars show titers obtained with serum pools for eight mice per group at two different 
concentrations of IPTG (0.5 and 0.05 mM) in order to investigate potential breadth of fHbp sequence coverage 
of antibodies induced by GMMA OE ID9 at 2 different quantities, 5 µg and 1.2 µg. 
 
When bactericidal activity was measured with human complement (Figure 56), no 
detectable bactericidal activity was observed in case of sera against GMMA with deleted 
fHbp, while bactericidal activity was observed raised against GMMA with over-expressed 
fHbp ID9, indicating activity of anti-fHbp antibodies, dependent on fHbp expression in 
GMMA. Titers ranged between 150 (anti GMMA OE fHbp ID9 5µg against strain 
expressing ID359 grown in presence of 0.05 mM IPTG) and >327680 (for example with 
anti GMMA OE fHbp ID9 5 µg and 1.2 µg against strain expressing ID5 grown in 
presence of 0.05 mM IPTG).For practical reasons serum pools have been used and 
therefore no statistical comparison between the strains can be performed. However, with 
human complement the data indicate a trend that differences in titers are observed 
against strains expressing the different fHbp ID in particular with 
ID359<ID15<ID473<ID5. The number of differences in the fH binding site can in part 
contribute to susceptibility. For example fHbp IDs 359 and 15 have a similer overall 
identity to ID 9 in the vaccine (90% and 89.6 %, respectively). However, ID359 has 10 
amino acid differences and ID 15 six amino acid differences in the factor H binding site 
comared to ID 9 and SBA titers measured against the strain engineered to express ID 
15 are higher. Similar observation can be made against the strains expressing fHbp ID 
473 and 5 (96.5 % and 95.3 % overall identity and 4 and 2 differences in the fH binding 
site, respectively). When expressed in the isogenic strain also the mutant with ID306 
was susceptible to killing. This indicates that in the wild type strain expressing this ID 
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other mechanisms contribute to the resistance and not the fHbp sequence expressed. 
Interestingly, also the strain engineered to express the fHbp v.1/2 hybrid protein was 
susceptible to killing. 
 
Figure 56: Serum bactericidal antibody responses observed against the isogenic strains generated, in 
presence of human complement. Mice were previously immunized twice four weeks apart with the vaccines 
over-expressing variant 1. Serum samples were obtained two weeks after the second dose. A control group of 
mice received GMMA without over-expressed fHbp. All vaccines were adsorbed on Aluminum hydroxide. 
Bars show titers obtained with serum pools for eight mice per group. For the assay strains were cultivated at 
two different concentrations of IPTG (0.5 and 0.05 mM). Sera were from mice immunized with 5 µg or 1.2 µg 
GMMA OE ID9. 
 
The detection breadth of sequence coverage of antibodies induced by GMMA OE ID5 
using rabbit and human complement are reported Figure 57 and Figure 58. 
In presence of rabbit complement (Figure 57), no detectable bactericidal responses 
were obtained in case of control sera against GMMA without fHbp while high SBA titers 
were obtained against the mutants expressing all the different fHbp sequences 
indicating activity of anti-fHbp antibodies with a range of titers between 3000 (anti 
GMMA OE fHbp ID5 0.5 µg against strain expressing hybrid v.1/v.2 ID283 grown in 
presence of 0.05 mM IPTG) and 400000 (anti GMMA OE fHbp ID5 2.5 µg and 0.5 µg 
against strain expressing ID5, 15, 55 and 306 grown in presence of both concentrations 
of IPTG). In general, titers observed were similar against the different strains grown at 
the two different concentration of IPTG and using the two different doses of vaccines. 
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Figure 57: Serum bactericidal antibody responses observed against the isogenic strains generated, in 
presence of 20% rabbit complement. Mice were previously immunized twice four weeks apart with the 
vaccines over-expressing variant 1. Serum samples were obtained two weeks after the second dose. A 
control group of mice received GMMA without over-expressed fHbp. All vaccines were adsorbed on 
Aluminum hydroxide. Bars show titers obtained with serum pools for eight mice per group. For the assay 
strains were cultivated at two different concentrations of IPTG (0.5 and 0.05 mM). Sera were from mice 
immunized with 2.5 µg or 0.5 µg GMMA OE ID5. 
 
When bactericidal activity was measured with human complement (Figure 58), no 
detectable bactericidal activity was observed in case of sera against GMMA with deleted 
fHbp. As expected, highest titers were observed against the strain engineered to 
express ID5 which is identical to the one used for immunization and lowest titers against 
the strain expressing fHbp v.1 ID 359 with the highest number of differences in the fH 
binding site and relatively low overall identity to ID5. Also in this experiment, the strain 
expressing ID15 was more susceptible than the strain expressing ID 359. The two IDs 
have overall 89 and 87.1 % identity to ID5 but ID359 has 10 amino acid differences in 
the fH binding site whereas ID 15 has 4. The data indicate that antibodies are directed at 
the fH binding site and differences contribute to differences in susceptibility to killing. 
Overall the SBA data obtained with the isogenic strains suggest that fHbp v.1 expressed 
in the context of the outer membrane induces antibodies with broad fHbp sequence 
coverage. Differences in the fH binding site appear to contribute to susceptibility but the 
overall sequence identity plays a role as well. 
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Figure 58: Serum bactericidal antibody responses observed against the isogenic strains generated, in 
presence of human complement. Mice were previously immunized twice four weeks apart with the vaccines 
over-expressing variant 1. Serum samples were obtained two weeks after the second dose. A control group of 
mice received GMMA without over-expressed fHbp. All vaccines were adsorbed on Aluminum hydroxide. 
Bars show titers obtained with serum pools for eight mice per group. For the assay strains were cultivated at 
two different concentrations of IPTG (0.5 and 0.05 mM). Sera were from mice immunized with 2.5 µg or 0.5 µg 
GMMA OE ID5. 
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VI Discussion 
 
Meningococcal disease occurs worldwide in both endemic and epidemic form. 
Humans are the only natural reservoir of meningococcus. 
In the past, Neisseria meningitidis belonging to capsular group A strains were 
responsible for the majority of cases in the African Meningitis Belt (an area which 
extends from Ethiopia to Senegal). 
In recent years, serogroup W, X and C strains have increasingly contributed to the 
burden of disease. 
The dynamic nature of meningococcal epidemiology is due to environmental, behavioral 
factors and principally to the antigenic variability that occurs mainly through horizontal 
gene transfer, which allows the organism to acquire large DNA sequences resulting in 
capsular switching. Moreover, the meningococcus also uses gene conversion, which is 
autologous recombination and does not require the acquisition of DNA from another 
strain and it is also capable of varying its antigenic profile through variable gene 
expression and phase variation, which can occur through slipped-strand mispairing of 
variable number tandem repeats, variation in poly-C tracts, and use of insertion 
sequences. 
Even though vaccines against meningococcus are available, an affordable and safe 
vaccine that protects against strains from all serogroups causing diseases in Africa is 
still needed. 
One meningococcal vaccine approach is based on GMMA (Generalized Modules for 
Membrane Antigens) from genetically engineered strains. 
GMMA are outer membrane blebs release by the bacteria that can be used as “carriers” 
of protective antigens. Moreover there is the possibility to “design” GMMA by targeted 
engineering of bacteria such as removing or modifying undesirable antigens, expressing 
desired antigens or engineering the strain to have increased release of GMMA. In 
addition, being in a vesicle structure that mimics the surface of the bacterium, antigens 
are likely to be presented to the host immune system in their native conformation and 
membrane environment. 
One of the main protective meningococcal antigens identified is factor H binding protein 
(fHbp) which binds human factor H (a negative regulator of the human complement 
cascade). This binding allows the meningococcus to avoid complement-mediated killing. 
The protein can be divided into 3 antigenic variants, v.1, v.2 and v.3. Each variant can 
be further divided into sub-variants (each one identified by a specific ID number) 
differing in their amino acid sequence. Moreover, fHbp is expressed by almost all strains 
independent of the serogroup and induces the production of functional bactericidal 
antibodies in mice and humans. In general antibodies against fHbp show cross 
protection within each variant group, but limited cross reactivity between variants, e.g. 
v.1 and v.2/v.3 and viceversa. A second main immunogenic antigen is PorA. However, 
multiple subtypes of PorA exist and protection is only observed against strain expressing 
the same subtype as that in the vaccine. African A, W and X strains are relatively 
conserved in terms of the fHbp and PorA that they express. Most serogroup A and X 
strains express fHbp belonging to variant 1, while W isolates express fHbp v.1, 2 or 3. 
The vast majority of W strains, however, expressed a single PorA subtype (1.5,2) while 
A and X strains showed broader heterogeneity. A single GMMA vaccine has been 
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developed from a W strain with PorA P1.5,2, engineered to over-express fHbp v.1. To 
increase safety of the vaccine strain, capsule biosynthesis genes were deleted. In order 
to increase the tolerability of the vaccine, the genetic modification of Lipooligosaccharide 
(LOS) is necessary. The lipid A, portion of the LOS is responsible for the endotoxin 
activity of LOS. Inactivation of lpxL1 gene that encodes for late-functioning 
acyltransferases of lipid A biosynthesis results in a penta-acylated lipid A, instead of the 
wild type hexa-acylated lipid A with lower toxicity, but retaining the adjuvant activity. To 
increase blebbing gna33 has been deleted. In mice, GMMA from this mutant elicited 
bactericidal antibodies against the homologous W strain and also cross protective 
antibodies against a panel of genetically diverse African A and X strains expressing 
fHbp v.1. 
The primary aim of the project is to systematically investigate and dissect the breadth 
and nature of fHbp sequence coverage by antibodies against fHbp. This is obtained by 
using a combination of bioinformatic tools as the basis to analyze functional antibody 
activity. The analysis can support the selection of fHbp sequences to be included in 
fHbp based vaccines for sub Saharan Africa. 
GMMA have been generated from an African serogroup W (ST11) meningococcus 
isolate expressing PorA subtype P1.5,2 (highly predominant among African W isolates) 
and genetically engineered to over-express native fHbp v.2 ID23, represented in 74% of 
W invasive strains. To attenuate virulence and avoid the possibility of generating 
serogroup-specific antibodies, mutants lack capsule biosynthesis. Furthermore, the 
lipooligosaccharide (LOS) has been genetically detoxified by deleting lpxL1 gene. To 
increase blebbing gna33 has been deleted. Once the mutant strain has been generated, 
GMMA have been collected and the amount of fHbp present has been detected by 
western blotting, comparing GMMA from mutants and wild type strain (FIG in Results). 
We observed more than 10-fold higher presence of the protein in GMMA from mutant 
strains than in GMMA from wild type meningococcus. We did not detect differences in 
the level of fHbp in GMMA from different mutants. This suggests that the over-
expression system used is a robust method for generating GMMA with high presence of 
the main vaccine antigen (fHbp). 
After separation by SDS PAGE and staining with coomassie blue we looked at the total 
protein composition of vesicle preparations, comparing GMMA from mutants and wild 
type strain. We observed that the protein pattern of mutants is similar to that of MenW 
wild type, however the mutations introduced modify or delete components of the outer 
membrane and changes in the protein composition would be expected.  SDS PAGE may 
not be sensitive enough to detect differences and quantitative proteomics on the 
different mutants could reveal differences in the composition after introduction of each of 
the mutation. 
In order to assess the reactogenicity of GMMA with detoxified LOS, we analized the 
release of cytokines by PBMC. We analyzed by ELISA the release of interleukin 6 (IL-6) 
from PBMC incubated for 4 hours with serial dilution of GMMA from different mutants. 
We saw that while non-detoxified GMMA started inducing IL-6 release already at low 
concentration (10-2ng/mL), detoxified GMMA started stimulating cytokine release at 100-
fold higher concentration (101ng/mL). 
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We analyzed serogroup W wild type and mutants, having the different combination of 
mutations described previously, by HPLC-SEC in order to evaluate their soluble protein 
content, the size and the presence of nucleic acids. 
In all the samples analyzed by fluorescence channel, there wasn‟t the presence of the 
peaks corresponding to soluble proteins, generally eluating at different times with 
respect to GMMA. By UV channel, based on the ABS260/ABS280 ratio, we verified also 
the absence of nucleic acids independently of benzonase treatment. These 
characterization suggest that the GMMA from the groupW strain with over-expression of 
the native fHbp v.2 are well purified. A mouse immunogenicity study would be the next 
step in order to investigate breadth of coverage of African isolates that express fHbp v.2 
or 3. 
The limited diversity among existing circulating African fHbp IDs and the possibility of 
changes of the fHbp sequences in the future was the rational for analysis of sequence 
coverage and test of functionality of anti-fHbp antibodies induced by a vaccine 
containing fHbp v.1 against a broad panel of highly diverse fHbp sequences IDs, 
independent of their prevalence. 
In order to reach this aim we performed a comparative sequence structure analysis of 
fHbp v.1, 2 and 3 analyzing the factor H binding site. Being a surface exposed portion of 
the molecule, the factor H binding site is subject to a balance between immunological 
selection and functional activity. 
By structure analysis and sequence alignment we identified the amino acids that are in 
contact with factor H in the published fHbp sequences belonging to v.1, 2 and 3. 
The analysis of polymorphic sites in factor H binding site using ID9 as reference 
sequence for variant 1, ID16 for variant 2 and ID28 for variant 3 revealed that there is a 
similarity in factor H binding site between v.1 and v.2 in terms of number of variable 
positions and ratio of conservative/not conservative substitutions, not observed between 
v.1 and v.3, while the matrix showed that there is lower variability overall in factor H 
binding site v.2 and v.3, compared with v.1. 
The differences in the relatively high frequency of conserved fH binding sites in the fHbp 
v.2 and 3 group versus the lower frequency of conserved amino acids in the variant 1 
group was unexpected. The biological reason is unknown, however it could be possible 
that greater proportion of strains expressing fHbp v.1 are invasive strains which are 
expected to be under greater immune selection pressure.  
However, the number of variable positions for v.1 and v.2 was similar and appears to be 
in contradiction with that obtained by matrix approach which indicated a relatively high 
conservation of the factor H binding site among the existing fHbp v.2 sequence IDs. A 
possible explanation of it is that few sequences in v.2 analysis are characterized by this 
variability. In fact, by the analysis of polymorphic sites, we looked only at the number of 
variable positions, without considering the distribution and the frequency of the event for 
all the sequences existing, differently from informations resulted by matrix. It is possible 
that v.1 and v.2 have the same number of variable positions, but this variability is most 
frequent for variant 1, that is for a higher number of sequences IDs (e.g.150 out of 300 
sequences compared have the apolar aminoacid isoleucine in place of the polar serine, 
or the positively charged aminoacid lysine in place of the negatively charged glutamate), 
with respect to variant 2 (e.g. 25 out of 150 sequences compared have the not 
conservative substitutions described in the previous example). 
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Another question has been the conflicting results observed, by analysis of polymorphic 
sites, between variant 2 and variant 3 (higher number of variable positions in v.2 than 
v.3), in respect to what we observed by matrix approach, which revealed a similar high 
conservation within the same variant. It has been observed that frequency with which 
invasive v.1, v.2 and v.3 occurs is respectively of 65%, 30% and 5%. The discrepancy 
detected by the analysis of fHbp v.2 and v.3 could be related to the fact that there is a 
major functional flexibility in factor H binding site of fHbp v.2 in respect to v.3, because 
most of variant 2 IDs, reported in database and analyzed could be related to invasive 
(and not carrier) strains and so, affected by a greater immune selection pressure. 
Therefore, the above-mentioned approach revealed a novel approach to analyze fHbp 
functional regions in the v.1, 2 and 3 group and may provide the bases for selection of 
sequences of fHbp containing vaccines and to provide a rational approach to select 
fHbp sequences in tests strain used in serum bactericidal assays. In fact, by matrix 
approach, we selected as model a panel of diverse fHbp sequences based on diversity 
in the factor H binding site and overall diversity using ID9 as reference in matrix from 
variant 1. On the basis of the first sequences selection we chose a panel of wild type 
strains. The isolates belonged to serogroup A, C, W, Y and X that expressed a subset of 
the selected sequences and a panel of isogenic strains. To generate the last panel we 
selected one parent strain and generated eight mutants that we engineered to express 
eight highly diverse fHbp sequences. The advantage of this panel is that it allowed us to 
specifically investigate functional activity of antibodies against fHbp because the 
mutants only differed by the fHbp sequence that they expressed, not looking only at 
sequence prevalence but also specifically at diversity. 
Serum bactericidal antibodies responses were measured using baby rabbit serum as 
complement source against a panel of 11 invasive wild type strains with diverse fHbp 
sequences and a heterologous PorA compared to that in the vaccine. 
High antibodies titers were observed in presence of sera against GMMA over-expressing 
fHbp v.1 ID9, except for one test strain expressing ID306. By western blotting fHbp 
expression was detected in N. meningitidis wild type strains expressing ID306, so the 
combination of both results suggest that it is not a feature of the fHbp sequence that this 
strain is resistant. High antibodies titers that were not significantly different from those 
induces by GMMA with over-expressed fHbp were observed against 8 strains 
(expressing fHbp ID9, 328, 15, 258, 37, 321, 5, 1) also in presence of sera against 
GMMA without fHbp, except for the test strains expressing ID74 and ID14 The 
observation of bactericidal activity also in presence of sera against GMMA without fHbp 
indicates that other antigens, in place of fHbp, are responsible for killing. In order to 
assess directly the contribution of antibodies against fHbp against these strains, the sera 
will have to be tested by serum bactericidal assay after adsorption of the anti-fHbp 
antibodies. Moreover immune precipitation experiments and mass spectrometry analysis 
could support the analysis in order to understand which proteins are involved in inducing 
the bactericidal activity. 
In addition, we applied the selection criteria adopted previously to generate, a panel of 
eight genetically defined isogenic strains that were engineered to express seven existing 
diverse fHbp v.1 sequences and one naturally existing fHbp v.1/2 hybrid protein. The 
advantage of this panel is that it allowed to specifically investigate functional activity of 
antibodies against fHbp because the mutant only differed by the fHbp sequence that 
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they expressed. Moreover the sequences chosen for the study were the most diverse in 
respect to fHbp ID9 (~95% overall identity) except for ID15 (89%) and for the hybrid 
v.1/v2 ID283. Moreover ID 306 was selected because the single wild type strain 
available with this ID was resistant to killing by antibodies against GMMA with over-
expressed fHbp and we wanted to test if this is because of the feature of this particular 
sequence ID or the strain. 
By using the isogenic strains we wanted to test susceptibility to killing under defined 
conditions having a combination of the different fHbp ID types and different levels of 
expression, independently of other intrinsic strain specific factors that influence 
susceptibility to killing. By FACS analysis fHbp is expressed on the surface of the 
mutants containing the different fHbp IDs at same levels. Therefore, we can control fHbp 
expression and investigate killing of the different mutants depending purely on the fHbp 
sequence at a given IPTG concentration. 
For SBA both rabbit and human complement were used to investigate potential breadth 
of coverage against the panel of the 8 isogenic strains. FHbp binds human factor H only 
and not rabbit factor H and it can be critical because I have selected fhbp sequences 
that differ in the factor H binding site. 
In presence of rabbit complement, no detectable bactericidal responses were obtained 
in case of control sera against GMMA without fHbp while high SBA titers were obtained 
against the mutants expressing all the different fHbp sequences. In general, titers 
observed were similar against the different strains grown at the two different 
concentration of IPTG and using the two different doses of vaccines.  
When bactericidal activity was measured with human complement, again no detectable 
bactericidal activity was observed in case of sera against GMMA with deleted fHbp while 
bactericidal activity was observed with sera against GMMA with over-expressed fHbp 
ID9, indicating activity of anti-fHbp antibodies, dependent on fHbp expression in GMMA. 
With human complement the data indicate a trend that with smaller number of 
differences in the factor H binding site the titers get higher and viceversa. The results 
observed suggested that amino acids involved in factor H binding played a role giving a 
contribution in bactericidal activity in respect to whole sequences of fHbp. 
In conclusion, antibody titers in presence of human complement (with factor H) are lower 
than titers in presence of rabbit complement. 
Using human complement, a higher number of differences in factor H binding site 
sequence could result in a lower fHbp antibodies affinity, so that factor H binding has an 
advantage and therefore the strain results more resistant. 
As described previously, with human complement, the data indicate a trend that with 
smaller number of differences in the factor H binding site the titers get higher and 
viceversa suggesting that amino acids involved in factor H binding played a role, giving 
a contribution in bactericidal activity versus the whole sequences. The overall sequence 
diversity also plays a role. It is not surprising because changes in any part of the 
molecule can have an effect on the structure and therefore minor changes in antibody 
susceptibility. However, the data suggest that fHbp sequence diversity plays a role in 
susceptibility to killing. 
It is known that the susceptibility of a strain not only depends on the fHbp sequence but 
also on fHbp expression level. In the FACS experiment we did not include a reference 
wild type strain known to express high levels of fHbp. However, the strong shift of the 
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peak relative to the negative control in the FACS experiment indicates that level of fHbp 
expression even with 0,05 mM IPTG is relatively high. A high fHbp expression induced 
in the isogenic strains could have masked to some extend the effect of the sequence 
diversity and their contribution to killing, Therefore, lower levels of fHbp could 
demonstrate better the differences between the fHbp IDs in susceptibility. In order to 
detect if fHbp expression is effectively crucial and if yes, how much it is (more or less 
than fHbp sequence) and also to detect if effectively the contribution of the factor H 
binding site differences in the isogenic strains compared with the overall sequence 
diversity has a most relevant role into strains susceptibility, additional assays could be 
done (FACS analysis and SBA) using IPTG concentrations lower than 0.05 Mm, as a 
way to regulate better fHbp expression. In addition individual sera should be used in the 
SBA, in place of single serum. In fact, for technical reasons, we used pooled sera which 
didn‟t allow a statistical analysis of the differences between the strains. 
 
Summarizing and concluding we observed a lower frequency of conserved amino acids 
in the factor H binding site of fHbp belonging to the variant 1 group, in respect to v.2 and 
v.3, However, a similar number of variable positions were observed for v.1 and v.2 in 
respect to variant 3. 
The bioinformatic analysis has provided a rational approach to systematically dissect the 
surface exposed factor H binding site versus the whole sequence of fHbp and their 
contribution in susceptibility to killing. Serum bactericidal assays revealed that fHbp v.1 
in the group W GMMA induce antibodies against a broad range of fHbp sequences. 
Susceptibility appears to be dependent on differences in the factor H binding site but 
also the overall fHbp sequence differences contribute. 
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